{
  "Topic 1": {
    "106693": "background large scale contemporary population based study heart failure incidence needed inform resource planning research prioritisation current evidence scarce aimed assess temporal trend incidence prevalence heart failure large general population cohort uk method population based study used linked primary secondary electronic health record million individual clinical practice research datalink cprd cohort representative uk population term age sex eligible patient aged year older contributed data jan dec acceptable record according cprd quality control approved cprd hospital episode statistic linkage registered general practice least month patient incident heart failure extracted recent measurement baseline characteristic within year diagnosis electronic health record well information comorbidities socioeconomic status ethnicity region calculated standardised rate applying direct age sex standardisation european standard population inferred crude rate applying year specific age specific sex specific incidence uk census mid year population estimate assumed heart failure patient aged year younger report total incidence prevalence age year finding heart failure incidence standardised age sex decreased similarly men woman per person year adjusted incidence ratio ci however estimated absolute number individual newly diagnosed heart failure uk increased largely due increase population size age estimated absolute number prevalent heart failure case uk increased even study period patient age multi morbidity first presentation heart failure increased mean age year sd year adjusted difference year ci mean number comorbidities sd v adjusted difference ci socioeconomically deprived individual likely develop heart failure affluent individual incidence rate ratio ci earlier life affluent group adjusted difference year ci socioeconomic gradient age first presentation heart failure widened socioeconomically deprived individual also comorbidities despite younger age interpretation despite moderate decline standardised incidence heart failure burden heart failure uk increasing similar four common cause cancer combined observed socioeconomic disparity disease incidence age onset within nation point potentially preventable nature heart failure still need tackled funding british heart foundation national institute health research:0.0168323598386420",
    "186864": "introduction secondary spontaneous pneumothorax ssp often linked chronic obstructive pulmonary disease copd frequency ssp occurrence copd patient varies among different research finding ssps commonly found elderly population diagnosed copd previous study reported pneumothorax rate per copd patient however notable lack detailed epidemiological information regarding ssp asia study focused determining occurrence rate ssp among copd patient taiwan using extensive national database additionally study aimed identify comorbidities associated ssp patient group method study used longitudinal health insurance database contains record million people randomly chosen among beneficiary taiwan national health insurance program dataset includes information end focus individual diagnosed copd identified icd cm code least one hospital admission two outpatient service copd diagnosis date index date exclusion criterion included individual younger year incomplete record previous diagnosis pneumothorax index date conducted matched comparison pairing copd patient control subject similar age sex comorbidities using propensity score matching follow participant started index date continued developed pneumothorax reached study end withdrew insurance program passed away primary objective evaluate compare incidence pneumothorax copd patient matched control result enrolled patient diagnosed copd mean age sd year approximately male follow period pneumothorax occurred patient equivalent cohort incidence rate ssp copd patient per person year whereas per person year without copd furthermore copd patient comorbidities atrial fibrillation congestive heart failure coronary artery disease diabetes mellitus hypertension cancer exhibited increased incidence ssp compared copd patient without comorbidities observed conducting multivariable cox regression analysis adjusted age sex comorbidities conclusion study revealed elevated risk ssp patient copd also suggested copd patient comorbidities atrial fibrillation congestive heart failure coronary artery disease diabetes mellitus hypertension cancer increased risk developing ssp:0.0162620491261754",
    "7499": "heart failure hf remains major public health problem western country despite enormous progress diagnosis treatment acute chronic decompensated hf leading medical cause hospitalization among people aged year european country usa australia new zealand however study acute chronic decompensated hf european society cardiology esc guideline subject published aim evaluate overall prevalence hospitalization due hf according subtypes comorbidities decompensating factor medical department central teaching hospital urban area method performed retrospective observational study patient admitted consecutively medical department via emergency room january june discharge casenotes admission reviewed diagnosis hf cardiovascular condition associated precursor hf analyzed case final diagnosis hf according criterion esc guideline included study evaluated overall prevalence hf subtypes cardiac dysfunction etiological risk factor patient demographic characteristic decompensating factor comorbidity mean length hospital stay hospital mortality rate result identified patient hf mean age male aged female aged left ventricular systolic dysfunction lvsd present case preserved left ventricular systolic function valvular heart disease hypertension coronary artery disease main etiological risk factor respectively atrial fibrillation recorded patient diabetes diagnosed anemia chronic obstructive pulmonary disease one third infection predominantly respiratory main factor triggering decompensation followed uncontrolled hypertension supraventricular tachyarrhythmia admission patient nyha class iii nyha class iv hf patient mean hospital stay day slightly shorter mean overall stay patient admitted medical department period day hospital mortality hf patient hf first cause admission medical department followed stroke conclusion study confirms high prevalence acute chronic decompensated hf patient hospitalized medical department central teaching hospital urban area patient mainly elderly gender slightly higher proportion hf due lvsd patient nyha class iii iv mean hospital stay longer patient admitted period hospital mortality rate low age group affected high prevalence multiple comorbidities emphasize need establish hf clinic multidisciplinary team manage patient health authority must made aware burden syndrome:0.0158247872755054",
    "120636": "background known mortality hip fracture increase compared general population trend mortality controversial issue objective study examine incidence trend factor associated mortality patient osteoporotic hip fracture method retrospective cohort study us registry hospital discharge national health system hospital patient older osteoporotic hip fracture identified demographic data comorbidities obtained survival analysis performed cox regression kaplan meier incidence rate standardized death rate sdr trend poisson regression risk hazard ratio calculated result hospital total patient admitted due osteoporotic hip fracture patient patient woman average age year sd men average age year sd cumulative incidence mortality cumulative mortality rate month annual mortality patient year year mortality rate increased significantly per year irr ci median overall survival day ci probability mortality density period year following hip fracture woman men first day sdr ci variable showed statistically significant association mortality aged masculine institutionalization mild severe liver disease chronic kidney disease copd dementia heart failure diabetes charlson index presence vision disorder hearing impairment incontinence downton scale conclusion last year increase mortality patient hip fracture higher mortality rate men woman observed institutionalization combined comorbidities associated higher mortality:0.0157460671149689",
    "147554": "introduction atrial fibrillation af major increasing public health problem worldwide clinical epidemiological difference men woman however contemporary population level data incidence survival scarce aim evaluate sex specific contemporary trend incidence prevalence long term survival non valvular af real world setting method af patient diagnosed insured large state mandated health organization israel maccabi healthcare service included af diagnosed based registered diagnosis patient valvular disease active malignancy cardiac surgery month recent pregnancy excluded annual incidence rate period prevalence year survival calendar year study period calculated result total eligible patient male female identified male likely younger higher rate underlying disease ischemic heart disease heart failure chronic obstructive pulmonary disease lower rate hypertension chronic kidney disease compared female patient study period age adjusted incidence decreased men person year p trend woman person year p five year survival rate significantly higher among men v woman v respectively p age adjusted prevalence increased significantly among men per year p trend yet decreased among woman per year p trend significant trend toward improved long term survival observed woman men conclusion current study show significant sex related disparity incidence prevalence survival af patient adjusted incidence decreased time prevalence mortality decreased significantly woman:0.0155342915213274",
    "93205": "importance despite considerable improvement heart failure care mortality rate among patient high income country changed little since early understanding reason underlying trend may provide valuable clue developing targeted therapy public health strategy objective investigate mortality rate following new diagnosis heart failure examine change time cause death important patient feature design setting participant population based retrospective cohort study analyzed anonymized electronic health record individual received new diagnosis heart failure january december followed december clinical practice research datalink link information primary care secondary care national death registry subset uk population data analyzed january february main outcome measure cause cause specific mortality rate year following diagnosis poisson regression model used calculate rate ratio rrs confidence interval comparing adjusting age sex region socioeconomic status major comorbidities result participant woman white mean sd age year cause mortality rate declined modestly time rr comparing ci underlying pattern presented explicit trend decline cardiovascular mortality rr ci offset increase noncardiovascular death rr ci subgroup analysis showed overall mortality rate declined among patient younger year rr ci among older year rr ci cardiovascular cause major cause death neoplasm respiratory condition infection latter explaining observed increase noncardiovascular mortality conclusion relevance among patient new heart failure diagnosis considerable progress achieved reducing mortality young middle aged patient cardiovascular mortality across age group improvement overall mortality hindered high increasing rate noncardiovascular event finding challenge current research priority management strategy call greater emphasis associated comorbidities specifically infection prevention present major opportunity improve prognosis:0.0154184967206496",
    "129639": "background type diabetes mellitus dm risk factor development heart failure reduced ejection fraction hfref aim describe compare clinical characteristic use diagnostic therapeutic procedure among subject hospitalized hfref according presence type diabetes mellitus dm sex assess effect dm sex hospital outcome among patient hospitalized hfref using propensity score matching psm identify clinical variable associated hospital mortality ihm among patient hospitalized hfref dm according sex method retrospective cohort study using spanish national hospital discharge database conducted diagnosis procedure codified international classification disease th version icd subject aged primary diagnosis hfref included included patient diagnosis dm diagnosis position descriptive statistic used total relative frequency percentage mean standard deviation median interquartile range control effect confounding variable dm patient non dm patient compared matched cohort using psm multivariable logistic regression model used identify study variable independently affected ihm among men woman hf dm also multivariable method applied sensitivity analysis confirm result psm result total patient included dm present woman dm frequently atrial fibrillation valvular heart disease anemia dementia depression hyponatremia men dm however men coronary heart disease chronic renal disease copd obstructive sleep apnea procedure significantly commonly used among men woman blood transfusion procedure frequently identified among woman dm sensitivity analysis patient dm hospitalized hfref confirmed result psm finding woman higher risk dying hospital men ci obesity seemed protective effect ci hospital morality conclusion subject diabetes admitted hfref greater number comorbidities non diabetic diabetic woman higher mortality rate men diabetes procedure evaluated significantly often used among men woman:0.0154036773778359",
    "114565": "objective describe characteristic prognosis patient copd admitted hospital due sars cov infection method semi covid registry ongoing retrospective cohort comprising consecutive covid patient hospitalized spain since beginning pandemic march data demographic clinical characteristic comorbidities laboratory test radiology treatment progress collected patient copd selected compared patient without copd factor associated poor prognosis analyzed result patient included semi covid registry may diagnosis copd patient copd older without copd year v year frequently male comorbidities hypertension hyperlipidemia diabetes mellitus atrial fibrillation heart failure ischemic heart disease peripheral vascular disease kidney failure higher charlson comorbidity index v p mortality rate copd patient compared patient without copd p male sex history hypertension heart failure moderate severe chronic kidney disease presence cerebrovascular disease sequela degenerative neurological disease dementia functional dependence higher charlson comorbidity index associated increased mortality due covid copd patient survival higher among patient copd treated hydroxychloroquine v p macrolides v p neither prone positioning non invasive mechanical ventilation high flow nasal cannula invasive mechanical ventilation associated better prognosis conclusion copd patient admitted hospital sars cov infection severe disease worse prognosis non copd patient:0.0152704562382391",
    "175466": "background atrial fibrillation af heart failure hf prevalent cardiovascular disorder frequently co occur exacerbating effect resulting adverse clinical outcome despite well established association condition paucity research examining af atrial flutter afl direct contributor hf related mortality across various demographic region within united state objective study aim investigate pattern af afl related hf mortality u stratified age gender race ethnicity urban rural classification geographic region method retrospective analysis conducted utilizing data center disease control prevention wide ranging online data epidemiologic research cdc wonder database mortality data extracted death certificate identified af afl related hf primary contributing cause death icd code age adjusted mortality rate aamrs per individual calculated annual percentage change apc assessed using joinpoint regression result death united state attributed atrial fibrillation flutter related heart failure af afl hf age adjusted mortality rate aamr rose significantly per population male consistently exhibited higher aamrs female v per respectively racial disparity evident non hispanic white highest cumulative aamr non hispanic asian pacific islander lowest geographic difference also prominent oregon recorded highest state level aamr hawaii lowest regionally west midwest highest cumulative aamrs place death trend showed shift toward home death became common location although aamrs increased sharply across subgroup rate stabilized conclusion af afl related heart failure mortality increased substantially past year u marked disparity sex race ethnicity region urbanization recent year seen plateau mortality rate continued burden especially among vulnerable population underscore need equitable targeted public health intervention improved access cardiovascular care:0.0152265720154613",
    "163305": "background covid caused sars cov infection reached pandemic proportion since several clinical characteristic associated poor outcome study aimed describe morbidity profile covid death portugal method study performed including death certificated portugal covid icd u u coded underlying cause death national e death certificate information system march december comorbidities derived icd code using charlson elixhauser index resident portuguese population estimate used result study included death death rate death inhabitant predominantly male male female mortality ratio male female mortality rate ratio however within age group varied fold covid death portugal occurred mainly individual aged year older predominantly public healthcare institution uncomplicated hypertension uncomplicated diabetes mellitus congestive heart failure renal failure cardiac arrhythmia dementia cerebrovascular disease observed among covid deceased patient prevalence higher high prevalence zero morbidity registered using elixhauser charlson comorbidities list nevertheless high multimorbidity also identified time covid death higher multimorbidity level observed men increasing age year old zero morbidity prevalence high multimorbidity prevalence varied throughout year seemingly elevated mortality wave peak suggesting variation according degree disease incidence given period conclusion study provides detailed sociodemographic clinical information certificated death covid portugal showing complex extreme level morbidity zero morbidity v high multimorbidity dynamic first year pandemic portugal:0.0152232371180887"
  },
  "Topic 2": {
    "133528": "background diabetic cardiomyopathy dcm increase risk hospitalization heart failure hf mortality patient diabetes mellitus however specific therapy delay progression dcm identified mitochondrial dysfunction oxidative stress inflammation calcium handling imbalance play crucial role pathological process dcm ultimately leading cardiomyocyte apoptosis cardiac dysfunction empagliflozin novel glucose lowering agent confirmed reduce risk hospitalization hf diabetic patient nevertheless molecular mechanism agent provides cardioprotection remain unclear aim investigate effect empagliflozin high glucose hg induced oxidative stress cardiomyocyte apoptosis underlying molecular mechanism method twelve week old db db mouse primary cardiomyocytes neonatal rat stimulated hg mmol l separately employed vivo vitro model echocardiography used evaluate cardiac function flow cytometry tdt mediated dutp biotin nick end labeling staining used assess apoptosis myocardial cell mitochondrial function assessed cellular atp level change mitochondrial membrane potential furthermore intracellular reactive oxygen specie production superoxide dismutase activity analyzed real time quantitative pcr used analyze bax bcl mrna expression western blot analysis used measure phosphorylation amp activated protein kinase ampk myosin phosphatase target subunit mypt well peroxisome proliferator activated receptor gamma coactivator alpha pgc alpha active caspase protein level result vivo experiment db db mouse developed dcm however treatment db db mouse empagliflozin mg kg wk substantially enhanced cardiac function significantly reduced myocardial apoptosis accompanied increase phosphorylation ampk pgc alpha protein level well decrease phosphorylation mypt heart vitro experiment finding indicate treatment cardiomyocytes empagliflozin mum fasudil fa rock inhibitor mum overexpression pgc alpha significantly attenuated hg induced mitochondrial injury oxidative stress cardiomyocyte apoptosis however effect partly reversed addition compound c cc cell exposed hg empagliflozin treatment increased protein level p ampk pgc alpha protein decreasing phosphorylated mypt level change mitigated addition cc adding fa overexpressing pgc alpha cell exposed hg substantially increased pgc alpha protein level addition sodium glucose cotransporter sglt protein expression detected cardiomyocytes conclusion empagliflozin partially achieves anti oxidative stress anti apoptotic effect cardiomyocytes hg condition activating ampk pgc alpha suppressing rhoa rock pathway independent sglt:0.0141801862327704",
    "176564": "background cardiac ischemia predominant cause heart failure marked profound mitochondrial dysfunction dysregulated ion homeostasis maladaptive cellular remodeling compromise cardiac performance mitochondrial inner membrane protein leucine zipper ef hand containing transmembrane protein letm implicated wolf hirschhorn syndrome essential mitochondrial function although genetic alteration letm linked cardiomyopathy specific contribution cardiac pathophysiology particularly context ischemic heart disease remain poorly defined study aim elucidate role letm ischemic cardiac pathology mechanistic impact cardiomyocyte function method letm expression assessed human murine model heart failure due ischemic cardiomyopathy icm cardiac hypertrophy letm overexpressed neonatal rat ventricular cardiomyocytes adult mouse cardiomyocytes human induced pluripotent stem cell ipsc derived cardiomyocytes study mitochondrial function seahorse assay structural molecular remodeling fluorescence microscopy transmission electron microscopy tem qpcr immunoblotting transcriptomic proteomic profile calcium handling electrophysiology patch clamp autophagic flux bafilomycin lc rfp gfp cell survival result letm markedly upregulated icm human murine heart unchanged hypertrophic heart failure overexpression letm cardiomyocytes resulted profound mitochondrial dysfunction including downregulation oxidative phosphorylation oxphos gene impaired membrane potential reduced atp output increased proton leak elevated ro level metabolic shift toward glycolysis observed accompanied reduced fatty acid oxidation electron microscopy revealed mitochondrial fragmentation mitophagic vesicle sarcomeric disarray transcriptomic proteomic analysis highlighted dysregulation gene linked mitochondrial organization ion transport autophagy electrophysiologically letm reduced l type ca current density significantly shortened action potential duration leading impaired contractility letm overexpression activated upstream autophagy regulator ampk ulk enhanced lc ii p accumulation autophagic flux impaired confirmed lc rfp gfp reporter exacerbated bafilomycin treatment dysregulated autophagy coupled mitochondrial stress increased apoptosis cleaved caspase reduced cardiomyocyte viability conclusion study indicates letm upregulation drive mitochondrial dysfunction electrophysiology alteration activation autophagy apoptosis culminating cardiomyocyte injury ischemic cardiomyopathy disrupting oxphos calcium handling cell survival pathway letm contributes ischemic remodeling cardiac dysfunction targeting letm present promising therapeutic strategy alleviate ischemic damage preserve cardiac function:0.0140144738023847",
    "174385": "background cardiac fibrosis following myocardial infarction mi drive adverse ventricular remodeling heart failure cardiac fibroblast cf playing central role gstm important member glutathione transferase gsts family play important role maintaining cell homeostasis detoxification study investigated role mechanism gstm post mi fibrosis method multi omics approach proteomics scrna seq identified gstm dysregulated target post mi fibroblast using murine coronary ligation model assessed gstm dynamic via molecular profiling western blotting immunofluorescence real time quantitative polymerase chain reaction aav mediated cardiac specific gstm overexpression achieved systemic delivery vitro study employed transforming growth factor beta tgf beta stimulated primary fibroblast sirna plasmid intervention mechanistic insight derived transcriptomics lipid peroxidation assay result expression gstm mouse cf mi significantly regulated transcriptional protein level human dilated cardiomyopathy dcm patient severe heart failure gstm expression decreased alongside aggravated fibrosis overexpression gstm post mi mouse improved cardiac function significantly reducing infarct size fibrosis compared control group vitro model demonstrated gstm markedly attenuated collagen secretion activation fibroblast well suppressed proliferation migration study revealed gstm overexpression significantly inhibited generation intracellular mitochondrial reactive oxygen specie ro pathological condition suggesting gstm exerts antioxidative stress effect post infarction fibroblast investigation molecular mechanism indicated gstm may suppress initiation progression fibrosis modulating lipid metabolism ferroptosis related pathway overexpression gstm significantly reduced lipid peroxidation free ferrous iron level fibroblast mitochondrion markedly decreased ferroptosis related indicator alleviated oxidative lipid level hydroxyeicosapentaenoic acid hepe dihydroxy octadecenoic acid dhome fibrotic condition gstm enhanced phosphorylation stat thereby upregulating downstream expression glutathione peroxidase gpx reducing ro production mitigating fibroblast activation phenotypic transformation inhibiting lipid peroxidation conclusion study identifies gstm key inhibitor fibroblast activation cardiac fibrosis highlighting ability target ferroptosis redox regulation aav mediated gstm therapy demonstrates significant therapeutic potential improving outcome post mi:0.0139177164652071",
    "170368": "background pathological cardiac remodeling critical process leading heart failure characterized primarily inflammation apoptosis matairesinol mat key chemical component podocarpus macrophyllus resin exhibit wide range pharmacological activity including anti hydatid antioxidant antitumor anti inflammatory effect purpose study aim investigate whether matairesinol alleviate cardiac hypertrophy remodeling caused pressure overload elucidate mechanism action method vitro pressure loading model established using neonatal rat cardiomyocytes treated angiotensin ii vivo model created using c mouse subjected transverse aortic constriction tac activate pi k akt foxo pathway y employed moreover small interfering rna sirna short hairpin rna shrna utilized silence prdx expression vitro vivo various technique including echocardiography wheat germ agglutinin wga staining staining psr staining masson trichrome staining used assess cardiac function cardiomyocyte cross sectional area fibrosis level rat apoptosis myocardial tissue vitro detected tunel assay reactive oxygen specie ro content tissue cell measured using dhe staining furthermore affinity prdx mat pi k analyzed using computer simulated molecular docking western blotting rt pcr utilized evaluate prdx level protein related apoptosis oxidative stress well mrna level cardiac hypertrophy fibrosis related indicator result mat significantly alleviated cardiac hypertrophy fibrosis induced tac preserved cardiac function markedly reduced cardiomyocyte apoptosis oxidative damage vitro mat attenuated ang ii induced hypertrophy nrvms activation neonatal rat fibroblast notably activation pi k akt foxo pathway downregulation prdx expression observed tac mouse however effect reversed mat treatment furthermore prdx knockdown activated pi k akt foxo pathway leading exacerbation disease molecular docking indicated molecular docking indicated mat upregulated prdx expression binding thereby inhibiting pi k akt foxo pathway protecting heart restoring prdx expression level conclusion matairesinol alleviates pressure overload induced cardiac remodeling vivo vitro upregulating prdx expression inhibiting pi k akt foxo pathway study highlight therapeutic potential matairesinol treatment cardiac hypertrophy remodeling providing promising avenue future research clinical application:0.0134646127405829",
    "142033": "calcium important second messenger cardiac function critical excitation contraction coupling relaxation heart bers also important activation signal transduction pathway responsible hypertrophic cardiac remodeling heart failure example controlling gene transcription via ca dependent signaling well cardiac development cardiac energy homeostasis eventually cell death frey et al frey et al roderick et al beating cardiomyocytes fast cycling change cytosolic ca concentration result timely coordinated interplay voltage gated ca channel sodium calcium exchanger ryanodine receptor serca atpase bers however channel pump mediating fast ca cycling beat beat cardiac action relevant physiological cardiac function also pathological process development pathological cardiac remodeling development heart failure pathological process essentially triggered neuroendocrine stimulus noradrenaline adrenaline angiotensin ii subsequently lead activation g protein dependent signaling pathway cardiomyocytes evoke ca entry ca dependent process e g activation calcineurin nuclear factor activated cell nfat cam kinase protein kinase c inducing development myocyte growth cardiac hypertrophy heineke molkentin although action sympathetic neurohormone represents adaptive response initially preserve cardiac function process triggered persistent activation long term cardiac stress lead cardiac failure many cardiovascular disease entity including arterial hypertension ischemic valvular heart disease source ca elevation mechanism whereby ca lead calcineurin activation repetitive ca concentration change contraction cycle still entirely understood sustained elevation diastolic ca level identified mechanism dolmetsch et al achieved cardiomyocytes e g increase ca transient frequency trigger remodeling process colella et al tavi et al molecular level due alteration ca release sr ca transport mechanism across plasma membrane change expression function serca ryr ip receptor sodium calcium exchanger ncx na h exchanger nhe goonasekera molkentin ca entry pathway unrelated initiating contraction evolve targeting individual channel subcellular microdomains caveolae subset l type ca channel functional makarewich et al may colocalize beta adrenergic receptor outside junctional ryanodine receptor tubular complex balijepalli et al complexity ca dependent regulation cardiac hypertrophy different molecular component vivo becomes evident considering even large increase voltage gated l type ca channel ltcc result mild cardiac hypertrophy beetz et al reduced ltcc activity also stimulate hypertrophy likely via compensatory neuroendocrine stress leading sensitized leaky sr ca release goonasekera molkentin concept different ca pool regulating contractility contractile ca remodeling signaling ca arising distinct spatial localization ca molecule furthermore complicated developmental stage neonatal adult localization atrial ventricular disease stage nonfailing failing investigated cardiomyocytes addition pathway directly associated fast ca cycling transient receptor potential trp protein uncovered recent year molecular constituent cation channel engaged example catecholamine angii cardiac cell determinant cardiac function although receptor store operated ca entry pathway previously described cardiac cell freichel et al trp protein form na ca conducting channel evoke change ca homeostasis beyond time scale beat beat ca transient mediate longer lasting modulation ca level mammalian trp protein classified according structural homology six subfamily trpc canonical trpv vanilloid trpm melastatin trpa ankyrin trpml mucolipin trpp polycystin activated numerous physical e g mechanical stretch chemical stimulus e g agonist including neurotransmitter contribute ca homeostasis directly conducting ca may contribute ca entry indirectly via membrane depolarization modulation voltage gated ca channel wu et al flockerzi nilius freichel et al thus proposed mediator different physiological pathophysiological cardiovascular process inoue et al dietrich et al abramowitz birnbaumer watanabe et al dietrich et al vennekens heart initial attention placed determine role trp channel development cardiac remodeling using vitro vivo model guinamard bois nishida kurose eder molkentin chapter summarize current knowledge regarding expression functional role trp channel ca homeostasis cardiomyocytes cardiac fibroblast contribution cardiac contractility conduction well development arrhythmia pathological remodeling process determined overexpression study cardiac cell tissue knockdown knockout corresponding gene use specific channel inhibitor based increasing experimental evidence role cardiac dy function derived animal model disease associated mutation individual trp channel becoming promising therapeutic target cardiac disease:0.0133155846197883",
    "151153": "background renin angiotensin system play crucial role development heart failure ang ii angiotensin ii act critical effector renin angiotensin system regulating cardiac fibrosis however mechanism cardiac fibrosis complex still fully understood igf r insulin like growth factor receptor multiple function maintaining cardiovascular homeostasis low dose igf treatment effective relieving ang ii induced cardiac fibrosis aimed investigate molecular mechanism igf r ang ii induced cardiac fibrosis method result using primary mouse cardiac microvascular endothelial cell fibroblast vitro experiment performed using c bl j mouse clustered regularly interspaced short palindromic repeat crispr crispr associated ca mediated igf r heterozygous knockout igf r mouse cardiac fibrosis mouse model induced ang ii week expression igf r examined quantitative reverse transcription polymerase chain reaction immunohistochemistry western blot mouse heart histologic change evaluated using masson picro sirius red staining fibrotic marker signal molecule indicating function akt protein kinase b erk extracellular signal regulated kinase nuclear factor kappab pathway detected using quantitative reverse transcription polymerase chain reaction western blot rna sequencing used explore igf r mediated target gene heart mouse association igf r g protein coupled receptor kinase identified coimmunoprecipitation important blocking igf r signaling significantly suppressed endothelial mesenchymal transition primary mouse cardiac microvascular endothelial cell mouse response transforming growth factor beta ang ii respectively deficiency inhibition igf r signaling remarkably attenuated ang ii induced cardiac fibrosis primary mouse cardiac fibroblast mouse observed patient heart failure exhibited higher blood level igf igf r healthy individual moreover ang ii treatment significantly increased cardiac igf r wild type mouse led slight downregulation igf r mouse interestingly igf r deficiency significantly alleviated cardiac fibrosis ang ii treated mouse mechanistically phosphorylation level akt erk upregulated ang ii treated mouse whereas blocking igf r signaling mouse inhibited change akt erk phosphorylation concurrently phosphorylated p nuclear factor kappab exhibited similar alteration corresponding group mouse intriguingly igf r directly interacted g protein coupled receptor kinase association decreased approximately igf r mouse addition grk deletion downregulated expression akt erk nuclear factor kappab signaling pathway primary mouse cardiac fibroblast conclusion igf r signaling deficiency alleviates ang ii induced cardiac fibrosis least partially inhibiting endothelial mesenchymal transition via akt erk nuclear factor kappab pathway interestingly g protein coupled receptor kinase associate igf r signaling directly concurrently act igf r downstream effector study suggests promising potential igf r therapeutic target cardiac fibrosis:0.0132341237405660",
    "73383": "rationale cardiac fibrosis play critical role pathogenesis heart failure excessive accumulation extracellular matrix ecm resulting cardiac fibrosis impairs cardiac contractile function increase arrhythmogenicity current treatment option cardiac fibrosis however limited clear need identify novel mediator cardiac fibrosis facilitate development better therapeutic exploiting coexpression gene network analysis rna sequencing data failing human heart identified txndc thioredoxin domain containing cardiac fibroblast cf enriched endoplasmic reticulum protein potential novel mediator cardiac fibrosis completed experiment test hypothesis directly objective objective study determine functional role txndc pathogenesis cardiac fibrosis method result rna sequencing western blot analysis revealed txndc mrna protein highly upregulated failing human left ventricle hypertrophied failing mouse left ventricle addition cardiac txndc mrna expression level positively correlated transcript encoding transforming growth factor beta ecm protein vivo txndc mrna protein increased human cf hcf transforming growth factor beta stimulation vitro knockdown txndc attenuated transforming growth factor beta induced hcf activation ecm protein upregulation independent smad smad family member whereas increasing expression txndc triggered hcf activation proliferation increased ecm protein production experiment showed txndc protein disulfide isomerase facilitated ecm protein folding depletion txndc led ecm protein misfolding degradation cf addition txndc promotes hcf activation proliferation enhancing c jun n terminal kinase activity via increased reactive oxygen specie derived nad p h oxidase transforming growth factor beta induced txndc upregulation hcf dependent endoplasmic reticulum stress activating transcription factor mediated transcriptional control targeted disruption txndc mouse txndc revealed protective effect isoproterenol induced cardiac hypertrophy reduced fibrosis approximately markedly improved left ventricle function post isoproterenol left ventricular ejection fraction versus p txndc versus wild type mouse respectively conclusion endoplasmic reticulum protein txndc promotes cardiac fibrosis facilitating ecm protein folding cf activation via redox sensitive c jun n terminal kinase signaling loss txndc protects beta agonist induced cardiac fibrosis contractile dysfunction targeting txndc therefore could powerful new therapeutic approach mitigate excessive cardiac fibrosis thereby improving cardiac function outcome patient heart failure:0.0131720964193558",
    "129287": "background calcium ca key regulator energy metabolism impaired ca homeostasis damage mitochondrion causing cardiomyocyte death pathological hypertrophy heart failure study investigates regulation role mitochondrial ca uniporter mcu chronic stress induced pathological cardiac remodeling method mcu knockout transgenic mouse infused isoproterenol iso mg kg per day week cardiac hypertrophy remodeling evaluated echocardiography histology primary cultured rodent adult cardiomyocytes treated iso nmol l hour intracellular ca handling cell death pathway monitored adenovirus mediated gene manipulation used vitro result chronic administration beta adrenergic receptor agonist iso increased level mcu mcu complex cardiac mitochondrion raising mitochondrial ca concentration vivo vitro iso also upregulated mcu without affecting regulatory protein adult cardiomyocytes interesting iso induced cardiac hypertrophy fibrosis contractile dysfunction cardiomyocyte death exacerbated global mcu knockout mouse cardiomyocytes knockout mouse overexpressing dominant negative mcu exhibited defective intracellular ca handling activation multiple cell death pathway conversely cardiac specific overexpression mcu maintained intracellular ca homeostasis contractility suppressed cell death prevented iso induced heart hypertrophy iso upregulated mcu expression activation ca calmodulin kinase ii deltab camkiideltab promotion nuclear translocation via calcineurin mediated dephosphorylation serine nuclear camkiideltab phosphorylated creb camp response element binding protein bound mcu promoter enhance mcu gene transcription conclusion beta adrenergic receptor camkiideltab creb pathway upregulates mcu gene expression heart mcu upregulation compensatory mechanism counteracts stress induced pathological cardiac remodeling preserving ca homeostasis cardiomyocyte viability:0.0130239190112756",
    "135515": "background heart failure leading cause death worldwide cyclic nucleotide phosphodiesterases pdes degradation cyclic nucleotide play critical role cardiovascular biology disease preliminary screening study revealed pde upregulation diseased heart however role pde cardiovascular biology disease largely uncharacterized current study aimed investigate regulation function pde cardiac cell progression cardiac remodeling dysfunction method used isolated adult mouse cardiac myocytes fibroblast well preclinical mouse model hypertrophy heart failure pde selective inhibitor tp global pde knock mouse used result found pde expression remains relatively low normal exercised heart tissue however pde significantly upregulated mouse human failing heart vitro pde deficiency inhibiting pde selective inhibitor tp attenuated cardiac myocyte pathological hypertrophy induced angiotensin ii phenylephrine isoproterenol affect cardiac myocyte physiological hypertrophy induced igf insulin like growth factor tp also reduced tgf beta transforming growth factor beta stimulated cardiac fibroblast activation proliferation migration extracellular matrix synthesis tp treatment elevated camp cgmp level cardiac myocytes cardiac fibroblast consistent pde camp cgmp dual specific pde vivo global pde deficiency significantly attenuated myocardial hypertrophy cardiac fibrosis dysfunction induced chronic pressure overload via transverse aorta constriction chronic neurohormonal stimulation via angiotensin ii infusion importantly demonstrated pharmacological effect tp specifically pde inhibition addition tp able reverse pre established cardiac hypertrophy dysfunction rna sequencing bioinformatics analysis identified pde regualted transcriptome involved cardiac hypertrophy fibrosis cardiomyopathy conclusion taken together study elucidates novel role pde regulation pathological cardiac remodeling development heart failure given pde proven safe drug target pde inhibition may represent novel therapeutic strategy preventing treating cardiac disease associated cardiac remodeling:0.0130120189840929",
    "111256": "increase protein activity upregulation g protein coupled receptor kinase grk hallmark cardiac stress heart failure inhibition grk improved cardiac function survival diminished cardiac remodeling various animal heart failure model aim present study investigate effect grk cardiac hypertrophy dissect potential molecular mechanism mouse observed increased grk mrna protein level following transverse aortic constriction tac conditional grk knockout mouse showed attenuated hypertrophic response preserved ventricular geometry week tac operation compared wild type animal isolated neonatal rat ventricular cardiac myocytes stimulation angiotensin ii phenylephrine enhanced grk expression leading enhanced signaling via protein kinase b pkb akt consecutively inhibiting glycogen synthase kinase beta gsk beta promoting nuclear accumulation activation nuclear factor activated cell nfat cardiac myocyte hypertrophy induced vitro grk overexpression increased cytosolic interaction grk phosphoinositide kinase gamma pi kgamma moreover inhibition pi kgamma well grk knock prevented akt activation resulting halted nfat activity reduced cardiac myocyte hypertrophy data show enhanced grk expression trigger cardiac hypertrophy grk pi kgamma mediated akt phosphorylation subsequent inactivation gsk beta resulting enhanced nfat activity:0.0129215200083132"
  },
  "Topic 3": {
    "181211": "heart failure substantial escalating global health challenge affecting million worldwide complex syndrome arises diverse etiology encompassing ischemic heart disease hypertension valvular abnormality cardiomyopathy heart failure characterized heart inability pump blood efficiently meet body metabolic demand leading debilitating symptom frequent hospitalization high mortality rate traditionally management heart failure focused alleviating symptom reducing fluid retention enhancing cardiac contractility goal achieved combination pharmacological therapy angiotensin converting enzyme inhibitor beta blocker diuretic often complemented device based intervention like implantable cardioverter defibrillator cardiac resynchronization therapy however despite advance relentless progression heart failure remains significant clinical challenge neurohormonal activation cardiac fibrosis cellular remodeling intricate process contributing disease progression recent year researcher clinician embarked quest identify novel therapeutic approach address underlying mechanism one avenue exploration involves revolutionary field gene therapy promising gene editing technique crispr ca offering potential route correcting genetic mutation contribute heart failure additionally regenerative medicine approach including stem cell therapy tissue engineering hold significant promise repairing damaged cardiac tissue restoring function furthermore precision medicine initiative gained traction aiming tailor heart failure therapy individual patient profile taking account genetics biomarkers comorbidities integrating artificial intelligence machine learning heart failure management also enabled development predictive model early intervention risk stratification personalized treatment recommendation narrative review navigates intricate landscape emerging therapy heart failure emphasizing potential revolutionize field targeting disease fundamental mechanism exploring innovative approach aspire provide comprehensive perspective evolving paradigm heart failure management fostering hopeful outlook patient clinician alike:0.0153966966342210",
    "150834": "sarcomeric hypertrophic cardiomyopathy hcm prevalent genetic disorder characterised left ventricular hypertrophy myocardial disarray increased risk heart failure sudden cardiac death despite advance understanding pathophysiology treatment option hcm remain limited narrative review aim provide comprehensive overview current clinical practice explore emerging therapeutic strategy sarcomeric hcm focus cardiac myosin inhibitor first discus conventional management hcm including lifestyle modification pharmacological therapy invasive intervention emphasizing limitation challenge next highlight recent advance molecular genetics potential application refining hcm diagnosis risk stratification treatment delve emerging therapy gene editing rna based therapy targeted small molecule cardiac myosin modulators like mavacamten aficamten hold promise modulating underlying molecular mechanism hcm mavacamten aficamten selective modulators cardiac myosin demonstrated encouraging result clinical trial reducing left ventricular outflow tract obstruction improving symptom patient obstructive hcm discus mechanism action clinical trial outcome potential implication future hcm management furthermore examine role precision medicine hcm management exploring individualised treatment strategy including exercise prescription part management plan may optimise patient outcome finally underscore importance multidisciplinary care patient centred approach address complex need hcm patient review also aim encourage research collaboration field hcm promoting development novel effective therapeutic strategy cardiac myosin modulators hopefully improve quality life outcome patient sarcomeric hcm:0.0147564713345791",
    "160461": "acute myocarditis encompasses diverse presentation inflammatory cardiomyopathy infectious non infectious trigger clinical presentation heterogeneous subtle symptom like mild chest pain life threatening fulminant heart failure requiring urgent advanced hemodynamic support review provides comprehensive overview current state knowledge regarding pathogenesis diagnostic approach management strategy direction future research acute myocarditis pathogenesis myocarditis involves interplay inciting factor subsequent host immune response infectious cause especially cardiotropic virus frequently identified precipitant however autoimmune process independent microbial trigger well toxic myocardial injury drug chemical metabolic derangement also contribute development myocarditis diverse mechanism furthermore medication like immune checkpoint inhibitor therapy increasingly recognized cause myocarditis elucidating nuance viral autoimmune hypersensitivity toxic subtypes myocarditis key guiding appropriate therapy heterogeneous clinical presentation coupled non specific symptom creates diagnostic challenge multifaceted approach required incorporating clinical evaluation electrocardiography biomarkers imaging study endomyocardial biopsy cardiovascular magnetic resonance imaging become pivotal non invasive assessment myocardial inflammation fibrosis however biopsy remains gold standard histological classification definitively establishing underlying etiology management relies supportive care disease specific therapy limited although patient recover well conservative measure severe fulminant myocarditis necessitates aggressive intervention mechanical circulatory support device transplantation immunosuppression beneficial certain histological subtypes clear evidence supporting antiviral immunomodulatory therapy majority acute viral myocarditis case remains insufficient substantial knowledge gap persist regarding validated diagnostic biomarkers optimal imaging surveillance strategy evidence based medical therapy risk stratification schema deeper understanding immunopathological mechanism rigorous clinical trial targeted therapy longitudinal outcome study imperative advance management improve prognosis across myocarditis spectrum:0.0142808702984122",
    "136821": "heart failure preserved ejection fraction hfpef major public health problem rising prevalence associated high morbidity mortality considered greatest unmet need cardiovascular medicine today general lack effective treatment address challenging syndrome national heart lung blood institute convened working group made expert hfpef novel research methodology discus research gap prioritize research direction next decade summarize discussion working group followed key recommendation future research priority uniform recognition hfpef highly integrated multiorgan systemic disorder requiring multipronged investigative approach human animal model improve understanding mechanism treatment hfpef recognized advance understanding basic mechanism role inflammation macrovascular microvascular dysfunction fibrosis tissue remodeling needed ideally would obtained improved animal model including large animal model incorporate effect aging associated comorbid condition repository deeply phenotyped physiological data human tissue made accessible researcher enhance collaboration research advance novel research method take advantage computational advance multiscale modeling analysis complex high density data across multiple domain working group emphasized need interaction among basic translational clinical epidemiological scientist across organ system cell type leveraging different area research focus research center network collaborative center accelerate basic translational clinical research pathobiological mechanism treatment strategy hfpef discussed example strategy advance research progress resource would facilitate comprehensive deep phenotyping multicenter hfpef patient cohort standardized protocol robust biorepository research priority outlined document meant stimulate scientific advance hfpef providing road map future collaborative investigation among diverse group scientist across multiple domain:0.0138483134831082",
    "39649": "new development epidemiology treatment prognosis thalassemia dramatically altered approach care affected patient development likely even greater impact next year demographic change required awareness understanding unique feature thalassemia disorder previously uncommon north america seen frequently child recognized consistently adult new method measuring tissue iron accumulation new drug remove excessive iron advancing two challenging area management thalassemia well transfusion dependent disorder improved survival patient thalassemia given new importance adult complication endocrinopathies hepatitis major impact quality life chapter describes change redefining clinical management thalassemia section dr renzo galanello describes recent advance iron chelation therapy several new chelators either licensed country clinical trial late stage preclinical development iron chelators deferiprone dfp icl orally active others hydroxybenzyl ethylenediamine diacetic acid hbed starch deferoxamine require parenteral administration may effective less frequent administration currently required deferoxamine chelation therapy employing two chelators offer possibility effective removal iron without compromising safety compliance strategy chelation therapy may take advantage ability particular chelators remove iron specific target organ heart liver section ii dr dudley pennell address cardiac iron overload frequent cause death chronic transfusion therapy cardiac complication related excessive iron may result long term iron deposition vulnerable area may due immediate effect nontransferrin bound iron cardiac disease reversible patient intensive iron chelation therapy identification cardiac problem prior onset serious arrhythmia congestive heart failure proven difficult new method using magnetic resonance imaging mri recently developed assess cardiac iron loading study suggest clinically useful relationship result using technique critical measure cardiac function measurement may help guide chelation therapy individual patient may also enhance assessment new chelators clinical trial use mri based technology also hold promise wider application non invasive assessment cardiac iron management patient thalassemia section iii dr melody cunningham describes important complication thalassemia emerging patient survive adulthood hepatitis c infection present majority patient older year however antiviral therapy patient thalassemia held back absence large clinical trial concern ribavirin induced hemolysis aggressive approach treatment hepatitis c may particularly valuable additive risk cirrhosis hepatocellular carcinoma posed infection iron overload thrombosis recognized increasing frequency significant complication thalassemia major thalassemia intermedia pulmonary hypertension focus intense study risk factor thrombosis splenectomy identified new approach anticoagulation initiated pregnancy woman thalassemia increasingly common without hormonal therapy require better understanding risk iron overload cardiac disease mother exposure fetus iron chelators section iv dr elliott vichinsky describes dramatic change epidemiology thalassemia north america hemoglobin e beta thalassemia seen increasing frequency pose particular challenge wide variability clinical severity affected patient may require little intervention others need chronic transfusion therapy may appropriate candidate hematopoietic stem cell transplantation enhancer fetal hemoglobin production may unique role hb e beta thalassemia since modest increase hemoglobin level may confer substantial clinical benefit alpha thalassemia also recognized increasing frequency north america newborn screening hemoglobin bart state leading early detection hb h disease hb h constant spring new data clarify importance distinguishing two disorder increased severity associated hb h constant spring use intrauterine transfusion sustain viability fetus homozygous alpha thalassemia created new population patient severe thalassemia raised new complex issue genetic counseling parent alpha thalassemia trait:0.0137191758082256",
    "195343": "background objective heart failure hf remains leading cause hospitalization mortality worldwide representing significant burden patient healthcare system despite advance pharmacological device based therapy readmission rate remain high traditional monitoring approach often fail detect early physiological deterioration review examines clinical utility implementation challenge remote hemodynamic monitoring hf highlighting role improving patient outcome guiding precision care method comprehensive narrative review conducted using pubmed scopus web science database identify peer reviewed english language study published past ten year result monitoring hemodynamic status essential preventing hf readmission elevated filling pressure often precede symptom previous study suggest traditional method may less effective detecting early change could contribute delay initiating treatment remote monitoring offer continuous individualized assessment shown potential reduce hospitalization though effectiveness varies across population setting telemonitoring primarily target patient higher risk hospitalization classified new york heart association nyha class iii individual comorbidities exacerbate hf remote hemodynamic monitoring present notable clinical advantage although widespread adoption face several challenge e invasiveness monitoring system limited patient adherence due technical complexity cognitive physical barrier difficulty associated comorbidities variability efficacy monitoring strategy across population difficulty faced healthcare team managing interpreting large volume real time data cost effectiveness issue related device infrastructure cost addressing limitation essential fully understanding potential remote monitoring hf care conclusion remote hemodynamic monitoring enables early detection physiological deterioration hf allowing timely intervention reduce hospitalization improve outcome emerging evidence suggests contrast traditional approach method potential support personalized data driven care integrating biopsychosocial gender intersectional perspective aligns strategy precision medicine enhancing effectiveness equity clinical practice despite promising recent advance research essential broaden scientific evidence base enhance support clinical decision making:0.0136043217096537",
    "192780": "heart failure hf complex clinical syndrome characterized heart inability meet body metabolic demand hf remains global health challenge high morbidity mortality outcome beta blocker angiotensin receptor neprilysin inhibitor arnis mineralocorticoid receptor antagonist mras hf remain suboptimal hf heterogeneous syndrome driven neurohormonal dysregulation fibrosis metabolic disturbance inflammation contributing symptom like dyspnea fatigue fluid retention recent advance pharmacological therapy including sodium glucose cotransporter inhibitor sglt inhibitor soluble guanylate cyclase stimulators sgc stimulators cardiac myosin activator shown promise hf reduced ejection fraction hfref hf preserved ejection fraction hfpef offering mechanism specific intervention moreover molecular targeted therapy clustered regularly interspaced short palindromic repeat crispr associated protein ca gene editing rna based therapeutic adeno associated virus serotype sarcoplasmic reticulum calcium atpase aav serca gene therapy emerging potential disease modifying treatment aimed addressing genetic inflammatory driver cardiomyopathy artificial intelligence ai transforming hf care enhancing predictive modelling risk stratification precision medicine application multi omics data integration ai driven tool including machine learning ml algorithm improve echocardiographic phenotyping optimize treatment strategy refine patient selection therapy despite promising development challenge data quality standardization scalability regulatory barrier remain furthermore gene therapy long term safety efficacy still uncertain concern immune response target effect sustained gene expression regenerative medicine strategy including induced pluripotent stem cell ipsc derived cardiomyocytes extracellular vesicle ev bioprinted cardiac patch offer potential solution myocardial repair however immune rejection graft integration long term viability remain significant obstacle additionally high cost associated novel biologics gene based therapy limit accessibility particularly low resource setting future hf management depends overcoming translational challenge key step include validating ai driven phenotyping tool clinical trial advancing scalable biomanufacturing technology refining regulatory framework facilitate clinical integration addressing barrier precision medicine ai regenerative therapy transform hf management providing personalized effective accessible treatment ultimately improving patient outcome globally:0.0135941813333009",
    "198787": "background objective heart failure preserved ejection fraction hfpef emerged one challenging syndrome modern cardiology due complex pathophysiology diagnostic ambiguity lack effective targeted therapy unlike heart failure reduced ejection fraction hfref hfpef encompasses highly heterogeneous patient population unified preserved left ventricular ejection fraction lvef broad definition overlook important biological clinical difference leading inconclusive result large scale therapeutic trial suboptimal patient outcome recent year advance data driven methodology unsupervised machine learning cluster analysis latent class modeling enabled identification distinct hfpef phenotype phenotype often defined demographic clinical hemodynamic biomarker profile exhibit differential prognosis treatment response method systematic review synthesizes finding study published examining phenotypic classification strategy clinical implication result despite methodological variation several recurring phenotype emerge including metabolic obese frail elderly atrial fibrillation dominant cardiorenal pulmonary hypertension right heart phenotype present distinct pathophysiological mechanism risk profile highlighting inadequacy current one size fit treatment approach review also explores prognostic value phenotype impact phenotypic variation treatment efficacy methodological challenge hinder translation clinical practice inconsistent input variable lack external validation limited integration real world data conclusion ultimately finding underscore need paradigm shift ejection fraction based classification phenotype guided management hfpef embracing precision medicine framework could enable personalized treatment strategy improve clinical trial design enhance outcome diverse patient population review concludes outlining future direction including development standardized phenotyping algorithm integration multi omic digital health data implementation pragmatic phenotype stratified clinical trial:0.0135244977722463",
    "196970": "heart failure hf complex clinical syndrome characterized heart inability maintain sufficient circulation leading inadequate organ perfusion fluid buildup thorough understanding molecular biochemical hemodynamic interaction underlie condition essential improving management enhancing patient outcome recent advancement cardiovascular research emphasized critical role micrornas mirnas post transcriptional regulator gene expression playing important part development progression hf review aim explore contribution mirnas systemic congestion marker traditional biomarkers pathophysiology heart failure objective clarifying prognostic value potential clinical application among mirnas studied mir mir p mir p identified key player process left ventricular remodeling regulation pulmonary artery pressure adaptation right ventricle finding underscore importance mirnas modulating structural functional change seen hf beyond heart hf affect multiple organ system including kidney liver marker dysfunction organ worsening renal function liver stiffness closely linked increased morbidity mortality highlight interdependence heart organ systemic congestion indicated elevated venous pressure exacerbates organ dysfunction context traditional biomarkers like natriuretic peptide cardiac troponins remain vital tool diagnosis management hf natriuretic peptide reflect ventricular strain troponins indicator myocardial injury critical risk stratification monitoring disease progression emerging diagnostic technique lung ultrasonography advanced echocardiographic method offer new way assess hemodynamic status aiding therapeutic decision making technique alongside established biomarkers provide comprehensive approach understanding complexity heart failure managing impact patient conclusion mirnas systemic congestion marker traditional biomarkers indispensable understanding hf pathophysiology determining patient prognosis integration novel diagnostic tool existing biomarkers hold promise improved strategy management heart failure however research needed validate prognostic value refine role optimizing treatment outcome:0.0134777215461443",
    "198861": "introduction cardiovascular disorder cvds remain leading cause global mortality surpassing chronic illness alarming rise cvd related death particularly among younger population intensified research effort better understand disease complication among myocardial fibrosis play central role development cardiac dysfunction heart failure given multifactorial nature diverse therapeutic strategy required manage progression effectively method comprehensive literature review conducted using database pubmed scopus elsevier clinicaltrials gov peer reviewed english language study focusing molecular mechanism therapeutic strategy myocardial fibrosis included irrelevant non english non peer reviewed source excluded data selected preclinical clinical investigation qualitatively synthesized result myocardial fibrosis arises various pathological condition including ischemia hyperlipidemia genetic disorder promote maladaptive cardiac remodeling although traditional treatment raas inhibitor beta blocker offer symptomatic relief halt disease progression recent evidence suggests multiple molecular pathway involved development fibrosis opening opportunity explore alternative therapeutic target discussion due complex pathophysiology myocardial fibrosis cannot addressed monotherapy alone anti tgf beta agent emerged promising candidate alongside newer therapy like sglt inhibitor mmp inhibitor additionally regenerative approach stem cell gene therapy offer future avenue though technical safety challenge accompany conclusion myocardial fibrosis remains critical contributor heart failure current treatment insufficient reverse course multifaceted therapeutic approach targeting different molecular mechanism hold key improved clinical outcome continued translational research crucial advancing emerging therapy bench bedside:0.0134766716274780"
  },
  "Topic 4": {
    "192425": "year old female hypertension depression asthma diagnosed chronic lymphocytic leukemia cll elevated beta microglobulin deletion q chromosome treated ibrutinib general weakness dyspnea fatigue shortness breath upper abdominal fullness discomfort splenomegaly ed oxygen saturation spo room air afebrile stable nasal oxygen l improved hypoxemia symptom exam showed bilateral crackle systolic murmur non tender abdomen splenomegaly lower extremity edema ct scan showed patchy ground glass opacity interlobular septal thickening bilateral pleural effusion diuretic given patient condition worsened requiring icu bi level positive airway pressure bipap staphylococcus hominis found blood culture vancomycin started respiratory distress necessitated mechanical ventilation intubation imaging suggested acute respiratory distress syndrome ards atypical pneumonia heart failure preserved ejection fraction transthoracic echocardiogram showed normal ejection fraction severely increased pulmonary artery pressure transesophageal echocardiogram showed vegetation blood culture monitored gram positive bacteremia biofire isolating candida zeylanoides initially subsequent culture week period positive c zeylanoides cryptococcus neoformans chest ct revealed large mass lymph node mediastinal area thought causing pulmonary hypertension compressing pulmonary artery multidisciplinary discussion ibrutinib withheld drug induced pneumonitis suspected fungemia found immunocompromised patient infectious disease team prescribed voriconazole day changed amphotericin fluconazole due lack improvement eye examination showed sign endophthalmitis lumbar puncture showed central nervous system cns fungal infection patient respiratory status worsened bronchoscopy bronchoalveolar lavage bal right middle lobe chest tube placement pleural effusion done microbiological examination bal pleural effusion revealed c neoformans klebsiella confirming disseminated c neoformans despite tough day hospital stay patient discharged stable condition physical therapy nutrition optimization used enhance health case report highlight rare serious complication cryptococcal disease patient using ibrutinib blood cancer early comprehensive diagnosis multi disciplinary involvement saved patient life:0.0186475682896331",
    "73266": "background eosinophilic myocarditis one fatal complication idiopathic hypereosinophilic syndrome given rarity form myocarditis often recognized describe young girl presented feature heart failure knowledge first reported case eosinophilic myocarditis young sri lankan female case presentation previously healthy year old sri lankan female admitted shortness breath week duration associated low grade fever profuse sweating mildly febrile dyspnoeic absent ankle oedema tachycardic elevated jugular venous pressure negative kussmaul sign blood pressure mmhg clinically cardiomegaly heart sound slightly muffled gallop rhythm bilateral basal fine end inspiratory crackle mild hepatosplenomegaly noted laboratory examination showed leucocytosis severe eosinophilia abnormal cell esr troponin brain natriuretic peptide elevated normal crp electrocardiogram showed sinus tachycardia wide spread st depression heart failure evident chest x ray echocardiogram showed global left ventricular hypokinesia ejection fraction thin layer pericardial effusion mild hepatosplenomegaly without lymphadenopathy detected ultrasound scan bone marrow biopsy showed hypereosinophilia evidence bone marrow infiltration fip l pdgfra fusion transcript bcr abl transcript detected secondary cause hypereosinophilia excluded diagnosis idiopathic hypereosinophilic syndrome eosinophilic myocarditis made good response steroid clinically biochemically complete recovery left ventricular function steroid continued least month year conclusion eosinophilic myocarditis rare fatal disease left untreated hence clinician high index suspicion diagnose eosinophilic myocarditis clinical context heart failure due myocarditis diagnosis eosinophilic myocarditis may often challenged especially poor recourse setting however available investigation used diagnose condition without delay early treatment systemic steroid may prevent fatal outcome therapy disease yet validated large prospective study:0.0178317306977891",
    "129861": "background dissecting aneurysm sinus valsalva sov interventricular septum rare entity multilobulated form dissection rupturing left ventricle lv never reported literature case summary year old male presented dyspnoea palpitation wide pulse pressure peripheral sign distal run continuous murmur along left parasternal area echocardiography revealed dilated right coronary cusp rcc burrowed interventricular septum iv forming multi loculated cystic lesion ruptured lv associated restrictive ventricular septal defect vsd severe aortic regurgitation computed tomography ct angiography confirmed cm x cm x cm multiseptated aneurysm surgery involved excision aortic valve av sinus ligation penetrating portion crest iv closure vsd av replacement postoperative echocardiography showed complete collapse iv component sov aneurysm normally functioning mechanical av discussion dissecting aneurysm iv rare variant sov aneurysm usually arising rcc mostly congenital origin wide variety presentation like congestive heart failure palpitation recurrent syncope chest pain sudden cardiac arrest infective endocarditis cerebral infarction asymptomatic aortic regurgitation present case conduction disturbance first degree block complete heart block common echocardiogram ct angio magnetic resonance imaging useful diagnosis surgical repair option treatment:0.0176634486796994",
    "138432": "infective endocarditis ie serious bacterial infection endocardium heart valve carry considerable morbidity mortality often presenting non specific symptom disease present many challenge emergency medicine practitioner year old male pertinent medical history presented emergency department complaining shortness breath stated symptom persistent last three week associated malaise fatigue ct abdomen pelvis iv contrast revealed cm hypodensity spleen concerning abscess versus infarct denied trauma iv drug use follow ultrasound ordered characterized hypodensity splenic abscess echocardiogram recommended possible ie cardiology consulted transthoracic echocardiogram performed hospital day showed minimal mitral valve thickening mild mitral regurgitation interventional radiology ir service consulted splenic abscess order perform ct guided drainage ir drain successfully placed hospital day day blood culture grew klebsiella pneumoniae hospital day patient transferred icu possible empyema formation sign respiratory distress patient underwent ct chest showed development left sided effusion patient also persistently tachycardic febrile high leukocytosis since admission worsening respiratory status transesophageal echocardiogram tee scheduled put hold due worsening respiratory status repeat tee scheduled five day later showed mitral regurgitation increased size vegetation despite antibiotic therapy two day later scheduled mitral valve repair reviewing case patient common uncommon aspect splenic abscess ie first despite respiratory symptom two week primary reason came hospital due new onset fever febrile tachycardic significant leukocytosis continued fever despite antibiotic therapy ir drainage abscess history iv drug use history negative transthoracic echocardiography lack immunocompromising condition blood culture gram negative rod ie became less likely diagnosis establishing diagnosis ie proved exceptionally complicated especially setting covid pandemic notable challenge high index suspicion despite risk factor patient previously healthy year old male medical problem ie continues clinical challenge physician especially emergency department due lack diagnostic criterion positive blood culture vegetation visualized echocardiographic study ie wide gamut presentation different level acuity diagnosis straightforward patient present obvious risk factor many case one risk factor may absent high index suspicion required especially patient additional finding splenic abscess embolic phenomenon focal neurologic deficit mycotic aneurysm decompensated heart failure new murmur pleural effusion:0.0173135883374475",
    "150142": "severe tricuspid regurgitation especially caused pulmonary hypertension primary tricuspid regurgitation absence pulmonary hypertension unknown etiology rare condition scarce data diagnosis treatment follow particularity surgery indication outcome still clearly known year old woman medical history coronary artery bypass grafting three year ago presented shortness breath low limb edema physical examination revealed prominent bilateral jugular turgescence hepatomegaly peripheral edema left midsternal border holosystolic murmur suggestive tricuspid regurgitation echocardiogram confirmed diagnosis showed preserved right left ventricular dimension function coronary angiography showed new obstructive lesion patent surgical graft right cardiac catheterization revealed mild pulmonary hypertension increased right atrium pressure cardiac magnetic resonance showed mild right ventricular dilation normal systolic function normal left chamber late gadolinium enhancement detected persistent symptom even optimization medical therapy patient submitted tricuspid valve replacement surgery immediately surgery patient developed significant right ventricular dysfunction need continuous hemodynamic support progressive clinical recovery confirmed serial echocardiogram showed improvement right ventricular volume function patient discharged sign symptom right heart failure histopathological examination showed significant diffuse myxomatous degeneration leaflet sign infection vegetation disruption strand observed report illustrates rare case symptomatic primary isolated severe tricuspid regurgitation caused myxomatous degeneration leaflet thoroughly diagnostic workup presented histopathological analysis leaflet revealed etiologic process surgical treatment indicated onset right ventricular failure essential patient full recovery:0.0172505914514703",
    "145750": "background although systemic lupus erythematosus sle affect cardiovascular system many way diverse presentation severe cardiogenic shock secondary sle myocarditis infrequently described medical literature variable presenting feature sle myocarditis also make diagnosis challenging case report allow learner consider sle myocarditis differential appreciate diagnostic uncertainty case presentation year old filipino male presented acute dyspnea pleuritic chest pain fever diffuse rash diagnosed sle six month ago treated hydroxychloroquine lab notable leukopenia non nephrotic range proteinuria elevated cardiac biomarkers inflammatory marker low complement serology suggestive active sle broad spectrum iv antibiotic corticosteroid initiated sepsis sle activity blood culture positive mssa likely skin source electrocardiogram showed diffuse st segment elevation without ischemic change ct chest demonstrated bilateral pleural pericardial effusion dense consolidation transthoracic transesophageal echocardiogram demonstrated reduced left ventricular ejection fraction lvef valvular pathology suggestive endocarditis although mssa bacteremia resolved patient rapidly developed cardiopulmonary decline repeat echocardiogram demonstrating lvef cardiac mri nondiagnostic study elucidate etiology decompensation given inability perform late gadolinium enhancement later cardiac catheterization revealed normal cardiac output non obstructive coronary artery disease clear etiology explaining dramatic heart failure endomyocardial biopsy obtained demonstrating diffuse myofiber degeneration inflammation pathological finding addition skin biopsy demonstrating lichenoid dermatitis granular full house pattern consistent sle myocarditis furthermore aggressive sle directed therapy demonstrated near full recovery heart failure conclusion although myocarditis sle flare well described cardiac manifestation progression cardiogenic shock infrequent fatal sle myocarditis promptly considered given heterogenous presentation sle combination serologic evaluation advanced imaging myocardial biopsy helpful diagnostic uncertainty exists case highlight diagnostic method clinical course de novo presentation cardiogenic shock sle myocarditis rapid improvement:0.0171855678858048",
    "71223": "case year old woman history hiv congestive heart failure secondary unknown congenital heart defect hypertension presented emergency department worsening edema room air oxygen saturation percent l oxygen via nasal cannula oxygen saturation percent physical examination notable central cyanosis facial lid edema ii vi holosystolic murmur across right chest radiating entire right back hemithorax decreased breath sound base pulmonary crackle clubbing finger edema bilateral lower extremity patient related lifelong knowledge congenital heart defect seen cardiologist adult asymptomatic yet sedentary one year ago first multiple hospitalization acute decompensated heart failure chest x ray showed massive cardiomegaly right sided calcified aortic arch patchy bilateral infiltrates transthoracic echocardiogram revealed severe right ventricular hypertrophy ventricular septal defect overriding aorta ejection fraction percent consistent unrepaired tof utilized multimodality imaging technique including ct angiography cardiac mri defined cardiac anatomy finding consistent unrepaired tof pulmonary atresia pulmonary artery arose directly aorta confluent fashion via large patent ductus arteriosus major aortopulmonary collateral artery arterialized pulmonary artery aneurysmal dissection mural thrombus formation discussion case illustrates patient rare presentation unrepaired tof pulmonary atresia go undiagnosed adulthood early recognition utilizing multimodality imaging approach lead proper diagnosing hopeful surgical repair provide considerable improvement functional status long term survival:0.0170229633053087",
    "42473": "patent arterial duct pad congenital heart abnormality defined persistent patency term infant older three month isolated pad found around full term infant higher prevalence found preterm infant especially low birth weight female male ratio patient asymptomatic duct small moderate large duct characteristic continuous heart murmur loudest left upper chest infraclavicular area typical precordium may hyperactive peripheral pulse bounding wide pulse pressure tachycardia exertional dyspnoea laboured breathing fatigue poor growth common large shunt may lead failure thrive recurrent infection upper respiratory tract congestive heart failure majority case pad identifiable cause persistence duct associated chromosomal aberration asphyxia birth birth high altitude congenital rubella occasional case associated specific genetic defect trisomy rubinstein taybi charge syndrome familial occurrence pad uncommon usual mechanism inheritance considered polygenic recurrence risk rare family isolated pad described mode inheritance appears dominant recessive familial incidence pad also linked char syndrome familial thoracic aortic aneurysm dissection associated patent arterial duct familial patent arterial duct bicuspid aortic valve associated hand abnormality diagnosis based clinical examination confirmed transthoracic echocardiography assessment ductal blood flow made using colour flow mapping pulsed wave doppler antenatal diagnosis possible pad normal structure antenatal life condition sign symptom pulmonary overcirculation secondary left right shunt must excluded coronary systemic pulmonary arteriovenous fistula peripheral pulmonary stenosis ventricular septal defect aortic regurgitation collateral vessel must differentiated pad echocardiogram preterm infant symptomatic heart failure secondary pad treatment may achieved surgical ligation medical therapy blocking prostaglandin synthesis indomethacin ibuprofen transcatheter closure duct usually indicated older child pad preterm low birth weight infant associated significant co morbidity mortality due haemodynamic instability asymptomatic patient small duct normal vital prognosis lifetime risk endocarditis patient moderate large duct significant haemodynamic alteration may develop irreversible change pulmonary vascularity pulmonary hypertension:0.0169832950635773",
    "175938": "cardiac myxoma rare benign tumor commonly located left atrium despite benign histology may present serious clinical consequence due obstruction embolism systemic symptom presentation mimic valvular heart disease heart failure often delaying diagnosis report case year old woman history diabetes hypertension presented progressive exertional dyspnea new york heart association nyha class iii evolving two week clinical examination revealed sign pulmonary congestion pulmonary hypertension transthoracic echocardiography demonstrated large heterogeneous mobile mass left atrium prolapsing mitral valve transmitral gradient mmhg estimated pulmonary artery pressure mmhg coronary angiography ruled associated coronary artery disease surgical excision mass performed successfully following day postoperative course uneventful resolution symptom histopathological examination confirmed diagnosis left atrial myxoma feature malignancy case highlight obstructive presentation left atrial myxoma mimicking mitral stenosis leading elevated left atrial pressure pulmonary hypertension echocardiography essential diagnosis surgical planning particularly given risk embolization hemodynamic deterioration clinician maintain high index suspicion structural cardiac tumor elderly patient presenting unexplained dyspnea preserved ejection fraction early recognition surgical management essential prevent serious complication ensure favorable outcome:0.0169321137934193",
    "178459": "background sinus valsalva aneurysm sovas infrequent finding generally diagnosed incidentally sova may risk rupture would lead aorto cardiac shunt patient present similarly decompensated heart failure case presentation present case year old female ruptured non coronary sova diagnosed echocardiogram evaluation exertional dyspnoea trans oesophageal echocardiogram tee revealed cm non coronary sova windsock communication right atrium patient refused surgery two year later presented florid right heart failure preserved left ventricular function right ventricle severely dilated hypokinetic right atrial enlargement finally agreeing surgery pre operative catheterization revealed non obstructive coronary significant left right shunt elevated pulmonary pressure patient suboptimal response diuretic therapy sent successful repair aneurysm closure aorto atrial fistula via bovine pericardial patch resolution left right shunt demonstrated intra operative tee right sided heart failure symptom subsequently resolved discussion sova rare finding still considered differential young middle aged patient symptom acute heart failure hemodynamic compromise new continuous heart murmur early surgical repair highly recommended prevent acute long term complication:0.0168433497423941"
  },
  "Topic 5": {
    "2079": "context result recent study effect beta blockade patient heart failure demonstrated reduction total mortality however effect beta blockade frequency hospitalization symptom quality life patient heart failure fully explored objective examine effect beta blocker controlled release extended release metoprolol succinate metoprolol cr xl mortality hospitalization symptom quality life patient heart failure design randomized double blind controlled trial preceded week single blind placebo run period conducted february october mean follow year setting three hundred thirteen site country participant patient n chronic heart failure new york heart association nyha functional class ii iv ejection fraction less stabilized optimum standard therapy intervention patient randomized metoprolol cr xl mg per day nyha class ii mg per day nyha class iii iv titrated week target dosage mg per day n matching placebo n main outcome measure total mortality hospitalization time first event number hospitalization worsening heart failure change nyha class intervention group quality life assessed substudy patient result incidence predefined end point lower metoprolol cr xl group placebo group including total mortality cause hospitalization prespecified second primary end point v event risk reduction confidence interval ci p total mortality hospitalization due worsening heart failure v event risk reduction ci p number hospitalization due worsening heart failure v p number day hospital due worsening heart failure v day p nyha functional class assessed physician mcmaster overall treatment evaluation score assessed patient improved metoprolol cr xl group compared placebo group p p respectively conclusion study patient symptomatic heartfailure metoprolol cr xl improved survival reduced need hospitalization due worsening heart failure improved nyha functional class beneficial effect patient well:0.0266874983429210",
    "23718": "background beta blocking agent reduce risk hospitalization death patient mild moderate heart failure little known effect severe heart failure method evaluated patient symptom heart failure rest minimal exertion clinically euvolemic ejection fraction less percent double blind fashion randomly assigned patient placebo patient treatment carvedilol mean period month standard therapy heart failure continued patient required intensive care marked fluid retention receiving intravenous vasodilator positive inotropic drug excluded result death placebo group death carvedilol group difference reflected percent decrease risk death carvedilol percent confidence interval percent p unadjusted p adjusted interim analysis total patient died hospitalized placebo group compared carvedilol group difference reflected percent decrease combined risk death hospitalization carvedilol percent confidence interval percent p favorable effect end point seen consistently subgroup examined including patient history recent recurrent cardiac decompensation fewer patient carvedilol group placebo group withdrew adverse effect reason p conclusion previously reported benefit carvedilol regard morbidity mortality patient mild moderate heart failure also apparent patient severe heart failure evaluated trial:0.0237910409286338",
    "47773": "background stromal cell derived factor sdf promotes tissue repair mechanism cell survival endogenous stem cell recruitment vasculogenesis stromal cell derived factor plasmid treatment patient heart failure stop hf phase ii double blind randomized placebo controlled trial evaluate safety efficacy single treatment plasmid stromal cell derived factor psdf delivered via endomyocardial injection patient ischaemic heart failure ihf method ninety three subject ihf stable guideline based medical therapy left ventricular ejection fraction lvef completed minnesota living heart failure questionnaire mlwhfq min walk distance mwd randomized receive single treatment either mg dose psdf placebo via endomyocardial injection safety efficacy parameter assessed month injection left ventricular functional structural measure assessed contrast echocardiography quantified blinded independent core laboratory stromal cell derived factor plasmid treatment patient heart failure powered based change mwd mlwhfq month result subject profile baseline mean sd age year lvef left ventricular end systolic volume lvesv ml n terminal pro brain natriuretic peptide bnp ntprobnp pg ml mlwhfq point mwd patient year post recent myocardial infarction study injection delivered without serious adverse event subject sixty two patient received drug unanticipated serious product related adverse event primary endpoint composite change mwd mlwhfq baseline month follow primary endpoint met p patient treated psdf trend toward improvement lvef month placebo v mg v mg deltalvef v v p pre specified analysis effect psdf based tertiles lvef entry revealed improvement ef lvesv lowest highest lvef patient first tertile ef received mg psdf demonstrated increase ef compared decrease placebo deltalvef p month also trend towards improvement lvesv treated patient demonstrating ml decrease compared ml increase placebo month deltalvesv ml p change end diastolic end systolic volume equated ml increase stroke volume patient treated mg psdf compared decrease ml placebo group deltasv ml p addition mg treated cohort exhibited trend towards improvement ntprobnp compared placebo month pg ml p conclusion blinded placebo controlled stop hf trial demonstrated safety single endocardial administration psdf failed demonstrate primary endpoint improved composite score month treatment pre specified analysis stop hf trial demonstrates potential attenuating lv remodelling improving ef high risk ischaemic cardiomyopathy safety profile support repeat dosing psdf degree left ventricular remodelling suggests potential improved outcome larger future trial:0.0217160231248626",
    "494": "background study evaluated short term long term effect angiotensin ii type receptor antagonist candesartan cilexetil hemodynamics neurohormone clinical symptom patient congestive heart failure chf method multicenter double blind parallel group study patient chf new york heart association class ii iii impaired left ventricular function ejection fraction pulmonary capillary wedge pressure mm hg randomly assigned week treatment placebo n candesartan cilexetil mg n mg n mg n mg n daily week placebo run period hemodynamic measurement performed right heart catheterization hour period single day repeated month treatment study drug result regression analysis time response curve single multiple dos candesartan cilexetil produced sustained significant dose dependent reduction pulmonary capillary wedge pressure short term effect p long term effect p mean pulmonary arterial pressure short term effect p long term effect p systemic vascular resistance showed trend toward decreasing dose short term long term treatment consistent change seen cardiac index compensatory increase plasma renin activity angiotensin ii level decrease aldosterone atrial natriuretic peptide dose dependent significant candesartan cilexetil improved clinical symptom stabilized patient new york heart association status compared placebo judged efficacious treatment investigator patient receiving placebo stopped trial prematurely adverse event candesartan cilexetil group excess death treatment group candesartan safe well tolerated dosage conclusion candesartan cilexetil demonstrated significant short term long term improvement hemodynamic neurohormonal symptomatic status well tolerated patient chf:0.0203312131015852",
    "103664": "background stem bark terminalia arjuna roxb ex dc wight arn arjuna used indian system medicine ayurveda treatment various cardiac disease including heart failure however well designed clinical trial exploring efficacy safety chronic heart failure chf lacking purpose ascertain add efficacy safety standardized water extract stem bark arjuna arjuna extract chf patient standard pharmacotherapy study design double blind parallel randomized placebo controlled add clinical trial method approval institutional ethic committee patient chf new york heart association nyha functional class ii standard pharmacotherapy echocardiographic left ventricular ejection fraction lvef consecutively recruited informed consent randomized arjuna extract mg matching placebo twice daily primary outcome measure change lvef week secondary outcome measure included change nyha functional class ii distance covered min walk test mwt iii quality life qol determined kansa city cardiomyopathy questionnaire kccq iv plasma brain natriuretic peptide v plasma cytokine interleukin high sensitivity c reactive protein tumour necrosis factor alpha vi oxidative stress marker serum thiobarbituric acid reactive substance tbars red blood cell rbc superoxide dismutase sod rbc catalase rbc glutathione gsh week safety assessment done adverse event monitoring laboratory investigation result expressed mean sd median interquartile range analysed intention treat principle using appropriate two sided statistical test p value considered significant result arjuna extract well tolerated change lvef versus p secondary outcome measure except preservation rbc catalase activity versus u g haemoglobin p compared placebo significantly greater percentage increase occurred distance covered mwt rbc sod rbc catalase rbc gsh symptom severity stability domain kccq patient arjuna extract versus placebo post hoc analysis subgroup patient improved outcome conclusion arjuna extract improve lvef chf patient week although improvement functional capacity antioxidant reserve symptom related qol domain patient:0.0203234137792106",
    "33923": "importance diastolic heart failure ie heart failure preserved ejection fraction common condition without established therapy aldosterone stimulation may contribute progression objective assess efficacy safety long term aldosterone receptor blockade heart failure preserved ejection fraction primary objective determine whether spironolactone superior placebo improving diastolic function maximal exercise capacity patient heart failure preserved ejection fraction design setting aldo dhf trial multicenter prospective randomized double blind placebo controlled trial conducted march april site germany austria included ambulatory patient mean age sd year female chronic new york heart association class ii iii heart failure preserved left ventricular ejection fraction greater evidence diastolic dysfunction intervention patient randomly assigned receive mg spironolactone daily n matching placebo n month follow main outcome measure equally ranked co primary end point change diastolic function e e echocardiography maximal exercise capacity peak vo cardiopulmonary exercise testing measured month result diastolic function e e decreased sd sd spironolactone increased sd sd placebo adjusted mean difference ci p peak vo significantly change spironolactone v placebo sd ml min kg sd ml min kg sd ml min kg sd ml min kg respectively adjusted mean difference ml min kg ci ml min kg p spironolactone induced reverse remodeling left ventricular mass index declined difference g ci g p improved neuroendocrine activation n terminal pro brain type natriuretic peptide geometric mean ratio ci p improve heart failure symptom quality life slightly reduced minute walking distance ci p spironolactone also modestly increased serum potassium level mmol l ci p decreased estimated glomerular filtration rate ml min ci ml min p without affecting hospitalization conclusion relevance randomized controlled trial long term aldosterone receptor blockade improved left ventricular diastolic function affect maximal exercise capacity patient symptom quality life patient heart failure preserved ejection fraction whether improved left ventricular function observed aldo dhf trial clinical significance requires investigation larger population trial registration clinicaltrials gov identifier isrctn eudra ct:0.0203023972406163",
    "99839": "background increased iron availability modifies cardiorespiratory function healthy volunteer improves exercise capacity quality life patient heart failure pulmonary hypertension hypothesised intravenous iron would produce improvement oxygenation exercise capacity quality life patient chronic obstructive pulmonary disease copd method performed randomised placebo controlled double blind trial participant copd mean sd age year haemoglobin g l ferritin microg l transferrin saturation gold grade ii iv received single dose intravenous ferric carboxymaltose fcm mg kg bodyweight saline placebo primary endpoint peripheral oxygen saturation spo rest week secondary endpoint included daily spo overnight spo exercise spo min walk distance symptom quality life score serum iron index spirometry echocardiographic measure exacerbation frequency result spo unchanged week fcm administration difference group ci however secondary analysis exercise capacity increased significantly fcm administration compared placebo mean difference min walk distance ci improvement observed iron treated placebo treated participant week p modified mrc dyspnoea scale score also significantly lower fcm fewer participant reported score fcm group compared placebo v p significant difference observed secondary endpoint adverse event rate similar group except hypophosphataemia occurred frequently fcm v p conclusion fcm improve oxygenation week patient copd however treatment well tolerated produced improvement exercise capacity functional limitation caused breathlessness effect secondary endpoint require confirmation future study trial registration number isrctn:0.0198754928434209",
    "70859": "aim determine tolerability optimal dose regimen soluble guanylate cyclase stimulator vericiguat patient chronic heart failure preserved ejection fraction hfpef method result socrates preserved prospective randomized placebo controlled double blind phase b dose finding study patient hfpef ejection fraction patient received vericiguat daily mg fixed dos mg titrated mg starting dose placebo week two primary endpoint change baseline log transformed n terminal pro b type natriuretic peptide nt probnp left atrial volume lav week patient n woman mean age year baseline atrial fibrillation randomized within week hf hospitalization outpatient treatment intravenous diuretic hf vericiguat n placebo n pooled three highest dose arm change lognt probnp vericiguat log pg ml n placebo log pg ml n one sided p two sided p change lav vericiguat ml n placebo ml n one sided p two sided p different placebo vericiguat well tolerated adverse event vericiguat mg arm placebo low discontinuation rate group change blood pressure mg compared placebo pre specified exploratory endpoint kansa city cardiomyopathy questionnaire clinical summary score improved vericiguat mg arm mean point median interquartile range baseline mean difference placebo point conclusion vericiguat well tolerated change nt probnp lav week compared placebo associated improvement quality life patient hfpef given encouraging result quality life effect vericiguat patient hfpef warrant study possibly higher dos longer follow additional endpoint:0.0194890509980703",
    "152909": "background beta ar beta adrenergic receptor stimulation improved systolic function sheep model systolic heart failure heart failure reduced ejection fraction hfref exploratory finding patient new york heart association functional class ii hfref treated beta ar agonist mirabegron supported observation measured hemodynamic response mirabegron patient severe hfref method randomized double blind placebo controlled trial assigned patient new york heart association functional class iii iv hfref left ventricular ejection fraction increased nt probnp n terminal pro b type natriuretic peptide level receive mirabegron mg daily placebo orally week add recommended hf therapy invasive hemodynamic measurement rest submaximal exercise baseline hour first study dose repeated week treatment obtained predefined parameter analysis change cardiac stroke volume index pulmonary systemic vascular resistance heart rate blood pressure result randomized patient age year men new york heart association functional class iii left ventricular ejection fraction median nt probnp ng l significant change seen hour week significantly larger increase cardiac index mirabegron group compared placebo group mean difference ci l min bsa p pulmonary vascular resistance decreased significantly mirabegron group compared placebo group ci wood unit p significant difference seen exercise difference change heart rate systemic vascular resistance blood pressure renal function group mirabegron well tolerated conclusion oral treatment beta ar agonist mirabegron week increased cardiac index decreased pulmonary vascular resistance patient moderate severe hfref mirabegron may useful patient worsening terminal hf registration url http www clinicaltrials gov unique identifier:0.0194005906321459",
    "493": "background diuretic accepted first line treatment refractory congestive heart failure chf lack response frequent event randomized single blind study performed evaluate effect combination high dose furosemide small volume hypertonic saline solution hs infusion treatment refractory new york heart association nyha class iv chf normosodic diet follow material method one hundred seven patient woman men age range year refractory chf nyha class iv different etiology unresponsive high oral dos furosemide angiotensin converting enzyme inhibitor digitalis nitrate enrolled inclusion criterion included ejection fraction ef serum creatinine level mg dl blood urea nitrogen level mg dl reduced urinary volume low natriuresis patient randomized group single blind patient group woman men received intravenous iv infusion furosemide mg plus hs ml nacl twice day minute patient group woman men received iv bolus furosemide mg twice day without hs period lasting day group received iv kcl meq prevent hypokalemia study entry patient underwent physical examination measurement body weight bw blood pressure bp heart rate hr evaluation sign chf measurement control level serum na k cl bicarbonate albumin uric acid creatinine urea glycemia daily hospitalization measurement daily output urine na k cl chest radiograph electrocardiogram echocardiogram obtained study entry hospitalization time discharge hospital treatment discharge daily dietary na intake mmol group versus mmol group fluid intake ml daily group assessment bw hour urinary volume serum urinary laboratory parameter performed daily patient reached compensated state iv furosemide replaced oral administration mg discharge hospital patient observed outpatient weekly first month subsequently month result group similar age sex ef risk factor treatment etiology chf patient showed clinical improvement ten patient group hyponatremia entry significant increase daily diuresis natriuresis observed group significant group receiving hs p serum na level increased group decreased group p serum k level decreased group p bw reduced group p group increase serum creatinine level serum uric acid level increased group bp value decreased hr corrected normal value group follow period month patient group readmitted hospital heart failure group patient readmitted hospital higher class discharge twenty four patient group died follow versus patient group p conclusion treatment effective well tolerated improves quality life relief sign symptom congestion may delay aggressive treatment effect also beneficial long period mortality reduction v survival rate clinical improvement:0.0193673497953786"
  },
  "Topic 6": {
    "142883": "background propionic acidemia pa myocardial involvement common includes development cardiomyopathy life threatening acute heart failure acquired long qt syndrome sought investigate echocardiographic parameter left ventricular systolic diastolic function indicate early cardiac disease manifestation pa method prospective observational study cross sectional design tertiary medical care center individual confirmed pa enrolled following cardiac investigation performed study individual echocardiographic measurement systolic diastolic left ventricular lv function lv fractional shortening lv f lv ejection fraction biplane modified simpson lv ef mitral annular plane systolic excursion mapse lv global longitudinal strain lv gls speckle tracking echocardiography ste pulsed doppler analysis mitral valve mv inflow velocity mv e mv deceleration time dt e tissue doppler imaging tdi mitral annulus mv e e lv myocardial performance index lv mpi lv left atrial la diameter assessed lead electrocardiogram ecg recorded corrected qt interval qtc calculated clinical phenotype laboratory parameter time cardiac investigation assessed besides descriptive analysis analyzed frequency onset combination echocardiographic ecg data well correlation clinical biochemical finding effect age visit lv functional parameter qtc analyzed multiple regression result total patient confirmed pa enrolled median age pa onset day range day median age visit cardiac evaluation year range year lv gls abnormal lv ef mapse mv e e lv mpi lv f mv e case normal near normal lv f lv gls pathological lv ef mapse probability developing lv dysfunction systolic diastolic increase age lv mpi reliable parameter indicate systolic lv dysfunction combination dilated lv e dilated cardiomyopathy dcm pa multiple regression reveals significant positive association lv diameter qtc abnormal lv gls significantly correlate reduced muscle strength muscle tone abnormal gross motor function conclusion data suggests high prevalence cardiac disease manifestation pa considerably higher previous study lv f used assess lv function usage advanced echocardiographic technique lv gls assessment may allow early detection subtle lv dysfunction pa may lead timely cardiac treatment also consideration liver transplantation prevent development manifest cardiac complication:0.0225416443956284",
    "84386": "background b type natriuretic peptide bnp used widely objective marker severity prognostic predictor heart failure recently reported plasma bnp level associated left ventricular lv diastolic dysfunction color kinesis ck technique based acoustic quantification developed facilitate evaluation regional wall motion lv function aim study investigate relationship plasma bnp level lv diastolic function using diastolic ck imaging method result study included subject sinus rhythm referred echocardiography evaluate cardiac function simultaneous measurement plasma bnp thirty five patient new york heart association class ii class iii iv performed echocardiography assessment lv function including lv ejection fraction ef transmitral flow e early diastolic mitral annular velocity e diastolic ck diastolic ck image obtained lv mid papillary short axis view analyzed using ick software ck diastolic index ck di defined calculated lv segmental filling fraction first diastole expressed percentage mean ck di determined average ck di six segment anterior anteroseptal septal inferior posterior lateral wall blood bnp collected day echocardiographic study found significant correlation mean ck di log bnp r p whereas log bnp correlated weakly ef r e r dt r e e r conclusion result suggest plasma bnp level may related lv relaxation analysis diastolic ck may useful quantitative assessment lv diastolic function patient heart failure:0.0224206548300147",
    "99296": "background left ventricular lv diastolic dysfunction main cause heart failure preserved ejection fraction hfpef characterized lv stiffness relaxation abnormal lv global longitudinal strain gls frequently observed l hfpef shown useful identifying hfpef patient high risk cardiovascular event cardiovascular magnetic resonance cmr feature tracking cmr ft enables reproducible non invasive assessment global strain cine cmr image however association gls invasively measured parameter diastolic function investigated sought determine prevalence severity gls impairment patient hfpef using cmr ft evaluate correlation gls measured cmr ft measured invasive diastolic functional index method eighteen patient hfpef age sex matched healthy control subject studied subject underwent cine pre post contrast mapping late gadolinium enhancement cmr hfpef patient invasive pressure volume loop obtained evaluate lv diastolic property gls quantified cine cmr extracellular volume fraction ecv quantified pre post contrast mapping known imaging biomarker predicting lv stiffness result gls significantly impaired patient hfpef v p thirty nine percent hfpef patient showed impaired gls cut statistically significant difference found ecv hfpef patient control v p hfpef patient time constant active lv relaxation tau strongly correlated gls r p global circumferential strain gc r p global radial strain grs r p multiple linear regression analysis revealed gls independent predictor altered tau beta p among age lv end diastolic volume index lv end systolic volume index lv mass index gc grs gls conclusion cmr ft noninvasive approach enables identification subgroup hfpef patient impaired gls cmr lv gls independently predicts abnormal invasive lv relaxation index tau measurement hfpef patient finding suggest feature tracking cmr analysis conjunction ecv may enable evaluation diastolic dysfunction patient hfpef:0.0222574067944649",
    "199048": "objective research investigated application real time three dimensional speckle tracking imaging rt sti evaluate left atrial la function individual suffering hypertensive heart disease hhd heart failure preserved ejection fraction hfpef material method retrospective study included patient hhd hfpef hospitalized august june hfpef group healthy individual undergoing physical examination comprised control group patient data collected echocardiography performed measure la diameter lad left ventricular end diastolic diameter lvedd interventricular septal thickness ivst left ventricular posterior wall thickness lvpwt left ventricular outflow tract diameter lvotd early diastolic maximum velocity mitral valve inflow mve late diastolic maximum velocity mitral valve inflow mva early diastolic late diastolic velocity mitral annulus measured tissue doppler ultrasound e tricuspid annular plane systolic excursion tapse left ventricular ejection fraction lvef la image analyzed using ge software following parameter measured l emptying fraction laef la emptying volume laev lavolume onset contraction lavprea minimum la volume lavmin maximum la volume lavmax la strain reservoir phase lasr la strain contraction phase lasct la strain conduit phase lascd roc curve adopted evaluate diagnostic value la parameter hfpef pearson correlation analysis examined relationship parameter n terminal pro b type natriuretic peptide nt probnp result compared control group blood pressure hfpef group significantly higher p lt hfpef group nt probnp concentration significantly greater observed control group p lt statistically significant variance detected lvef lvedd lvotd tapse mve mva ratio e wave velocity wave velocity e laev lavmin lavprea two group p gt compared control group hfpef group dramatically higher lad ivst lvpwt p lt hfpef group also lower e laef lasr lascd lasct e e maximum la volume index lav imax lavmax higher p lt lasr negatively associated nt probnp r p whereas significant correlation found among lascd lasct nt probnp p gt conclusion la strain parameter serve non invasive method quantitatively assessing la dysfunction patient hfpef:0.0221254490860385",
    "14596": "background spectrum diabetic heart disease involves progression normal heart preclinical left ventricular diastolic systolic dysfunction followed overt echocardiographic evidence left ventricular lv dysfunction finally symptomatic heart failure objective compare value tissue doppler imaging tdi conventional echocardiography assessment early myocardial dysfunction type diabetic correlation serum n terminal pro brain natriuretic peptide nt pro bnp state metabolic control diabetes duration method sixty subject included type diabetic aged year twenty matched subject served control subjected clinical examination assessment cardiovascular reflex autonomic neuropathy laboratory investigation included mean random blood sugar mrbs hemoglobin c hba c urinary microalbumin serum determination nt pro bnp echocardiography chamber dimension systolic diastolic function tie index longitudinal myocardial global biventricular function pulsed tdi lv wall right ventricle rv free wall result diabetic control normal lv dimension lv mass index systolic function except higher left ventricular posterior wall lvpw diabetic p lv rv diastolic dysfunction diagnosed diabetic conventional doppler higher peak p p lower e p p compared control diabetic larger tie index p tdi showed delayed myocardial relaxation diabetic lower lv rv peak em p p em p p compared control nt pro bnp elevated diabetic p best cut value fmol ml sensitivity specificity detection isolated diastolic dysfunction diabetic correlated negatively lv em p em p positively p impaired diastolic velocity associated higher hba c conclusion asymptomatic diabetic evidence subtle right lv dysfunction delayed myocardial relaxation related metabolic control tissue doppler td additional value evaluating ventricular filling nt pro bnp considered sensitive specific predictive marker diastolic dysfunction:0.0217805040023203",
    "44434": "background combination early transmitral inflow velocity mitral annular tissue doppler imaging e em ratio widely applied noninvasively estimate left ventricular lv filling pressure however e em ratio significant gray zone accuracy patient heart failure debated left atrial la deformation analysis speckle tracking echocardiography ste recently proposed alternative approach estimate lv filling pressure study aimed exploring correlation la longitudinal function ste doppler measurement direct measurement lv filling pressure patient heart failure method total patient advanced systolic heart failure ejection fraction undergoing right heart catheterization studied simultaneously pulmonary capillary wedge pressure pcwp determination peak atrial longitudinal strain pal mean e em ratio measured subject two independent operator pal value obtained averaging segment global pal separately averaging segment measured chamber chamber view result significant correlation found mean e em ratio pcwp r close negative correlation global pal pcwp found r p furthermore global pal demonstrated highest diagnostic accuracy auc excellent sensitivity specificity respectively predict elevated filling pressure using cutoff value less bland altman analysis confirmed close agreement pcwp estimated global pal invasive pcwp mean bias mmhg conclusion group patient advanced systolic heart failure e em ratio correlated poorly invasively obtained lv filling pressure however la longitudinal deformation analysis ste correlated well pcwp providing better estimation lv filling pressure particular clinical setting:0.0216110807500139",
    "103638": "background echocardiographic evaluation longitudinal axis left ventricular lv function used diagnosis assessment heart failure normal ejection fraction hfnef evaluation global segmental peak systolic longitudinal strain pslss two dimensional speckle tracking echocardiography ste may correlate conventional echocardiography finding aimed use ste evaluate longitudinal function lv patient hfnef method study patient hfnef diastolic dysfunction normal subject conventional echocardiography underwent ste evaluation including lv end diastolic end systolic dimension interventricular septal thickness posterior wall thickness lv volume lv ejection fraction left atrial volume index early diastolic peak flow velocity late diastolic peak flow velocity ratio deceleration time early diastolic myocardial velocity e late diastolic myocardial velocity systolic myocardial velocity global basal mid apical pslss correlation method assessed result mean age year hfnef patient year control group hfnef group comprised male female normal group consisted male female global basal mid apical pslss significantly lower hfnef group p value significant positive correlation global psls septal e p value negative correlation global psls e e ratio p value significant negative correlation e e ratio mid psls p value basal psls p value weak positive correlation septal e mid psls p value basal psls p value also weak negative correlation isovolumic relaxation time global psls p value mid psls p value also new york heart association functional class mid psls p value basal psls p value conclusion hfnef patient conventional echocardiography different ste finding compared normal subject indicative diastolic dysfunction longitudinal systolic function lv measured ste reduced segment denoting degree subclinical systolic dysfunction patient:0.0215194101608736",
    "104089": "background transplanted heart dysfunction serious life threatening condition pediatric transplant recipient several study focused echocardiographic detection early sign cardiac dysfunction population evaluated advanced echocardiographic index cardiac function large sample child young adult heart transplant apparently normal cardiac function method study included patient normal ejection fraction transplantation performed pediatric age healthy control subject patient control subject underwent complete transthoracic echocardiographic examination including tissue doppler analysis dimensional speckle tracking dimensional echocardiography two dimensional speckle tracking analysis used obtain measure left ventricular lv radial circumferential longitudinal strain derive lv twist torsion basal apical rotation three dimensional echocardiography used measure lv volume ejection fraction evaluate lv systolic synchrony result difference observed group lv volume left atrial diameter lv ejection fraction right ventricular fractional area change however patient showed lower value longitudinal systolic excursion valvular plane mitral tricuspid valve level well higher mitral e e ratio cardiac radial strain similar group significant net reduction global left right ventricular longitudinal strain lv global circumferential strain could observed group p addition reduced lv twist torsion found patient compared healthy control subject p mainly owing significant reduction basal rotation degree v degree p none control subject demonstrated lv dyssynchrony whereas systolic dyssynchrony observed heart transplant recipient conclusion even absence sign graft failure presence normal ejection fraction transplanted heart show significant reduction biventricular function additional prognostic study needed establish whether abnormality predict development overt heart failure:0.0213425221673209",
    "169003": "objective adhd one common neurodevelopmental disorder seen child adolescent often treated various pharmacological agent especially methylphenidate differing opinion literature regarding cardiovascular safety long term methylphenidate use study suggest drug may increase risk hypertension myocardial infarction ventricular arrhythmia sudden cardiac death cardiomyopathy heart failure hf pulmonary hypertension stroke study aimed compare clinical echocardiographic characteristic patient diagnosed adhd using long acting methylphenidate extended period age gender matched healthy volunteer material method total patient diagnosed adhd using long acting methylphenidate year healthy volunteer referred clinic included study patient evaluated basic advanced technique motion mode mode two dimensional doppler speckle tracking ste using transthoracic echocardiography data evaluated instantly processing strain image analysis program result statistically significant difference observed case control group term body mass index bmi systolic blood pressure sbp bmi negatively correlated sbp positively correlated methylphenidate use duration significant difference group apical four chamber three chamber two chamber global longitudinal strain gls value obtained ste technique indicating early deterioration left ventricular lv lateral e value indicates diastolic dysfunction lower drug group still within normal limit lateral lv e right ventricular rv e rv value showed significant negative correlation duration drug use remained within normal limit parameter evaluating systolic diastolic function e e left ventricular ejection fraction lvef myocardial performance index mpi tricuspid mitral annular plane systolic excursion tapse mapse differ significantly group within normal limit valve structure regurgitation also significantly different two group conclusion considering parameter conclude long term use long acting methylphenidate cause cardiovascular dysfunction late adolescent early adult individual observed difference e lateral value case control group well slight correlation lateral lv e rv e rv value duration use directly indicate cardiac dysfunction:0.0212231050910948",
    "150937": "background diabetes mellitus dm documented among strongest risk factor developing heart failure preserved ejection fraction hfpef earliest imaging change patient dm left atrial la functional volumetric change aim study determine correlation epicardial fat thickness eft longitudinal la reservoir strain lars patient type dm dm compared non diabetic control result study sample case control study comprised consecutive patient dm n matched non diabetic control n echocardiography performed patient eft volumetric longitudinal lars left ventricular lv global longitudinal strain lvgls pulsed wave doppler derived transmitral early e wave late wave diastolic velocity tissue doppler derived mitral annular early diastolic e peak systolic velocity obtained study result demonstrated patient dm thicker eft v mm increased la volume index lavi v ml comparison non diabetic one p value respectively hand direct association observed eft e e ratio inverse correlation established eft lars patient dm r p value r p value respectively however regression analysis showed lv mass index lvmi beta ci p value lavi beta ci p value eft beta ci p value independently correlated lars conclusion lars considered important early marker subclinical cardiac dysfunction thickened epicardial fat may independent risk factor decreased la reservoir strain diabetic especially considered high risk group due increased epicardial adipose tissue thickness:0.0211449885537124"
  },
  "Topic 7": {
    "198383": "objective heart failure important health problem patient generally older several comorbidities multidisciplinary heart failure care therefore recommended however little evidence real world setting involve primary care health professional evaluate programme main objective study integrate evaluate several disease management intervention primary care setting design prospective non randomised observational implementation study mixed method process evaluation conducted year setting primary care practice two regional hospital one tertiary one secondary leuven region belgium serving approximately inhabitant participant general practitioner gps practice participated total patient included disease management programme inclusion criterion patient included high risk status heart failure hf readmission based clinical criterion exclusion criterion explicitly defined participation required informed consent intervention four intervention implemented online hf education gps reimbursed natriuretic peptide np testing patient education trained primary care hf educator structured transitional care protocol posthospital discharge primary secondary outcome measure primary outcome included gp self efficacy hf management np testing rate hf registration electronic health record patient self efficacy item european heart failure self care behaviour scale ehfscb secondary outcome included patient quality life short form questionnaire sf hospital readmission rate provider satisfaction result gps felt competent management hf online education eight point increase self efficacy score month follow ci p gps conducted reimbursed np test half scored age specific threshold referral initiation significant increase np testing bayes factor total rate test per patient year proportion registered hf patient aged year older gps electronic health record increased patient included disease management programme inclusion followed transitional protocol discharge hf significant improvement patient self efficacy month follow ehfscb score change point ci significant change quality life sf score change point ci adherence transitional protocol depended presence specialist hf nurse admission patient seen within day discharge general practitioner time trend analysis revealed increase hf secondary rather primary cause admission participating healthcare professional reported satisfaction programme conclusion impact b study demonstrated integrated disease management programme hf could implemented assessed routine clinical practice programme resulted increased awareness registration hf primary care increased self management patient improved follow discharge although result interpreted cautiously given uncontrolled pre post study design trial registration trial registration nct clinicaltrials gov:0.0203048062002236",
    "172992": "background heart failure hf remains disease notable disparity rural veteran despite recent advancement clinical treatment managing hf home stressful complex rural veteran experience unique barrier optimal physical mental health necessitating adequate support problem solving skill objective study aim adapt rural sociocultural context culturally sensitive tailored telephone support problem solving intervention care hf supporting physical mental health rural veteran heart failure using finding preliminary qualitative research evaluate effect care hf problem solving physical mental health outcome among rural veteran hf method study involves repeated measure single group design intervention content adapted tailored rural sociocultural context using preliminary qualitative data guided theory social problem solving stress appraisal coping veteran recruited veteran administration home based cardiac rehabilitation clinic cardiology clinic serve veteran veteran based community resource center social medium campaign veteran hf n receive care hf intervention nurse led intervention comprises telephone session use five step problem solving process manage common hf problem home identifying problem viewing positive manner goal setting generating potential strategy problem management choosing implementing strategy manage problem evaluating strategy effectiveness veteran receive initial problem solving training first session follow session focusing problem solving skill reinforcement assisting veteran applying principle manage self identified hf related problem experienced home data collected baseline month baseline problem solving outcome interest ie hf self care hf symptom health care utilization depressive symptom anxiety hf specific health related quality life stress resilience coping demographic data analyzed using descriptive statistic multilevel growth curve modeling restricted maximum likelihood estimation compare series model using akaike information criterion bayesian information criterion fit index controlling covariates result recruitment started april december enrolled veteran recruitment anticipated end june data collection continuing enrolled veteran completed month follow period conclusion adapting testing culturally sensitive tailored telephone intervention aid support problem solving home potential provide individualized care rural veteran reside thereby reducing travel burden also increasing access evidence based care program effective telephone support problem solving intervention could low cost accessible method improve physical mental health rural veteran hf trial registration clinicaltrials gov nct http clinicaltrials gov study nct international registered report identifier irrid derr:0.0201633754320296",
    "128554": "background despite growing prevalence people complex condition evidence positive impact telemonitoring single condition little research exists telemonitoring population objective randomized controlled trial embedded qualitative study aim evaluate impact experience patient health care provider hcps using telemonitoring system decision support manage patient complex condition including multiple chronic condition compared standard care method pragmatic unblinded month randomized controlled trial sought recruit patient diagnosis heart failure hf uncontrolled hypertension ht insulin requiring diabetes mellitus dm outpatient specialty setting toronto ontario canada participant randomized control telemonitoring group latter instructed take reading relevant condition telemonitoring system contained algorithm generated decision support form actionable self care directive patient alert hcps primary outcome health status item short form health survey questionnaire secondary outcome included anxiety depression self efficacy chronic disease management self reported health service use hf related quality life self care measure also collected patient followed hf within group change score analyzed statistical significance p convenience sample hcps patient intervention group interviewed experience result total patient recruited randomized recruitment terminated early implementation challenge onset covid pandemic significant within group difference found main primary secondary outcome however within group analysis patient hf found improvement self care maintenance p physical quality life p opinion expressed hcps patient interviewed differed based monitored condition although patient hf reported benefitting actionable self care guidance meaningful interaction hcps patient hcp user dm ht module think telemonitoring improved clinical management condition degree differing experience largely attributed siloed nature specialty care design decision support whereby fluctuation status ht dm typically required less urgent intervention compared patient hf conclusion recommend future research conceive telemonitoring program self management clinical decision support necessary sufficient component program patient complex condition lower acuity conclude telemonitoring patient complex condition within multidisciplinary care setting may best operationalized nurse led model care trial registration clinicaltrials gov nct http clinicaltrials gov ct show nct international registered report identifier irrid rr resprot:0.0198695356007934",
    "93493": "background heart failure hf associated high rate hospitalization morbidity mortality cost remote patient monitoring mobile health mhealth show promise improving self care hf management thus increasing quality care reducing hospitalization cost however limited information exists regarding perception older adult hf mhealth use objective study aimed compare perspective older adult hf randomized either mhealth equipment connected hour call center digital home equipment standard care regard ease satisfaction equipment provider communication engagement ability self monitor manage disease method performed pilot study using mixed method descriptive design pre postsurveys following participant week augmented data semistructured qualitative interview learn feasibility satisfaction communication self management result enrolled patient hf aged year male non hispanic white multiple comorbid condition baseline rated health fair poor often always frustrated discouraged health baseline monitor weight monitor blood pressure monitor symptom post intervention equipment group home monitored daily technology anxiety indicated technology made nervous reported fear technology without significant change post intervention technology usability post intervention scored high reflecting ease use majority indicated health care provider managing health reported one trust question provider moreover believed better seek professional help caring oneself post intervention mhealth user relied mirrored home equipment standard care group participant satisfied communication engagement provider yet many described access problem distressing symptom unpredictable prevailed week provider visit visit emergency department nurse call center received reading completed telephone call participant narrative data revealed following main theme traditional communication engagement provider prevailed delaying access care home monitoring technology described useful mhealth user felt secure knowing someone observing equipment group felt confident self monitoring managing finally uncertainty frustration persistent health problem conclusion mhealth equipment feasible potential improve patient centered outcome increase self management older adult hf:0.0198508064353472",
    "137097": "background mobile health mhealth apps dramatically changing patient provider manage monitor chronic health condition especially area self monitoring african american higher mortality rate heart failure racial group united state therefore self management heart failure may improve health outcome african american patient objective aim present study determine feasibility using mhealth app explore outcome quality life including self care maintenance management confidence among african american patient managing condition discharge diagnosis heart failure method prior development app conducted qualitative interview african american patient diagnosed heart failure african american patient diagnosed cardiovascular disease health care provider cardiologist nurse practitioner geriatrician worked heart failure patient addition asked hospital chaplain provide positive spiritual message patient since spirituality important coping method many african american formative data used creating prototype app named healthy heart specifically healthy heart app incorporated following evidence based feature promote self management one way message journaling ie weight symptom graphical display data customized feedback ie clinical decision support based daily weekly weight educational message heart failure self management derived teaching material provided patient diagnosed heart failure included information diet sleep stress medication adherence information condensed simplified appropriate text message meet health literacy standard message derived interview conducted formative stage app development including interview african american chaplain usability testing conducted series meeting nurse social worker computer engineer pilot one group pretest posttest design employed participant using mhealth app week descriptive statistic computed demographic variable overall subscales health related quality life scale hqol subscales self care heart failure index schfi version using frequency categorical measure mean standard deviation continuous measure baseline postintervention comparison computed using fisher exact test overall health paired test hqol schfi questionnaire subscales result total african american participant men woman aged year diagnosed heart failure recruited study significant increase quality life p clinically relevant change self care maintenance management confidence observed conclusion mhealth app assist self management heart failure feasible patient low literacy low health literacy limited smartphone experience based clinically relevant change observed feasibility study healthy heart app research explore effectiveness vulnerable population:0.0195631029915853",
    "198513": "background heart failure prevalent debilitating condition affecting million globally imposing significant burden patient family health care system despite advancement medical treatment gap effective continuous personalized supportive care remains glaringly evident address pressing issue virtual health care service delivered interdisciplinary team represent promising solution understanding outcome experience remote monitoring enabled interdisciplinary chronic disease management program inform resource allocation health care policy decision objective purpose study evaluate clinical behavioral outcome patient undertaking virtual home health heart failure program vhhhfp explore experience patient health care practitioner hcps method vhhhfp virtual postdischarge support service patient heart failure includes intensive month period followed maintenance period delivered interdisciplinary team mixed method study conducted patient hcps self reported outcome data kccq kansa city cardiomyopathy questionnaire phq patient health questionnaire pam patient activation measure prems patient reported experience measure obtained record patient n completed intensive phase vhhhfp interview conducted patient n hcps n paired test used compare quantitative data month intervention thematic qualitative analysis undertaken interview data result thirty one patient completed baseline month follow kccq assessment mean kccq summary score month sd significantly higher mean summary score baseline sd p finding similar kcccq subscales physical limitation mean sd mean sd p quality life mean sd mean sd p symptom frequency median iqr median iqr p social limitation median iqr median iqr p phq measure psychological health completed patient median score baseline follow total distress median iqr median iqr p anxiety subscale median iqr median iqr p reduced time six hospital admission recorded patient within day nine patient interview aligned value based health care vbhc capability comfort calm ccc framework three theme identified follows enhanced patient capability improved patient comfort positive influence calm six health care professional shared experience vhhhfp three emerging theme improved patient capability shared decision making improving capability care practice promoting comfort calm virtual coordination collaboration conclusion use technology support management hf area growth study contributes understanding remote patient monitoring interdisciplinary chronic disease support integrated existing system improve clinical outcome patient:0.0195411653136247",
    "91662": "background end life may time high service utilisation older adult transition care setting occur frequently may produce little improvement symptom control quality life patient ensuring patient experience co ordinated care move occur individual need rather system imperative crucial patient well containing health care cost objective aim study understand experience influence consequence transition setting older adult end life three condition focus study chosen represent differing disease trajectory setting england participant thirty patient aged year last year life diagnosed heart failure lung cancer stroke caregiver decedent aged year died heart failure lung cancer stroke chronic obstructive pulmonary disease selected cancer provider commissioner service primary care hospital hospice social care ambulance service design method mixed method study composed four part depth interview older adult qualitative interview structured questionnaire bereaved carers older adult decedent telephone interview care commissioner provider using case scenario derived interview carers analysis linked hospital episode statistic he mortality data relating hospital admission heart failure lung cancer england result transition care setting last year life common component end life care across data set made study many move made shortly death patient carers experience transition disjointed system organisational process prioritised individual need many case family carer co ordinator provider care home excluded participation institutional care lacking information support extend role confidence general practitioner gp valued central figure end life care across setting though discipline critical gps expertise adherence guideline hour service care home identified many contributor unnecessary transition good relationship communication professional different setting sector recognised family one important influence transition rarely acknowledged staff conclusion development shared understanding professional carer role end life transition may one effective way improving patient experience patient carers manage many aspect end life care identifying way extend skill strengthen voice particularly hospital setting would welcomed may reduce unnecessary end life transition experience carers appear changed little despite implementation range relevant policy important question answered recommendation future research include relationship policy intervention experience end life carers identification way harmonise understanding carers role strengthen voice particularly hospital setting identification way reduce influence interprofessional tension end life care development intervention enhance patient experience across transition funding national institute health research health service delivery research programme:0.0195190316052639",
    "139905": "introduction despite evidence cardiac rehabilitation cr essential component care people heart failure uptake low centre based format known barrier suggesting home based programme might improve accessibility aim scot rehabilitation enablement chronic heart failure reach hf assess implementation reach hf home based cr intervention context national health service nh scotland paper present design protocol observational implementation study specific objective scot reach hf assess service level facilitator barrier implementation reach hf compare real world patient caregiver outcome seen prior clinical trial estimate economic health social impact implementing reach hf scotland method analysis reach hf intervention delivered partnership four beacon site across six nh scotland health board covering rural urban area health professional site trained facilitate delivery week programme people heart failure caregiver patient caregiver outcome assessed baseline month follow assessment include minnesota living heart failure questionnaire mlhfq five dimension euroqol l hospital anxiety depression scale caregiver burden questionnaire qualitative interview conducted health professional involved programme delivery eg cardiac nurse physiotherapist facilitator patient consultation audio recorded assessed fidelity integrative analysis address key research question fidelity context cr participant related outcome scot reach hf finding inform future potential roll reach hf scotland ethic dissemination study given ethical approval west scotland research ethic service reference w approved march written informed consent obtained participant study listed isrctn registry study id isrctn research team ensure study conducted accordance general data protection regulation university glasgow research governance framework finding reported funder shared beacon site facilitate service evaluation planning good practice broaden interest understanding reach hf seek publish peer reviewed scientific journal present stakeholder event national international conference:0.0194508130426467",
    "164237": "aim identify describe self care behaviour performed chinese immigrant living cardiovascular disease australia factor perceived barrier facilitator evidence based cardiac self care design qualitative descriptive design method individual semi structured phone interview conducted among participant meeting following criterion first generation chinese immigrant australia born mainland china hong kong macao taiwan australian permanent resident citizen self reported medically diagnosed coronary heart disease stroke heart failure able speak english mandarin able provide informed consent excluding history evidence impaired cognition dementia participant recruited via social medium chinese community association medical centre september june data analysed using inductive deductive thematic analysis guided middle range theory self care chronic illness study reported line coreq checklist result twenty participant interviewed female mean age year migrated australia older age following retirement china limited english proficiency many practiced adequate self care cvd self care maintenance monitoring variously adopted heart healthy diet developed exercise routine attended medical service closely monitored body sign symptom however self adjusting medication taking traditional chinese medicine self administering health supplement prevalent practice first response management acute cardiac symptom suboptimal linguistic cultural barrier obtaining mainstream heart health information meant participant resorted informal anecdotal mainland chinese source conclusion diverse factor held responsible sub optimal self care behaviour lack access linguistically culturally appropriate heart health information widely blamed linguistically culturally appropriate community based heart health education programme urgently needed targeting healthy lifestyle modification medication literacy cardiac symptom management impact study finding used improve cardiac nurse cultural sensitivity practice targeting chinese immigrant partnering chinese community association offer health service provider policymakers innovative route co design deliver targeted heart health education intervention support population public contribution chinese community centre manager contributed data collection supporting participant recruitment:0.0192030911852686",
    "62761": "review question objective objective review identify effectiveness group visit patient heart failure hf knowledge quality life self care behavior hospital readmission research question background heart failure hf continues major health burden throughout world currently million american million european australian living hf number expected double patient caregiver perform majority hf care home patient hf need learn successful self managing condition lessen burden symptom fatigue dyspnea edema patient education primary process used increase knowledge self care practice patient hf patient hf need follow complex medical regimen adhering low sodium diet prescribed fluid restriction addition patient monitor physical condition daily exacerbation symptom sign fluid overload education behavior modification skill development necessary patient hf successful self managing condition hf education occurs one one visit patient health care provider examination room regular clinic visit however usually limited time address needed education topic depth meaningful manner information patient take home utilize daily routine group visit provide alternative venue provide care complex patient population group visit interactive process health care provider small group patient caregiver usually share common medical concern participant group visit benefit knowledge experience participant providing support encouragement learn cope living chronic condition process group visit first developed dr john c scott kaiser permanente system colorado united state dr scott nurse held monthly group visit lasting minute group patient manage complex medical condition group visit model vary across setting including patient hour period varying time devoted education discussion health concern group visit typically incorporates one one physical examination physician nurse practitioner conjunction group discussion medical management group visit shown beneficial improving patient outcome condition diabetes hypertension chronic illness goal group visit patient hf increase patient knowledge self care ability improving self efficacy self care incorporates decision making process patient undergoes deciding course action maintain stability result change symptom improved self care improve symptom likely result increase quality life reduction hospitalization related decompensation quality life qol refers patient perception impact health condition treatment patient health status measured valid reliable tool minnesota living heart failure questionnaire mlhfq kansa city cardiomyopathy questionnaire kccq self care ability measured using instrument self care heart failure index schfi hf knowledge measured using instrument atlanta heart failure knowledge test group visit used continue optimize medication therapy providing forum knowledge acquisition fostering support search cochrane library systematic review joanna briggs library systematic review medline cinahl identify previously conducted systematic review effectiveness group visit outcome patient heart failure therefore review seek identify study evaluating effectiveness group visit patient heart failure patient knowledge quality life self care behavior hospital readmission:0.0190342717419909"
  },
  "Topic 8": {
    "86141": "recent advance medical device therapy heart failure improved survival patient heart failure however due limited availability suitable heart donor left ventricular assist device lvads become important tool bridge heart transplantation patient refractory heart failure singapore report experience heartmate ii hmii lvad thoratec corporation pleasanton ca usa bridge heart transplant center retrospective review consecutive patient underwent hmii lvad implantation center may december patient classified interagency registry mechanically assisted circulatory support intermacs level underwent lvad implantation bridge heart transplant male female patient mean age year old range etiology heart failure included ischemic heart disease idiopathic dilated cardiomyopathy viral myocarditis chemotherapy induced cardiomyopathy nine patient intermacs level patient level two patient level patient successfully underwent hmii lvad implantation mortality within first postoperative day postoperative complication included stroke full neurological recovery mediastinal infection cardiac tamponade mediastinal collection requiring reopening chest cardiac arrhythmia pump thrombosis pump replacement patient discharged hospital lvad implantation three patient experienced driveline infection outpatient follow readmission due following condition sub therapeutic anticoagulation gastrointestinal bleeding suspected pump thrombosis transient ischemic attack arrhythmia congestive cardiac failure due severe aortic regurgitation right ventricular failure rhabdomyolysis hematuria post lvad implantation patient functionally new york heart association nyha class reported nyha iii symptom three patient successfully bridged heart transplantation one patient successfully explanted month lvad implantation two mortality follow period average duration lvad support day range day heartmate ii lvad proven effective asian population driveline infection rate remains low even tropical hot humid climate singapore patient ending extended period lvad support increased emphasis detection management long term complication ventricular assist device needed:0.0285049351658522",
    "18907": "objective levitronix centrimag ventricular assist device vad centrifugal pump designed short term extracorporeal support cardiogenic shock aim study report clinical experience levitronix centrimag uni biventricular support method july december patient supported using levitronix centrimag device nineteen male mean age range year indication support implantation cardiogenic shock included end stage heart failure ill undergo transplantation questionable neurologic status subject right ventricular failure left vad lvad implantation subject post cardiotomy status subject acute donor graft failure heart transplantation subject result post vad day survival patient mean support time day patient range day mean support time levitronix biventricular vads range day mean support time levitronix lvads range day highest survival rate levitronix support donor graft failure cardiotomy levitronix right vad rvad support long term lvad insertion incurred hospital mortality survived patient discharged home vad support remain alive date two patient bridged primary another bridged repeat heart transplantation five patient weaned recovery operation bleeding occurred patient clinical evidence cerebral thromboembolism overwhelming sepsis aortic thrombus formation clot formation tubing observed patient necessitating emergent replacement bedside successful conclusion levitronix centrimag system reliable facile temporary circulatory support system bridge decision patient refractory acute cardiogenic shock:0.0273765597244944",
    "73038": "background heart transplantation gained recognition gold standard therapy advanced heart failure scarcity donor organ become important concern evolution surgical alternative ventricular assist device vads allow recovery myocardium ensure patient survival heart transplantation becomes possible report elaborates role vads bridge heart transplantation infant child year old end stage heart failure method retrospective review medical record heart transplant recipient may september identified child mean age year old iqr year advanced heart failure supported vad left vad lvad biventricular vad bvad bridge heart transplantation fourteen patient less year old child cardiac arrest underwent cardiopulmonary resuscitation patient also requiring extracorporeal membrane oxygenation ecmo support prior implantation vad aetiology heart failure primarily cardiomyopathy dilative restrictive endocardial fibrosis idiopathic toxic induced reported patient vads employed primarily berlin heart excor r n heartware n berlin heart incor r n toyobo n result mean duration vad support day range day iqr day donor heart became available primary complication encountered patient bridged transplant mediastinal bleeding main indication pump exchange thrombus formation valve incidence technical failure blood pump driving system component skin infection around cannulae occurred adverse neurological symptom thromboembolism cerebral haemorrhage occurred permanent neurological sequela could detected clinical examination study mean duration follow year iqr year cumulative survival rate patient bridged transplantation vad day year respectively statistically significant difference p survival rate patient bridged heart transplantation vad compared underwent primary heart transplantation post transplant survival rate stratified according type vad implanted number ventricle supported statistically different p respectively addition post transplant survival rate significantly different age gender diagnosis adjusted furthermore statistically significant difference found post transplant survival rate child episode rejection compared episode rejection conclusion result series demonstrate vads satisfactorily support paediatric patient advanced heart failure variety aetiology heart transplantation data suggests patient bridged vads comparable long term post transplant survival undergoing primary heart transplantation:0.0273640318062915",
    "80594": "child heart failure unresponsive medical therapy left option survival ventricular assist device vads life saving option patient allowing bridge transplantation cardiac recovery retrospective review case may october undertaken fourteen patient underwent implantation vads refractory heart failure mean age year range year weight kg range kg indication support end stage cardiomyopathy n myocarditis n univentricular failure n congenital heart disease postcardiotomy n level limitation time implant included critical cardiogenic shock six progressive decline eight extracorporeal membrane oxygenation used bridge vad five patient preimplant variable patient requiring mechanical ventilation mean day hyperbilirubinemia acute renal insufficiency device selection systemic vad biventricular assist device three berlin heart excor used eight patient six patient received thoratec implantable vad paracorporeal vad mean duration support day range day overall survival ten patient successfully bridged transplantation three died device one remains support patient weaned vad child supported single ventricle heart failure survival none currently bridged transplantation complication included bleeding requiring reoperation n stroke n driveline infection n two patient total six pump exchange performed thrombus formation survival pediatric patient age excellent using current device technology majority patient successfully bridged transplantation morbidity acceptably low considering severity illness significant challenge exist long term extracorporeal support due lack donor availability high incidence preformed alloantibody especially failing single ventricle:0.0267311883393427",
    "112319": "background end stage heart failure major cause morbidity mortality prevalence expected rise ageing population suitable patient orthotopic heart transplantation remains gold standard therapy however paucity donor organ led development left ventricular assist device lvad device utilized either bridge transplant btt alternative heart transplantation device prolong life improve quality life associated significant number adverse event aim systematically review literature quantify survival incidence adverse event following implantation continuous flow lvads cf lvad method systematic review performed determine outcome following implantation cf lvad primary outcome survival frequency adverse event bleeding infection thrombosis stroke right ventricular failure secondary outcome included quality life assessment functional status result sixty three study reported clinical outcome patient survival cf lvad varied study industry funded trial generally reported better overall survival single multi center case series showed significant variation largest registry report documented twelve twenty four forty eight month survival rate respectively commonly reported adverse event gastrointestinal bleeding gib device related infection neurological event right heart failure rhf bleeding rhf infection frequent complication experienced supported cf lvad occurring patient respectively quality life measured using kansa city cardiomyopathy questionnaire kccq functional status measured minute walk test mwt improved cf lvad implantation decline evident two year implantation conclusion paucity donor heart led development left ventricular assist device btt destination therapy dt outcome cf lvad implantation excellent short term survival comparable heart transplantation long term survival remains limited due incidence post implantation adverse event despite complication quality life functional status improve significantly post implantation remain improved long term study demonstrates potential benefit cf lvad therapy whilst also identifying adverse event area increased morbidity mortality:0.0266550866262760",
    "48043": "introduction heartmate ii hmii thoratec corporation pleasanton calif united state continuous flow pump approved food drug administration fda bridge transplantation btt since destination therapy dt since herein present postoperative outcome hmii implantation due end stage heart failure center method twenty eight patient mean age year female implanted hmii august august indication dilated n ischemic n cardiomyopathy intended treatment btt dt patient preoperative clinical status international registry mechanical circulatory support intermacs patient respectively procedure performed via conventional sternotomy cardiopulmonary bypass heparin acetylsalicylic acid warfarin used postoperative anticoagulation result mean duration support day median three patient underwent heart transplantation remain pump support one patient died discharge due respiratory failure others died following cerebral bleeding day postoperatively respectively survival rate month respectively temporary right ventricular failure observed patient two patient pump thrombosis treated anticoagulation management pump exchange whereas another patient aortic root thrombosis underwent reoperation removal thrombus discussion mechanical circulatory support hmii axial flow pump seems effective may provide good survival rate compared optimum medical management old generation device patient selection timing implantation crucial success:0.0262849733503846",
    "107974": "background interagency registry mechanically assisted circulatory support intermacs joint effort among national heart lung blood institute food drug administration center medicare medicaid service others established university alabama birmingham registry examined clinical outcome quality life metric patient received food drug administration approved durable mechanical circulatory support mc device treat advanced heart failure january intermacs database became part society thoracic surgeon national database providing additional resource quality assessment improvement scientific advancement method intermacs database annual report summarizes outcome patient year age underwent durable mc implant june december outcome presented patient underwent isolated continuous flow left ventricular assist device cf lvad support cf lvad support concomitant right ventricular assist device rvad implant total artificial heart implant analysis patient cf lvads stratified axial flow centrifugal flow configuration association era outcome survival analysis restricted isolated cf lvads implanted era result adult patient mc reported intermacs received cf lvads rvad cf lvad received total artificial heart received isolated rvad cf lvads mean age year listed transplantation cardiogenic shock profile preoperatively cf lvads included axial flow centrifugal flow device intermacs patient phenotype evolved time include patient profile versus fewer patient profile versus patient better marker preoperative renal hepatic function patient received implant destination therapy versus indication centrifugal flow implant approximated axial flow device mean cf lvad support duration month patient year one year survival isolated cf lvads year survival one year survival centrifugal versus axial flow device respectively patient required concomitant rvad support year survival respectively freedom cause readmission month year year stroke occurred patient centrifugal flow patient axial flow support p gastrointestinal bleeding affected patient centrifugal flow device patient axial flow device p pump related infection occurred patient centrifugal flow device versus patient axial flow device p neurologic dysfunction death multisystem organ dysfunction common cause death conclusion evolution mc patient phenotype outcome also changing time cf lvad support increasingly used less ill patient phenotype patient supported destination therapy mean survival approaching year adverse event especially neurologic event continue detrimental impact success cf lvad support:0.0262641061041631",
    "107973": "background interagency registry mechanically assisted circulatory support intermacs joint effort among national heart lung blood institute food drug administration center medicare medicaid service others established university alabama birmingham registry examined clinical outcome quality life metric patient received food drug administration approved durable mechanical circulatory support mc device treat advanced heart failure january intermacs database became part society thoracic surgeon national database providing additional resource quality assessment improvement scientific advancement method intermacs database annual report summarizes outcome patient year age underwent durable mc implant june december outcome presented patient underwent isolated continuous flow left ventricular assist device cf lvad support cf lvad support concomitant right ventricular assist device rvad implant total artificial heart implant analysis patient cf lvads stratified axial flow centrifugal flow configuration association era outcome survival analysis restricted isolated cf lvads implanted era result adult patient mc reported intermacs received cf lvads rvad cf lvad received total artificial heart received isolated rvad cf lvads mean age year listed transplantation cardiogenic shock profile preoperatively cf lvads included axial flow centrifugal flow device intermacs patient phenotype evolved time include patient profile versus fewer patient profile versus patient better marker preoperative renal hepatic function patient received implant destination therapy versus indication centrifugal flow implant approximated axial flow device mean cf lvad support duration month patient year one year survival isolated cf lvads year survival one year survival centrifugal versus axial flow device respectively patient required concomitant rvad support year survival respectively freedom cause readmission month year year stroke occurred patient centrifugal flow patient axial flow support p gastrointestinal bleeding affected patient centrifugal flow device patient axial flow device p pump related infection occurred patient centrifugal flow device versus patient axial flow device p neurologic dysfunction death multisystem organ dysfunction common cause death conclusion evolution mc patient phenotype outcome also changing time cf lvad support increasingly used less ill patient phenotype patient supported destination therapy mean survival approaching year adverse event especially neurologic event continue detrimental impact success cf lvad support:0.0261829397734661",
    "78412": "recent outstanding clinical advance new mechanical circulatory system mc led additional strategy treatment end stage heart failure hf heart transplantation htx postponed certain patient even replaced smaller implantable left ventricular assist device lvad mechanical support failing left ventricle enables appropriate hemodynamic stabilisation recovery secondary organ failure often seen severely ill patient new device may great help bridge patient suitable cardiac allograft available also discussed definitive treatment patient qualify transplantation main indication lvad implantation bridge recovery bridge transplantation destination therapy lvad may important tool patient expected prolonged period waiting list instance blood group b body weight kg potentially reversible secondary organ failure pulmonary artery hypertension however lvad implantation mean additional heart operation inherent peri operative risk complication waiting period finally cardiac transplantation patient prior implantation lvad represents surgical challenge review summarises current knowledge lvad continuous flow device especially since latter increasingly used worldwide recent year review also based institutional experience berne university hospital apart short term device impella cardiac assist deltastream ecmo used approximately case pulsatile long term lvad rvad bi vad non pulsatile lvad mainly heartmateii heartware implanted initial learning curve one year mortality dropped last patient:0.0261244436506926",
    "183893": "left ventricular assist device lvad therapy well established treatment end stage cardiac failure indication bridge transplant btt bridge candidacy btc bridge recovery btr destination therapy dt durability adverse event ae rate lvads improved year however due donor shortage duration support btt population increased tremendously similarly dt patient device long time consequently number readmission long term lvad patient increased case severe aes intensive care unit icu treatment necessary infectious complication common ae furthermore embolic hemorrhagic stroke occur due foreign surface acquired von willebrand syndrome anticoagulation treatment another consequence coagulative status combination continuous flow gastrointestinal bleeding event moreover patient isolated lvad implanted involves risk late right heart failure adjustment pump speed optimization volume status help solve issue malignant arrhythmia pre existing de novo lvad implantation life threatening ae antiarrhythmic medical therapy ablation potential treatment option specific lvads medtronic heartware ventricular assist device hvad manufactured distributed currently however patient still device pump thrombosis occur wherein thrombolytic therapy first line treatment option additionally hvad fail restart controller exchange due technical issue precaution must taken momentum trial showed superior survival without pump exchange disabling stroke patient treated heartmate r hm abbott abbott park il usa device comparison heartmate ii hmii however case twisted graft bio debris formation outflow graft bend relief could observed causing outflow graft obstruction patient lvads still heart failure patient many case comorbidities therefore many situation occur requiring icu treatment ethical aspect always focus taking care patient:0.0261202316301445"
  },
  "Topic 9": {
    "75826": "background previous clinical trial reported ivabradine effectively treat heart failure hf however systematic review explored efficacy safety hf systematic review aim evaluate efficacy safety ivabradine treatment patient hf method search literature following electronic database inception january cochrane central register controlled trial embase mediline web science cumulative index nursing allied health literature allied complementary medicine database chinese biomedical literature database china national knowledge infrastructure vip information wanfang data randomized controlled trial rcts ivabradine hf fully considered inclusion without restriction additionally grey literature including clinical trial registry dissertation reference list included study conference abstract also searched two researcher review literature extract data assess risk bias included rcts separately data pooled either fixed effect model random effect model meta analysis conducted appropriate result primary outcome cause mortality secondary outcome comprise change body weight urine output change serum sodium adverse event conclusion result study summary provide dated evidence assessing efficacy safety ivabradine hf ethic dissemination necessary acquire ethical approval systematic review individual patient data used study result systematic review published peer reviewed journal systematic review registration prospero crd:0.0269743948416763",
    "172536": "background heart failure hf global health concern affecting million individual worldwide leading significant morbidity mortality despite advance conventional therapeutic strategy prognosis hf patient remains challenging constant search novel therapeutic option among panax quinquefolius saponin pqs demonstrated promising pharmacological property may benefit hf however efficacy safety pqs hf comprehensively evaluated objective systematic review meta analysis aim provide reliable estimation efficacy safety pqs hf help clinician make informed decision regarding potential use pqs managing hf patient method comprehensively systematically searched published randomized controlled trial rcts following eight electronic database pubmed cochrane library embase web science wos china national knowledge infrastructure cnki china science technology journal database vip wanfang data china biology medicine database cbm database inception march cochrane risk bias rob assessment tool used quality assessment review manager revman version used meta analysis mean difference md credible interval ci relative risk rr estimate calculated random effect model also used grade profiler gradepro version analyze quality outcome addition protocol registered international platform registered systematic review meta analysis protocol inplasy registry number result study included nine rcts involving total patient hf result meta analysis random effect model showed adjuvant pqs therapy significantly increased lvef md ci p mwtd md ci p decreased bnp nt pro bnp md ci p lvedv md ci p lvedd md ci p lvesv md ci p patient hf conclusion evidence provided systematic review suggests adjunctive pqs therapy hf improved clinical efficacy hold potential advantage improving cardiac function increasing exercise tolerance however given limitation inherent review conclusion study interpreted cautiously therefore clinical practice recommended physician tailor treatment strategy according specific circumstance individual patient systematic review registration http inplasy com:0.0266820345090680",
    "99215": "background sacubitril valsartan first class angiotensin receptor neprilysin inhibitor used treat heart failure evidence novel medication largely based one pivotal phase iii trial stopped early due significant clinical benefit shown however potential limitation trial design highlighted recent literature necessitating thorough review evidence sacubitril valsartan method review conducted using prisma reporting guideline relevant randomised controlled trial rcts sacubitril valsartan systematically searched medline pubmed embase cochrane library google scholar web science toxline scopus clinical trial registry searched eight grey literature database addition unpublished clinical study report csrs relevant trial requested european medicine agency ema clinical study data request database study included involve randomising adult patient heart failure either sacubitril valsartan usual care either active comparator placebo control heart failure subtype nyha class included relevant clinical safety outcome reviewed particularly hospitalisation due heart failure cardiovascular mortality two reviewer assess eligibility selected study inclusion data extraction performed separately trial publication clinical trial registry csrs using piloted form methodological quality included trial published source assessed separately using cochrane risk bias tool rob narrative synthesis included study conducted appropriate meta analysis clinical efficacy safety outcome discussion review collate available rct data sacubitril valsartan including published unpublished source order obtain complete picture evidence base sacubitril valsartan registration protocol registered prospero reference crd:0.0262274048382660",
    "187598": "introduction chronic disease self management cdsm vital component congestive heart failure chf programme recent chf guideline downgraded cdsm programme citing lack gold standard evidence protocol describes aim method systematic review collate synthesise published research evidence determine effectiveness cdsm programme intervention patient treated chf method medline pubmed embase central cinahl cochrane central register controlled trial psycinfo scopus web science science citation index register clinical trial searched addition reference list shortlisted article reviewed randomised controlled trial case management intervention cdsm chf reported major adverse cardiovascular event mace extracted analysed restriction language study protocol template developed cochrane collaboration reporting adheres preferred reporting item systematic review meta analysis protocol guideline systematic review meta analysis two independent author apply inclusion exclusion criterion limit article search assess bias certainty evidence rating data extraction study description included study include quality appraisal study quantitative synthesis data undertaken ascertain evidence study aim subgroup analysis conducted different cdsm programme primary outcome significant change mace parameter intervention control arm meta analysis conducted using statistical software feasible ethic dissemination ethic approval sought study collecting primary patient data result study disseminated peer reviewed scientific journal also presented audience meeting scientific conference prospero registration number crd:0.0261926720882616",
    "89130": "background cell transplantation offer potential therapeutic approach repair regeneration damaged vascular cardiac tissue acute myocardial infarction ami resulted multiple randomised controlled trial rcts across world objective determine safety efficacy autologous adult bone marrow stem cell treatment acute myocardial infarction ami focusing clinical outcome search method cochrane review update previous version published searched cochrane central register controlled trial central issue medline march embase march cinahl march transfusion evidence library march addition searched several international ongoing trial database march handsearched relevant conference proceeding january selection criterion rcts comparing autologous bone marrow derived cell cell patient diagnosed ami eligible data collection analysis two review author independently screened reference assessed risk bias included trial extracted data conducted meta analysis using random effect model throughout analysed outcome short term less month long term month follow dichotomous outcome reported risk ratio rr continuous outcome reported mean difference md standardised md smd performed sensitivity analysis evaluate result context risk selection performance attrition bias exploratory subgroup analysis investigated effect baseline cardiac function left ventricular ejection fraction lvef cell dose type timing administration well use heparin final cell solution main result forty one rcts total participant cell therapy control eligible inclusion cell treatment associated change risk cause mortality versus rr ci participant study moderate quality evidence cardiovascular mortality versus rr ci participant nine study moderate quality evidence composite measure mortality reinfarction hospitalisation heart failure versus rr ci participant six study moderate quality evidence long term follow statistical heterogeneity low serious periprocedural adverse event rare generally unlikely related cell therapy additionally cell therapy effect morbidity quality life performance lvef measured magnetic resonance imaging meta analysis lvef measured echocardiography single photon emission computed tomography left ventricular angiography showed evidence difference mean lvef treatment group although mean difference ranged accepted clinically relevant result robust risk selection performance attrition bias individual study author conclusion result review suggest insufficient evidence beneficial effect cell therapy ami patient however evidence come small trial showed difference clinically relevant outcome adequately powered trial needed efficacy intervention remains unproven:0.0256212801063450",
    "198324": "objective evaluate whether remdesivir associated cardiac adverse event caes addressing concern raised basic experiment clinical case report observational study design systematic review meta analysis data source medline embase searched january december study selection randomised controlled trial rcts comparing remdesivir placebo standard care patient covid primary focus cardiac safety eligibility criterion selecting study included rcts evaluated safety remdesivir patient covid eligible study compared remdesivir placebo standard care adult patientscovid inclusion criterion emphasised safety outcome particularly caes primary endpoint data extraction synthesis two reviewer independently extracted data reporting followed preferred reporting item systematic review meta analysis prisma harm guideline risk bias rob assessed using cochrane collaboration tool random effect model used data synthesis grading recommendation assessment development evaluation grade approach applied assess certainty evidence primary outcome incidence caes defined composite reported cardiac related harm secondary outcome included specific caes arrhythmia heart failure myocardial disorder result identified study seven rcts met inclusion criterion comprising total participant rob assessed across multiple domain four rcts showing low risk three showing moderate risk specific area pooled analysis revealed significant association remdesivir use caes rr ci p subgroup analysis showed consistent finding across different patient demographic comorbidities grade assessment indicated moderate certainty overall caes low certainty arrhythmia heart failure due imprecision study level bias low certainty myocardial disorder due small sample size indirectness conclusion contrary preliminary concern case report meta analysis found evidence statistically significant association remdesivir caes among patient covid finding provide reassurance clinician regarding safety profile remdesivir patient population supporting use antiviral therapy treatment covid research warranted validate finding clarify whether remdesivir may neutral potentially protective effect cardiac outcome prospero registration number crd:0.0254456024115454",
    "17284": "background cardiac rehabilitation important component recovery coronary event uptake adherence programme recommended level aim update previous non cochrane systematic review examined intervention may potentially improve cardiac patient uptake adherence rehabilitation component concluded insufficient evidence make specific recommendation objective determine effect intervention increase patient uptake adherence cardiac rehabilitation search strategy previous systematic review identified study published prior june searched cochrane central register controlled trial central cochrane library issue medline january embase january cinahl january psycinfo january web science isi proceeding april nh centre review dissemination crd database health technology assessment hta database abstract review effect dare january reference list identified systematic review randomised control trial rcts also checked additional study selection criterion adult myocardial infarction coronary artery bypass graft percutaneous transluminal coronary angioplasty heart failure angina coronary heart disease eligible cardiac rehabilitation randomised quasi randomised trial intervention increase uptake adherence cardiac rehabilitation component part study reporting measure adherence included data collection analysis title abstract identified reference screened eligibility two reviewer independently full paper potentially relevant trial obtained checked included study assessed risk bias two reviewer main result ten study identified three intervention improve uptake cardiac rehabilitation seven intervention increase adherence meta analysis possible due multiple source heterogeneity three intervention targeting uptake cardiac rehabilitation effective two seven study intended increase adherence significant effect one study reported non significant effect intervention cardiovascular risk factor study reported data mortality morbidity cost health care resource utilisation author conclusion evidence suggest intervention increase uptake cardiac rehabilitation effective practice recommendation increasing adherence cardiac rehabilitation made time intervention targeting patient identified barrier may increase likelihood success high quality research needed:0.0249426447186834",
    "118575": "background heart failure end stage heart disease prevalence incidence condition rapidly increasing although heart transplantation one type surgical treatment people end stage heart failure donor availability limited implantable ventricular assist device vads therefore offer alternative treatment heart transplantation although two study reported beneficial effect exercise based cardiac rehabilitation cr functional capacity quality life qol performing systematic review meta analysis systematic review included study limited design e g non randomised retrospective study participant implantable extracorporeal vads objective determine benefit harm exercise based cr people implantable vads search method searched cochrane central register controlled trial central cochrane library medline embase psycinfo conference proceeding citation index science cpci web science cinahl lilac october limitation date language publication status also searched two clinical trial register august checked reference list primary study review article selection criterion randomised controlled trial rcts regardless cluster individual randomisation full text study published abstract unpublished data eligible however individually rcts full text publication included data collection analysis two review author independently extracted outcome data included study double checked data entered correctly comparing data presented systematic review study report dichotomous data analyse used mean difference standardised mean difference confidence interval ci continuous data furthermore assessed quality evidence relates study contribute data meta analysis prespecified outcome using gradepro software main result included two study total participant review exercise based cr consisted aerobic resistance training three time per week six eight week exercise intensity oxygen consumption vo reserve ranged heart rate reserve two serious adverse event observed one trial participant complete study due infection furthermore total four participant group required visit emergency department although participant complete study summary score item short form health survey sf kansa city cardiomyopathy questionnaire kccq measured quality life one trial reported kccq summary score improved point exercise group compared point usual care group trial reported sf total score improved point exercise group compared point usual care group large difference quality life observed group end follow standardised mean difference ci participant study low quality evidence however evidence effectiveness exercise based cr due young age participant high risk performance bias small sample size wide confidence interval resulted low quality evidence furthermore able determine effect exercise based cr mortality rehospitalisation heart transplantation cost outcome reported author conclusion evidence currently inadequate assess safety efficacy exercise based cr people implantable vads compared usual care amount rct evidence limited low quality addition training duration short term six eight week high quality well reported rcts exercise based cr people implantable vads needed trial need collect data event mortality rehospitalisation patient related outcome including quality life cost effectiveness:0.0249066646779132",
    "174892": "objective sympathetic crashing acute pulmonary oedema scape menacing medical emergency severe form acute heart failure requires urgent intervention nitroglycerin ntg commonly used scape management optimal dosing remains uncertain meta analysis compared efficacy safety high dose v low dose ntg scape patient assessing mechanical ventilation need symptom resolution hospital stay major adverse cardiovascular event mace design systematic review meta analysis conducted per preferred reporting item systematic review meta analysis guideline registered prospective register systematic review crd data source comprehensive search pubmed europe pmc sciencedirect november reference list included study also reviewed eligibility criterion randomised controlled trial rcts observational study comparing high dose ntg mcg min low dose ntg mcg min scape patient included key inclusion criterion acute dyspnoea hour systolic blood pressure sbp mmhg mean arterial pressure map mmhg respiratory rate rr breath min sympathetic activation exclusion criterion included non cardiogenic pulmonary oedema immediate intubation ntg contraindication pregnancy acute coronary syndrome data extraction synthesis two author independently screened title abstract identified study eligibility full text potentially relevant article reviewed discordance disagreement resolved discussion final decision made consensus risk bias assessed using newcastle ottawa scale meta analysis performed using stata review manager mantel haenszel method applied dichotomous outcome inverse variance approach continuous outcome heterogeneity assessed via squared random effect model applied needed result four study one rct three observational scape patient met inclusion criterion high dose ntg reduced mechanical ventilation need rr ci p high certainty increased symptom resolution within hour rr ci p moderate certainty hospital stay shorter md hour ci p low certainty significant difference found mace risk rr ci p low certainty hypotension incidence group conclusion high dose ntg improved clinical outcome scape reducing mechanical ventilation need symptom duration hospital stay without increased adverse event finding suggest high dose ntg promising treatment strategy large scale study needed optimise dosing protocol:0.0248748030535442",
    "108093": "background international clinical practice guideline routinely recommend cardiac patient participate rehabilitation programme comprehensive secondary prevention however data show small proportion patient utilise rehabilitation objective first assess intervention provided increase patient enrolment adherence completion cardiac rehabilitation second assess intervention cost associated harm well intervention intended promote equitable cr utilisation vulnerable patient subpopulation search method review author performed search july identify study published since publication previous systematic review searched cochrane central register controlled trial central national health service nh centre review dissemination crd database health technology assessment hta database abstract review effect dare cochrane library wiley medline ovid embase elsevier cumulative index nursing allied health literature cinahl ebscohost conference proceeding citation index science cpci web science clarivate analytics checked reference list relevant systematic review additional study also searched two clinical trial register applied language restriction selection criterion included randomised controlled trial rcts adult myocardial infarction angina undergoing coronary artery bypass graft surgery percutaneous coronary intervention heart failure eligible cardiac rehabilitation intervention aim increase utilisation comprehensive phase ii cardiac rehabilitation included study measured one primary outcome secondary outcome harm cost focused equity data collection analysis two review author independently screened title abstract identified reference eligibility obtained full paper potentially relevant trial two review author independently considered trial inclusion assessed included study risk bias extracted trial data independently resolved disagreement consultation third review author performed random effect meta regression outcome explored prespecified study characteristic main result overall included study participant comparison participant primarily male ten study included patient heart failure assessed study low unclear risk bias sixteen study participant reported intervention improve enrolment cardiac rehabilitation study participant reported intervention improve adherence cardiac rehabilitation seven study participant reported intervention increase programme completion researcher tested variety intervention increase utilisation cardiac rehabilitation many study consisted contact made healthcare provider shortly acute care hospitalisation low quality evidence show effect intervention increasing programme enrolment comparison risk ratio rr confidence interval ci meta regression revealed intervention deliverer nurse allied healthcare provider p delivery format face face p influential increasing enrolment low quality evidence show intervention increase adherence effective nine comparison standardised mean difference smd ci particularly delivered remotely home based program smd ci moderate quality evidence show intervention increase programme completion also effective eight comparison rr ci applied multi centre study less effective given single centre study leading question regarding generalisability moderate level statistical heterogeneity across intervention study reflects heterogeneity intervention approach evidence small study bias enrolment insufficient study test outcome regard secondary outcome study reported harm associated intervention two study reported cost term equity trialists tested intervention designed improve utilisation among woman older patient evidence insufficient quantitative assessment whether woman tailored programme associated increased utilisation study assess motivating woman needed older participant quantitative assessment could undertaken peer navigation may improve enrolment author conclusion intervention may increase cardiac rehabilitation enrolment adherence completion however quality evidence low moderate due heterogeneity intervention used among factor effect enrolment larger study targeting healthcare provider training nurse allied healthcare provider intervene face face effect adherence larger study tested remote intervention research needed particularly discover best way increase programme completion:0.0248741812967777"
  },
  "Topic 10": {
    "143240": "purpose advanced lung cancer inflammation index ali novel inflammatory nutritional index exerts prognostic value various type cancer previous study demonstrated ali discharge could predict prognosis patient acute decompensated heart failure adhf however long term prognostic value ali admission elderly heart failure hf inpatient remains unclear material method retrospectively collected hf inpatient year old hospitalized cardiology center whole year ali calculated body mass index bmi x serum albumin alb neutrophil lymphocyte ratio nlr patient divided two group optimal cutoff value ali predicting cause mortality using time dependent receiver operating characteristic roc curve spearman rank correlation coefficient computed evaluate correlation ali geriatric nutritional risk index gnri kaplan meier curve cox survival analysis time dependent roc analysis net reclassification improvement nri analysis used assess prognostic effect ali cause mortality cardiovascular mortality result month median follow cause cardiovascular mortality occurred patient respectively optimal cutoff value ali predicting cause mortality year spearman correlation coefficient showed moderate positive linear correlation ali gnri r p kaplan meier analysis revealed cumulative incidence cause cardiovascular mortality significantly higher patient lower ali log rank test cause mortality p cardiovascular mortality p multivariate cox proportional hazard analysis indicated ali independent predictor cause mortality hr ci p cardiovascular mortality hr ci p time dependent roc analysis showed ali comparable gnri predicting long term cause mortality auc ali gnri p cardiovascular mortality auc ali gnri p year however estimated nri indicated addition ali could significantly improve risk stratification base model cause mortality categorical nri p continuous nri p cardiovascular mortality categorical nri p continuous nri p conclusion higher ali significantly associated lower cause cardiovascular mortality elderly hf patient ali admission could competent nutrition inflammation marker independent predictive value evaluating long term mortality hf elder population:0.0213183157404829",
    "162994": "background recent study fibroblast growth factor fgf first recognized regulator glucose lipid metabolism found level serum fgf associated prognosis many cardiovascular disease relationship acute heart failure ahf patient remains unknown study aimed investigate whether circulating fgf could predict short term prognosis ahf patient method four hundred two ahf patient healthy control recruited prospective cohort study blood sample participant collected tube without anticoagulant within first h hospital admission serum fgf level detected enzyme linked immunosorbent assay elisa patient followed least month discharge primary endpoint cause death secondary endpoint composite endpoint death heart failure readmission mortality composite end point event analyzed using kaplan meier curve roc curve compared difference fgf nt probnp predicting month mortality time event data evaluated using kaplan meier estimation cox proportional hazard model result present study serum fgf concentration significantly higher ahf patient enrolled compared healthy control p average age year male participant divided two group according median fgf level pg ml high fgf group n fgf pg ml low fgf group n fgf pg ml fgf positively correlated nt probnp bun ast creatinine cholesterol negatively correlated alb hdl median follow day high fgf group higher mortality composite endpoint event compared low fgf group hr ci p even adjusting nt probnp hr ci p roc analysis show fgf better nt probnp predicting death auc v p month auc v conclusion high baseline fgf level associated adverse clinical outcome ahf patient serum fgf might potential predictive biomarker ahf patient:0.0209293837390020",
    "167281": "introduction previous study shown fibroblast growth factor fgf involved ventricular remodeling process heart failure preserved ejection fraction hfpef hypothesized high level fgf correlated ventricular remodeling heart failure patient mildly reduced hfmref reduced ejection fraction hfref method total participant hfmref hfref enrolled followed june june subject without heart failure hf underwent physical examination time selected control group primary endpoint occurrence major adverse cardiovascular event mace defined cause cardiac mortality rehospitalization decompensation serum fgf level measured early next morning admission using enzyme linked immunosorbent assay elisa result fgf level significantly higher patient hfmref hfref control group pg ml pg ml v pg ml p serum level fgf n terminal pro b type natriuretic peptide nt probnp higher endpoint event group non endpoint event group regardless hfmref hfref group p spearman correlation revealed fgf positively correlated left ventricular end systolic diameter left ventricular end diastolic diameter left ventricular mass index p moreover negative correlation fgf left ventricular ejection fraction addition relative wall thickness p area receiver operating characteristic roc curve auc fgf optimal cut value fgf determined roc curve pg ml kaplan meier analysis demonstrated low fgf level group increased mace free survival rate compared high fgf level group univariate multivariate cox analysis seen serum fgf nt probnp independent predictor poor prognosis hf patient conclusion baseline level fgf nt probnp related ventricular remodeling patient mildly reduced reduced ejection fraction fgf nt probnp good prognostic value mace heart failure patient mildly reduced reduced ejection fraction:0.0200785907244301",
    "93871": "background clinical assessment treatment guidance heart failure depends variety biomarkers objective study investigate prognostic predictive value growth differentiation factor gdf n terminal prohormone brain natriuretic peptide nt probnp assessing hospitalized patient acute heart failure ahf method total patient admitted ahf first affiliated hospital nanjing medical university enrolled april may medical history blood sample collected within h admission primary endpoint cause mortality within year patient divided survival group death group based endpoint established mortality risk factor serum gdf level receiver operator characteristic roc analysis performed cox regression analysis used analyze combination value nt probnp gdf result baseline gdf nt probnp significantly higher amongst deceased survivor p roc analysis area curve auc gdf predict year mortality confidence interval ci p nt probnp ci p statistically significant difference found two marker p based optimal cut offs gdf ng l nt probnp ng l combination gdf nt probnp increased auc year mortality prediction auc ci p conclusion gdf prognostic marker patient ahf inferior nt probnp combining two marker could provide early recognition high risk patient improve prediction value ahf long term prognosis clinical trial registration chictr onc http www chictr org cn:0.0197845597306001",
    "111549": "background systematic inflammation nutritional status cardiovascular function associated outcome acute exacerbation chronic obstructive pulmonary disease aecopd patient heart failure hf however value relevant biomarkers predicting mortality well defined yet aimed investigate prognostic value circulating biomarkers including c reaction protein crp albumin alb neutrophil lymphocyte ratio nlr platelet lymphocyte ratio plr n terminal pro brain natriuretic peptide nt probnp aecopd patient hf method retrospective study carried second clinical college jinan university january january total case aecopd complicated hf enrolled classified survivor group n non survivor group n baseline characteristic crp alb ratio nlr plr serum level nt probnp indicator collected predictor prognosis analyzed multivariate logistic regression ability predict day mortality evaluated receiver operating characteristic curve roc area curve auc result patient non survivor significantly higher level crp crp alb nlr pct nt probnp lower alb level compared survivor v mg l v v v ng ml v ng ml v g l p respectively significant difference plr found two group p logistic analysis revealed crp alb ci p nt probnp ci p nlr ci p independent risk factor predicting day mortality auc roc curve crp alb pct crp nt probnp alb nlr respectively combination crp alb nlr nt probnp biomarkers shown better accuracy predicting prognosis auc ci p higher specificity specificity compared single biomarkers conclusion high level nlr crp alb nt probnp may clinical usefully predictor death aecopd patient hf combination nlr crp alb nt probnp provide higher accuracy predicting day mortality patient:0.0192239068862886",
    "47023": "neutrophil gelatinase associated lipocalin ngal described chronic heart failure hf marker tubular damage renal dysfunction however less data available patient acute hf high rate acute kidney injury aki development aimed investigate role ngal predicting early aki development second compared ngal respect cystatin c b type natriuretic peptide bnp renal function blood urea nitrogen bun outcome prediction measured admission serum ngal cystatin c bnp patient affected acute hf patient submitted daily creatinine estimated glomerular filtration rate measurement identify inhospital aki defined risk injury failure loss end stage kidney disease acute kidney injury network criterion also measured admission discharge estimated glomerular filtration rate creatinine bun evaluate prognostic role month follow period patient developed aki hospitalization subject ngal level significantly increased respect patient without aki v ng ml p cutoff ng ml related aki good sensibility specificity respectively area curve p bnp also mildly increased v pg ml p cystatin c patient chronic kidney disease demonstrated higher ngal level compared subject preserved renal function ng ml p receiver operating characteristic curve analysis demonstrated increased ngal value associated increased mortality cutoff ng ml sensibility specificity accuracy area curve p significant correlation also found bun discharge cutoff mg dl sensibility specificity accuracy area curve p multivariable cox regression analysis showed cutoff ng ml related adverse outcome hazard ratio confidence interval p conclusion ngal measurement sensible tool predict aki hospitalization elevated ngal level appear related bun increase post discharge outcome suggests prognostic role tubular damage beyond renal dysfunction:0.0190921163715881",
    "69263": "background aim rate incidence prevalence acute kidney injury increasing due increased number patient heart failure therefore pertinent early detect level renal injury make necessary heart failure prediction thus aim study determine renal function prognosis stratification chronic heart failure patient importance neutrophil gelatinase associated lipocalin ngal early diagnostic marker acute kidney injury well stratification cardiovascular risk heart failure patient method data including age gender comorbidities medical history outpatient hospitalized patient farmacology neurohumoral activation far nhl multicenter prospective registry comprising three cardiological center czech republic collected st october th november one year follow data collected november way patient least one year data time recruitment two year time follow one year data used whole set patient data month used kaplan meier survival curve analyse patient survival data blood sample collected patient basic parameter evaluated order analyse neutrophil gelatinase associated lipocalin ngal plasma level n terminal pro brain natriuretic peptide nt probnp using lipocalin ngal human elisa kit bio vendor czechia cobas e nt probnp immunoassay kit roche diagnostics indianapolis usa respectively statistical analysis carried explain level significance evaluated parameter using spearman correlation mann whitney kruskal wallis test log rank test result patient farmacology neurohumoral activation far nhl multicenter prospective registry available data hospitalization mortality biomarkers one year follow recorded male median age year least one month stable patient left ventricle ejection fraction lv ef recorded etiology heart failure ischemic heart disease dilated cardiomyopathy others patient new york heart association functional class ii event cause mortality acute heart failure hospitalization left ventricle assist device implantation orthotopic heart transplant first day follow area receiver operating characteristic curve higher nt probnp creatinine ngal creatinine clearance multivariable analysis nt probnp p ngal p significant predictor event subject nt probnp ngal cut value nt probnp pg ml ngal ng ml survived without event subject nt probnp ngal cut value survived without event two year p conclusion finding study showed ngal associated nt probnp stronger predictor primary endpoint ngal nt probnp alone level ngal rising hypertension ischemia anemia hypoalbuminemia diabetes arrhythmia:0.0190092488050817",
    "149085": "aim serum n terminal pro brain natriuretic peptide nt probnp b type natriuretic peptide bnp level rarely evaluated simultaneously acute phase acute heart failure ahf method result total ahf patient enrolled patient analysed blood sample collected within min admission patient divided two group according median value nt probnp bnp ratio low nt probnp bnp group group l v high nt probnp bnp group group h multivariate logistic regression model showed c reactive protein level per mg dl increase controlling nutrition status score per point increase estimated glomerular filtration rate egfr per ml min increase independently associated group h odds ratio confidence interval ci ci ci respectively kaplan meier curve analysis showed prognosis significantly poorer group h group l multivariate cox regression model revealed group h independent predictor day mortality hazard ratio hr ci hf event hr ci trend prognostic impact significantly observed low bnp pg ml n high bnp pg ml n low egfr ml min n cohort tended observed normal egfr ml min n cohort conclusion high nt probnp bnp ratio associated non cardiac condition e g inflammatory reaction nutritional status renal dysfunction independently associated adverse outcome ahf:0.0188280723158328",
    "196986": "background objective heart failure hf one common initial presentation cardiovascular disease cvd patient type diabetes mellitus dm different cardiac biomarkers related pathophysiological mechanism hf dm current research aim identify additional biomarkers could improve diagnosis prognosis hfpef currently assessed using nt pro bnp level nt pro bnp valuable tool diagnosing heart failure may always correlate clinical symptom severity present normal level certain case obesity biomarkers like fgf galectin could provide greater insight heart failure severity especially diabetic patient main objective current study assess performance nt probnp fgf galectin copeptin discriminate advanced mild hf material method total patient enrolled study divided two group patient nyha functional class ii mild hf patient nyha iii iv advanced hf nt pro bnp fgf galectin copeptin serum level determined elisa method receiver operating characteristic roc analysis binomial logistic regression analysis used measure ability studied biomarkers distinguish advanced mild hf patient result patient dm advanced hf serum fgf level significantly positively correlated egfr rho p triglyceride rho p significantly negatively correlated serum level hdl cholesterol rho p rv ra gradient rho p patient mild hf serum fgf level significantly negatively correlated nt probnp level rho p e e ratio rho p tr velocity rho p rv ra gradient rho p fgf auc ci nt probnp auc ci demonstrated significant predictive value discriminate dm patient advanced hf mild hf elevated value fgf ng ml ntprobnp pg ml significantly associated increased odds advanced hf adjusting demographic clinical covariates conclusion ntpro bnp fgf similar ability discriminate dm patient advanced hf mild hf univariable multivariable logistic model showed fgf ntprobnp independent predictor advanced hf patient preserved mildly reduced ejection fraction dm:0.0187772997071336",
    "153153": "introduction hospitalization acute decompensation heart failure adhf frequent event associated long term adverse effect prognosis even worse acute kidney injury aki occurs hospitalization objective study aimed determine whether kidney damage biomarkers neutrophil gelatinase associatedlipocalin ngal kidney injury molecule kim interleukin il might predict aki prognostic value adhf patient method serum ngal admission urine ngal kim il discharge determined adhf patient enrolled prospective observational unblinded study aki diagnosed using kidney disease improving global outcome criterion patient followedfor month record cause mortality result total patient died follow dying within month discharge serum ngal p urine ngal p urinary kim p level significantly higher deceased patient discharge adjustment estimated glomerular filtration rate egfr urinary kim independently predicted mortality month hazard ratio hr ci p month hr ci p cox regression model receiver operating characteristic roc analysis urinary kim area roc curve auc outperformed marker renal function kaplan meier survival analysis showed kim predictive value additive aki incidence admission egfr admission serum ngal higher aki patient p modest diagnostic performance auc urea auc creatinine auc cystatin c auc conclusion discharge urinary kim strong independent predictor mortality particularly vulnerable period shortly hospitalization admission serum ngal inferior conventional renal function parameter predicting aki adhf:0.0187771113064327"
  },
  "Topic 11": {
    "138426": "hypertrophic cardiomyopathy hcm common inherited disease prevalence worldwide cause hcm usually present autosomal dominant mutation gene encoding one sarcomeric protein incomplete penetrance variable expressivity hcm classically manifest unexplained thickness interventricular septum iv left ventricular lv wall without obstruction lv outflow tract lvot variable cardiac arrhythmia present rare case mixed cardiomyopathy cardiac hypertrophy dilation erythrocytosis young patient year old man admitted clinic due biventricular heart failure hf nyha class iii personal medical record included diagnosis dilated cardiomyopathy dcm since age year time considered outcome myocarditis severe respiratory infection led circulatory decompensation acute femoral thrombosis combination non obstructive lv hypertrophy lv wall mm lv dilatation decreased contractility lv ef lv apical thrombosis seen cardiac mri showed complex pattern late gadolinium enhancement lge endomyocardial biopsy emb revealed primary cardiomyopathy intravascular coagulation inflammatory response viral genome detected plasma emb sample whole exome sequencing wes revealed homozygous frame deletion p del mybpc gene clinically unaffected mother heterozygous carrier deletion father unavailable clinical genetic testing essential erythrocytosis remains unexplained significant improvement achieved conventional treatment including prednisolone mg therapy icd implanted due sustained vt high risk scd orthotopic heart transplantation htx considered optimal early manifestation combined hypertrophic dilated phenotype progression may reflect complex genotype one pathogenic allele combination genetic disease one patient:0.0350824020304029",
    "128384": "left ventricular non compaction lvnc rare genetically heterogeneous cardiomyopathy disorder vastly affect infant young child severe neonatal lvnc relatively rare prevalence genetic defect underlying pediatric adult onset lvnc mutation myh mybpc sarcomeric gene found vast majority positive pediatric case pkp encodes plakophilin non sarcomeric desmosomal protein multiple role cardiac myocytes including cell cell adhesion tightening gap junction transcriptional factor reported pkp mutation heterozygous missense truncating variant associated adult onset autosomal dominant disorder namely arrhythmogenic right ventricular dysplasia cardiomyopathy arvd c homozygous pkp mutation rarely described herein present rare case infant neonatal onset congestive heart failure owing severe lvnc multiple muscular vsd medical treatment failed control heart failure patient died month age whole exome sequencing identified novel homozygous pkp variant c g c patient mrna analysis revealed aberrant transcript lacking exon predicted cause frameshift truncated peptide p gly glufster heterozygous parent normal cardiac structure function demonstrated electrocardiogram echocardiography pathogenic variant sarcomeric gene analyzed found patient conducted literature review identified eight family biallelic pkp mutation observed three family included null variant linked lethal phenotype homozygous missense mutation resulted less severe manifestation adolescent onset arvd c childhood onset dcm data support previous notion severe neonatal lvnc might represent unique entity distinct genetic spectrum conclusion present study extended phenotype genotype pkp related disorder lethal lvnc:0.0345963501352906",
    "140545": "background hereditary transthyretin amyloidosis hattr autosomal dominantly inherited disorder caused accumulation amyloid fibril tissue due mutation transthyretin ttr gene prevalence hattr still unclear likely underestimated many country order apply new therapy targeted manner early diagnosis knowledge phenotype genotype correlation mandatory study aimed assess prevalence phenotypic spectrum hattr austria method within period patient attr associated cardiomyopathy unexplained progressive polyneuropathies screened mutation ttr gene result identified case family carrying different ttr missense mutation confirmed two mutational hot spot c g p arg c g c p val leu two patient late onset attr carried ttr variant unknown significance majority patient initially presented heart failure symptom subsequently accompanied progressive polyneuropathy case total history carpal tunnel syndrome onset organ manifestation conclusion study underlined relevance hattr pathogenesis amyloid driven cardiomyopathy axonal polyneuropathy indicated considerable genetic heterogeneity disease austrian population estimated prevalence hattr austria based study potentially higher number unknown case must taken account respect new therapeutic approach strongly propose genetic testing ttr gene extended cohort patient unexplained heart failure progressive polyneuropathy:0.0331149322165341",
    "69417": "background transthyretin amyloidosis systemic disorder caused extracellular deposition insoluble amyloid fibril peripheral autonomic nerve heart kidney gastrointestinal tract organ hereditary transthyretin amyloidosis autosomal dominant disease mutation reported transthyretin gene considerable phenotypic heterogeneity geographic diversity among sporadic case hereditary transthyretin amyloidosis cardiac predominant phenotype rare progressive potentially fatal left undiagnosed however clinical diagnosis cardiac amyloidosis still remains challenging due non specific symptom less sensitivity specificity medical examination case presentation year old japanese man history embolic stroke hypertrophic cardiomyopathy visited department heart failure present case exhibited cardiomyopathy without clinical sign systemic amyloidosis manifested carpal tunnel syndrome polyneuropathy autonomic dysfunction echocardiogram revealed severe asymmetric left ventricular hypertrophy biatrial dilatation pericardial effusion preserved left ventricular ejection fraction severe diastolic dysfunction technetium pyrophosphate scintigraphy indicated marked diffuse myocardial uptake technetium pyrophosphate strongly suggesting transthyretin cardiac amyloidosis firmly confirmed left ventricular endomyocardial biopsy genetic analysis demonstrated transthyretin c pro ser heterozygous mutation tafamidis transthyretin stabilizer started cardiac symptom remained unchanged month conclusion report case patient hereditary cardiac amyloidosis associated pro ser mutation transthyretin first case reported japan technetium pyrophosphate scintigraphy extremely useful definitive diagnosis thus propose nuclear imaging technique taken account even exploratory diagnosis transthyretin cardiac amyloidosis:0.0330050673180907",
    "94324": "left ventricular noncompaction lvnc cardiomyopathy characterized two layered structure composed prominent trabecular meshwork deep intertrabecular recess lvnc thought rare however heightened awareness resulted increased detection morphological feature lvnc routine clinical practice especially adult population although lvnc classified independent primary cardiomyopathy genetic origin american heart association definition diagnostic criterion clinical implication still debated clinical manifestation highly variable even family ranging symptom disabling congestive heart failure life threatening arrhythmia systemic thromboemboli sudden cardiac death among phenotypic subtypes lvnc child isolated lvnc normal cardiac function best outcome child lvnc dilated cardiomyopathy worst outcome myocardial dysfunction ventricular arrhythmia predictor mortality adult lvnc lvnc like form inherited cardiomyopathy genetically heterogeneous inherited autosomal dominant x linked recessive disorder linked mutation many gene including zasp taz g encoding sarcomeric z disc cytoskeleton protein mitochondrion disturbance notch signaling pathway reported part genetic pathway lvnc well although increasing number report genotype phenotype correlation challenging investigation ongoing patient mutation likely major adverse cardiovascular event lv systolic dysfunction mutation carrier make high risk cardiac event treatment focus improvement cardiac function reduction mechanical stress patient systolic dysfunction treatment arrhythmia implantation automatic implantable cardioverter defibrillator prevention sudden death given case may familial family screening recommended:0.0319787444986031",
    "58426": "inherited cardiomyopathy major cause sudden cardiac death scd heart failure hf disease associated extensive genetic heterogeneity pathogenic mutation cardiac sarcomere protein gene cytoskeletal protein gene nuclear envelope protein gene linked etiology early diagnosis conducive clinical monitoring allows presymptomatic intervention needed present study entire coding sequence flanking region major disease cardiomyopathy related gene namely myosin heavy chain cardiac muscle beta myh myosin binding protein c cardiac mybpc lamin c lmna troponin type cardiac tnni troponin type cardiac tnnt actin alpha cardiac muscle actc tropomyosin alpha tpm sodium channel voltage gated type v alpha subunit scn myosin light chain regulatory cardiac slow myl myosin heavy chain cardiac muscle alpha myh myosin light chain alkali ventricular skeletal slow myl protein kinase amp activated gamma non catalytic subunit prkag patient dilated cardiomyopathy dcm patient hypertrophic cardiomyopathy hcm amplified sequenced using ion torrent personal genome machine pgm system result novel heterozygous mutation myh p asn thr variant uncertain significance tnnt p arg identified patient hcm missense mutation absent sample obtained healthy control subject altered amino acid evolutionarily conserved among number vertebrate specie illustrates non synonymous mutation play role pathogenesis hcm moreover double heterozygous mutation prkag p gly ser plus myh p arg trp identified patient severe familial hcm first time best knowledge patient provided u information regarding genotype phenotype correlation mutation myh prkag taken together finding provide insight molecular mechanism underlying inherited cardiomyopathy mutation identified study may investigated future order improve diagnosis treatment patient inherited cardiomyopathy furthermore finding indicated sequencing using ion torrent pgm system useful approach identification pathogenic mutation associated inherited cardiomyopathy may used risk evaluation individual possible susceptibility inherited cardiomyopathy:0.0317069563991054",
    "56842": "dilated cardiomyopathy one leading cause heart failure primary cause heart transplantation patient age year despite major advance diagnostic procedure examination myocardial biopsy etiology remains unknown many patient chronic inflammation myocarditis chronic alcohol abuse considered two main etiologic factor dilated cardiomyopathy third causal factor namely genetic transmission disease least common myocardial inflammation toxic damage several prospective study relative patient dilated cardiomyopathy proved case familial etiology common mode inheritance autosomal dominant less frequently disease inherited x chromosomal trait autosomal recessive mitochondrial transmission rare penetrance highly variable age dependent many relative patient dcm show minor cardiac abnormality unknown whether progress full cardiomyopathy later life examination family identified far eight disease gene namely dystrophin tafazzin cardiac actin desmin lamin c delta sarcoglycan cardiac beta myosin heavy chain cardiac troponin gene certain mutation lamin c cause conduction system disease dilated cardiomyopathy whereas mutation cause addition skeletal muscle myopathy dystrophin mutation cause rare x linked dilated cardiomyopathy without skeletal muscle involvement progressive course young men mutation dystrophin gene mainly deletion cause muscular dystrophy becker duchenne also present dilated cardiomyopathy mutation desmin delta sarcoglycan cardiac actin beta myosin heavy chain well troponin gene known cause autosomal dominant dilated cardiomyopathy without abnormality infantile x linked dcm caused mutation tafazzin gene onset disease typically within first year life death occurs usually childhood patient may addition characterized skeletal myopathy short stature neutropenia abnormal mitochondrion also referred barth syndrome knowledge dcm disease gene led new hypothesis dilated cardiomyopathy disease myocardial force generation force transmission many disease locus known responsible disease gene yet identified better understanding expression function disease gene may eventually result new diagnostic therapeutic tool order improve prognosis severe disorder:0.0313887240421108",
    "92137": "idiopathic dilated cardiomyopathy heritable genetically heterogeneous disorder characterized progressive heart failure dilated cardiomyopathy typically exhibit autosomal dominant inheritance yet frequently remains clinically silent adulthood sought discover molecular basis idiopathic non syndromic dilated cardiomyopathy one month old male presenting severe heart failure previous comprehensive testing blood urine skin biopsy specimen negative metabolic mitochondrial storage infectious etiology ophthalmologic examination normal chromosomal microarray commercial dilated cardiomyopathy gene panel testing failed identify causative mutation parental screening echocardiogram revealed evidence clinically silent dilated cardiomyopathy whole exome sequencing carried family trio research basis filtering rare deleterious recessive de novo genetic variant pathogenic compound heterozygous truncating mutation identified alms diagnostic alstrom syndrome prompting disclosure genetic finding alstrom syndrome known cause dilated cardiomyopathy child yet delayed mi diagnosis common owing rarity age dependent emergence multisystem clinical manifestation six month age patient ultimately developed bilateral nystagmus hyperopia feature characteristic syndrome early diagnosis guiding clinical monitoring organ system allowing presymptomatic intervention furthermore recognition recessive inheritance mechanism sporadic disease informed family planning case highlight limitation standard gene testing panel pediatric dilated cardiomyopathy exemplifies potential whole exome sequencing solve diagnostic dilemma enable personalized care:0.0309569002489219",
    "129158": "transthyretin ttr related hereditary amyloidosis attrv rare autosomal dominant disorder caused pathogenic missense mutation ttr gene today ttr gene variant reported occur causal mutation herein present three familial patient attrv caused thr ser p thr ser variant including phenotype penetrance first patient year old woman history carpal tunnel syndrome referred department heart failure symptom echocardiography technetium tc pyrophosphate scintigraphy myocardial biopsy confirmed diagnosis ttr related amyloidosis genetic testing ttr gene performed confirmed presence thr ser p thr ser variant second patient year old woman niece first patient presented dyspnea exertion clinical manifestation included cardiac symptom addition polyneuropathy similarly myocardial biopsy showed ttr amyloid deposition within cardiac tissue ttr gene sequencing detected presence thr ser p thr ser variant final patient year old man nephew first patient presented numbness hand abdominal wall fat pad biopsy showed ttr amyloid deposition ttr gene sequencing performed considering familial history confirm presence thr ser p thr ser variant cardiac symptom dysfunction observed yet imaging detected ttr amyloid deposition heart present three patient thr ser p thr ser variant showed variation phenotype including cardiac neurological manifestation fairly young age addition familial relationship report suggested variant highly penetrant early genetic diagnosis due collecting genetic information family medical history may beneficial improve patient prognosis via early therapeutic intervention:0.0309382099233541",
    "93988": "background familial dilated cardiomyopathy dcm genetically heterogeneous associated mutation least different gene apart ttn encoding giant protein titin none gene expected diagnostic yield complicating genetic diagnosis whole exome sequencing wes powerful alternative identification causal gene however variant interpretation remains challenging report wes large family autosomal dominant dcm complicated end stage heart failure non sustained ventricular arrhythmia causative mutation identified using targeted gene panel including gene method result wes applied affected cousin stringent filtering identified genetic variant performed including population variant frequency silico analysis orthologous paralogous conservation subsequently sanger sequencing performed potential disease causing variant order confirm presence variant evaluate co segregation one variant exon rbm gene c p met lys nm showed full co segregation affected family member resulting maximum point lod score suggesting pathogenic mutation responsible phenotype recently mutation rbm linked arrhythmogenic dilated cardiomyopathy caused defective splicing giant sarcomere protein titin abnormal calcium handling conclusion report identification novel mutation rbm wes large pedigree dcm:0.0309109914826874"
  },
  "Topic 12": {
    "199656": "introduction bleeding serious complication cardiac surgery especially among patient receiving combined anticoagulant antiplatelet therapy current prediction model rarely include undergoing valve surgery coronary artery bypass grafting cabg account postoperative factor dual antithrombotic therapy limiting clinical utility aim study aimed develop validate machine learning model individualized prediction bleeding event within three month discharge patient receiving warfarin plus aspirin following combined cabg valve surgery method data adult patient underwent cardiac surgery received combined anticoagulant antiplatelet therapy june december retrospectively analyzed patient randomly assigned training internal validation cohort eleven key bleeding predictor selected using least absolute shrinkage selection operator lasso method seven machine learning algorithm logistic regression decision tree random forest rf support vector machine extreme gradient boosting xgboost light gradient boosting machine lightgbm k nearest neighbor subsequently trained using predictor model performance evaluated based area receiver operating characteristic curve auc accuracy sensitivity specificity positive predictive value ppv negative predictive value npv f score brier score external validation performed temporally independent cohort patient model interpretability assessed shapley additive explanation shap used visualize global individual risk contribution result eleven clinical variable including anemia diabetes heart failure atrial fibrillation age postoperative drainage previous bleeding stroke body mass index estimated glomerular filtration rate intraoperative bleeding identified predictor among model rf algorithm demonstrated best performance internal validation auc accuracy sensitivity specificity ppv npv f score external validation rf model maintained strong performance auc accuracy sensitivity specificity ppv npv f score decision curve analysis confirmed clinical utility model shap visualization provided transparent interpretation individualized bleeding risk conclusion study demonstrates feasibility clinical utility ml based prediction short term bleeding risk cardiac surgery patient dual antithrombotic therapy rf model enables individualized risk assessment shap interpretation supporting clinical applicability:0.0336123723926914",
    "195038": "background sepsis induced coagulopathy sic fatal complication icu patient yet early risk prediction remains challenging study aimed develop interpretable machine learning model predicting sic within seven day icu admission method clinical data model development retrieved medical information mart intensive care iv mimic iv database feature selection performed using three distinct algorithm least absolute shrinkage selection operator lasso regression random forest recursive feature elimination rf rfe boruta method ten machine learning model underwent training employing fold cross validation training subset subsequent evaluation validation subset encompassing discrimination calibration clinical utility metric optimal model underwent interpretability analysis shapley additive explanation shap elucidate variable contribution directional effect external validation conducted using electronic intensive care unit collaborative research database eicu crd finally best performing model implemented web based shiny application featuring interactive interface result among patient mimic iv developed sic within day post icu admission lightgbm model thirteen variable demonstrated optimal performance achieving area receiver operating characteristic curve auroc confidence interval ci internal validation set ci external eicu crd cohort key predictive variable included prothrombin time international normalization ratio inr platelet count sequential organ failure assessment sofa lactate systolic blood pressure sbp red cell distribution width rdw bicarbonate phosphate hemoglobin age presence heart failure hf ischemic heart disease ihd use continuous renal replacement therapy crrt model deployed clinician oriented web application providing accessible interface http shatao shinyapps io sepsis induced coagulopathy conclusion model demonstrated strong predictive ability clinical interpretability enabling early sic identification targeted intervention:0.0336097422882763",
    "194293": "background early prediction heart failure hf acute myocardial infarction ami essential personalized treatment aimed use interpretable machine learning ml method develop risk prediction model hf ami patient method retrospectively included patient initially ami received percutaneous coronary intervention pci hospital november february primary endpoint occurrence hf within year operation developing predictive model hf risk ami patient least absolute shrinkage selection operator lasso regression used feature selection four ml algorithm including random forest rf extreme gradient boost xgboost support vector machine svm logistic regression lr employed develop model training set performance evaluation prediction model carried training set testing set utilizing metric including auc area receiver operating characteristic curve calibration plot decision curve analysis dca addition used shapley additive explanation shap value determine importance selected feature interpret optimal model result total ami patient included patient developed hf follow among four evaluated ml model xgboost model exhibited exceptional accuracy auc value shap method showed left ventricular ejection fraction lvef left ventricular end systolic diameter lvds lactate dehydrogenase ldh identified three important characteristic predict hf risk ami patient individual risk assessment performed using shap plot waterfall plot analysis conclusion research demonstrates potential ml method early prediction hf risk ami patient furthermore enhances interpretability xgboost model shap analysis guide clinical decision making:0.0334982753247368",
    "182984": "objective risk stratification patient congestive heart failure hf vital clinical practice aim study construct machine learning model predict hospital cause mortality intensive care unit icu patient hf method extreme gradient boosting algorithm xgboost used construct new prediction model xgboost model medical information mart intensive care iv database mimic iv training set eicu collaborative research database dataset eicu crd used external validation test set xgboost model performance compared logistic regression model existing model get guideline heart failure model mortality test set area receiver operating characteristic cure brier score employed evaluate discrimination calibration three model shapley additive explanation shap value applied explain xgboost model calculate importance feature result total patient congestive hf training set test set respectively included study hospital cause mortality occurred patient respectively training set feature highest predictive value selected model lasso regression acute physiology score iii aps iii age sequential organ failure assessment sofa strongest predictor shap external validation xgboost model performance superior conventional risk predictive method area curve confidence interval brier score evaluation clinical effectiveness machine learning model brought positive net benefit threshold probability prompting evident competitiveness compare two model model translated online calculator accessible freely public http nkuwangkai app mortality prediction app mhkf streamlit app conclusion study developed valuable machine learning risk stratification tool accurately assess stratify risk hospital cause mortality icu patient congestive hf model translated web based calculator access freely:0.0319759574296877",
    "192758": "background currently paucity literature addressing personalized risk stratification using multimodal data patient symptomatic aortic stenosis heart failure preserved ejection fraction hfpef following transcatheter aortic valve replacement tavr objective study aimed enhance performance risk assessment model patient population developing predictive model adverse outcome using various machine learning ml technique method multicenter cohort study included patient diagnosed severe hfpef underwent tavr january december patient allocated training n independent validation n set based hospital affiliation dual phase feature selection process combining least absolute shrinkage selection operator logistic regression boruta algorithm used identify relevant variable multimodal dataset total ml model decision tree k nearest neighbor random forest support vector machine extreme gradient boosting used construct visualization explainable predictive framework elucidate model decision making process result primary feature identified included age n terminal pro brain natriuretic peptide fasting blood glucose triglyceride high density lipoprotein cholesterol ratio triglyceride glucose index triglyceride glucose bmi index atherogenic index plasma index apolipoprotein b among model support vector machine demonstrated best predictive performance major adverse cardiovascular cerebrovascular event patient severe hfpef following tavr achieving area curve ci independent validation set model exhibited good calibration robust predictive power training validation set demonstrated highest net benefit decision curve analysis compared model extract significant variable influencing algorithm ensure model appropriateness interpreted cohort personalized model prediction using shapley additive explanation value conclusion ml based multimodal model incorporating readily accessible predictor demonstrated robust predictive capability month major adverse cardiovascular cerebrovascular event risk model used identify high risk individual hfpef following tavr potentially aiding risk stratification personalized treatment strategy:0.0319233143366755",
    "197911": "background currently heart failure become one major complication advanced stage various cardiovascular disease numerous predictive model developed estimate mortality rate heart failure patient however model often require measurement multiple indicator inclusion various scoring system critically ill patient often unsuitable extensive diagnostic test many primary care hospital lack comprehensive diagnostic equipment contrast blood test simpler also reflect overall health status body therefore using simpler method predict mortality intensive care unit icu patient become focus study method total case eicu database utilized model development case mimic iv database employed external testing patient primarily diagnosed heart failure data included demographic information blood oxygen saturation white blood cell red blood cell platelet hemoglobin electrolyte lactate glucose biochemical physiological indicator collected icu stay enhance accuracy data analysis improve universality model data underwent rigorous preprocessing prior training combined data standardization utilized variety machine learning algorithm modeling purpose including logistic regression lr support vector machine svm decision tree random forest gradient boosting machine gbm xgboost neural network performance model assessed cross validation evaluated using f score conclusion feature selection key variable ultimately identified among nine machine learning model evaluated multilayer perceptron mlp demonstrated best overall performance predicting mortality e deceased population mlp achieved f score recall precision relatively high f score mlp highlight potential clinical application value:0.0314609390225599",
    "127217": "objective study aim construct validate several machine learning ml algorithm predict long term mortality identify risk factor unselected patient post cardiac surgery method medical information mart intensive care mimic iii database used perform retrospective administrative database study candidate predictor consisted demographic comorbidity vital sign laboratory test result scoring system treatment information first day icu admission four year mortality set study outcome used ml method logistic regression lr artificial neural network nnet naive bayes nb gradient boosting machine gbm adapting boosting ada random forest rf bagged tree bt extreme gradient boosting xgb prognostic capacity clinical utility ml model compared using area receiver operating characteristic curve auc calibration curve decision curve analysis dca result patient mimic iii included final cohort total patient died year follow among variable extracted database total predictor selected using recursive feature elimination included subsequent analysis ada model performed best among eight model discriminatory ability highest auc goodness fit visualized calibration curve moreover dca show net benefit rf ada bt model surpassed ml model almost threshold probability value additionally ada technique determined red blood cell distribution width rdw blood urea nitrogen bun sap ii anion gap ag age urine output chloride creatinine congestive heart failure sofa top predictor feature importance ranking conclusion ada model performs best predicting year mortality cardiac surgery among eight ml model might significant application development early warning system patient following operation:0.0312726431073958",
    "190772": "introduction heart failure hf may induce bowel hypoperfusion leading hypoxia villa bowel wall occurrence clostridioides difficile infection cdi however risk factor development cdi hf patient yet fully illustrated especially lack evidence real world data method clinical data survival situation hf patient cdi admitted icu extracted medical information mart intensive care mimic iv database developing model predict day cause mortality hf patient cdi recursive feature elimination cross validation rfe cv method used feature selection nine machine learning ml algorithm including logistic regression lr decision tree bayesian adaptive boosting random forest rf gradient boosting decision tree xgboost light gradient boosting machine categorical boosting applied model construction training hyperparameter optimization model grid search fold cross validation performance model evaluated area curve auc accuracy sensitivity specificity precision negative predictive value f score furthermore shapley additive explanation shap method used interpret optimal model result total hf patient cdi included study case experienced death within day eighteen variable selected model construction algorithm model construction among ml model considered rf model emerged optimal model achieving accuracy f score auc value respectively net benefit model surpassed model threshold probability based decision curve analysis according importance feature rf model red blood cell distribution width blood urea nitrogen simplified acute physiology score ii sequential organ failure assessment white blood cell count highlighted five influential variable conclusion developed ml model predict day cause mortality hf patient associated cdi icu effective conventional lr model rf model best performance among ml model employed may useful help clinician identify high risk hf patient cdi:0.0312258912225179",
    "174187": "background heart failure hf rank among foremost cause mortality globally exhibiting particularly high prevalence significant impact within intensive care unit icu study sought develop validate deploy time dependent machine learning model aimed predicting one year cause mortality risk icu patient diagnosed hf thereby facilitating precise prognostic evaluation risk stratification method study encompassed cohort icu patient hf sourced medical information mart intensive care iv mimic iv database version latest version database added data basis version covering data therefore data spanning n designated training set data n reserved test set primary endpoint interest one year cause mortality least absolute shrinkage selection operator lasso regression employed select predictive feature initial pool candidate variable including demographic characteristic vital sign comorbidities complication therapeutic intervention routine laboratory data disease severity score four predictive model developed compared cox proportional hazard random survival forest rsf cox proportional hazard deep neural network deepsurv extreme gradient boosting xgboost model performance assessed using concordance index c index brier score model interpretability addressed shapley additive explanation shap time dependent survival shapley additive explanation survshap result study revealed one year mortality rate within population investigation training set lasso effectively identified feature model test set xgboost model exhibited superior predictive performance evidenced c index brier score outperforming cox model c index brier score rsf model c index brier score deepsur model c index brier score decision curve analysis validated clinical utility xgboost model across broad spectrum risk threshold feature importance analysis identified red cell distribution width albumin ratio rar charlson comorbidity index simplified acute physiology score ii sap ii acute physiology score iii aps iii age bilirubin inr creatinine abic score top five predictive factor consequently online risk prediction tool based model developed publicly accessible conclusion time dependent xgboost model demonstrated robust predictive capability evaluating one year cause mortality risk critically ill hf patient model offered useful tool early risk identification supported timely intervention:0.0310650653932942",
    "193902": "background chronic heart failure chf serious threat human health high morbidity mortality rate imposing heavy burden health care system society abundance medical data rapid development machine learning ml technology new opportunity provided depth investigation mechanism chf construction predictive model introduction health ecology research methodology enables comprehensive dissection chf risk factor wider range environmental social individual factor help identify high risk group early stage also provides scientific basis development precise prevention intervention strategy objective study aim use ml construct predictive model risk occurrence chf analyze risk chf health ecology perspective method study sourced data jackson heart study database stringent data preprocessing procedure implemented included meticulous management missing value standardization data principal component analysis random forest rf used feature selection technique subsequently several ml model namely decision tree rf extreme gradient boosting adaptive boosting adaboost support vector machine naive bayes model multilayer perceptron bootstrap forest constructed performance evaluated effectiveness model validated internal validation using fold cross validation approach training validation set addition performance metric model including accuracy precision sensitivity f score area curve auc compared selecting best model used hyperparameter optimization construct better model result rf selected feature total average root mean square error outperforming principal component analysis synthetic minority oversampling technique edited nearest neighbor showed better accuracy data balancing adaboost model effective auc accuracy precision sensitivity f score validation training validation set fold cross validation gave auc accuracy precision sensitivity f score random search processing accuracy auc adaboost improved accuracy auc conclusion study offered insight chf risk prediction future research focus prospective study diverse data advanced technique longitudinal study exploring factor interaction better chf prevention management:0.0309282503558012"
  },
  "Topic 13": {
    "130454": "background left bundle branch area pacing lbbap emerged promising technique deliver cardiac resynchronization therapy crt however safety efficacy ventricular arrhythmia sensing via left bundle implantable cardioverter defibrillator icd recipient remain unclear sought evaluate feasibility single lbbap lead connected dual chamber icd patient indicated crt implantation method cross left pilot study prospectively included consecutive patient reduced ejection fraction complete left bundle branch block indicated prophylactic crt df lead implanted right ventricular rv apex lbbap lead interventricular septum ventricular fibrillation induced implantation conventional rv left bundle branch area sensing configuration latter final sensing configuration patient implanted dual chamber df icd connected atrial lead ra port lbbap lead rv port defibrillation lead rv df port pin capped atrioventricular delay optimized ensure fusion lbbap native conduction right bundle patient followed month result difference configuration observed regarding r wave sensing sinus rhythm p ventricular fibrillation median interval detection p total induced episode duration p lbbap resulted significant reduction median qrs width m p median ventricular sensing significantly improved implantation mv month p median lvef also significantly improved month p conclusion ventricular arrhythmia sensing defibrillation performed via single lbbap lead connected dual chamber icd associated significant electromechanical reverse remodeling clinical trial registration number nct patient presenting left bundle branch block left ventricular systolic dysfunction left bundle branch area pacing lead connected df dual chamber implantable cardioverter defibrillator provides safe ventricular arrhythmia sensing efficient electro mechanical resynchronization:0.0280391608064977",
    "188647": "background patient heart failure non left bundle branch block non lbbb qrs pattern limited response biventricular pacing bvp objective personalized cardiac resynchronization therapy crt implantation approach guided real time electrocardiographic imaging ecgi studied method twenty patient left ventricular ejection fraction lvef qrs duration m non lbbb right bundle branch block intraventricular conduction delay recruited crt implantation right atrial right ventricular coronary sinus bundle left bundle lead inserted total activation time tat different pacing combination measured real time implantation ecgi configuration producing shortest tat chosen clinical response defined new york heart association class improvement echocardiographic response defined left ventricular end systolic volume reduction lvef improvement month result ecgi guided crt implantation lvef improved p new york heart association class improved p clinical echocardiographic response rate ecgi approach resulted better acute electrical resynchronization bvp measured tat reduction v p percentage tat reduction found strong predictor echocardiographic response area curve receiver operating characteristic curve confidence interval strong positive correlation percentage tat reduction percentage lvef improvement pearson r p found conclusion ecgi guided crt implantation patient non lbbb generates superior acute electrical resynchronization compared bvp associated favorable clinical echocardiographic outcome:0.0262982531528371",
    "41895": "background aim cardiac resynchronization therapy crt improves ventricular dyssynchrony associated improvement symptom quality life prognosis patient severe heart failure intraventricular conduction delay different pacing modality produce variable activation pattern may cause different haemodynamic change aim study investigate acute haemodynamic change different crt configuration optimization procedure method study included patient severe left ventricular systolic dysfunction left bundle branch block wide qrs ef qrs m new york heart association iii iv implanted crt device whole group patient severe mitral regurgitation order measure dp dt implantation discharge patient underwent optimization procedure guided doppler echocardiography left right ventricular pre ejection interval lvpei rvpei interventricular mechanical delay ivd maximal rate ventricular pressure rise early systole max dp dt measured left biventricular pacing three different atrioventricular av delay result crt device optimization optimal av delay crt mode defined left ventricular pre ejection interval changed p rvpei p ivd p dp dt p conclusion patient receiving crt echocardiographic assessment acute haemodynamic response crt useful tool optimization procedure variability doppler parameter different crt modality emphasizes necessity individualized approach optimization procedure:0.0259796125048816",
    "123344": "background cardiac resynchronization therapy crt based conventional biventricular pacing biv crt technique sometimes result broad qrs complex suboptimal response objective aimed assess feasibility outcome crt based left bundle branch area pacing lbbap lieu right ventricular lead combined coronary venous left ventricular pacing international multicenter study method lbbap optimized crt lot crt attempted nonconsecutive patient crt indication addition lbba coronary venous lead discretion implanting physician guided suboptimal paced qrs complex clinical ground result lot crt successful patient baseline characteristic follows mean age year female left ventricular ejection fraction left ventricular end diastolic diameter mm n terminal pro b type natriuretic peptide level pg ml left bundle branch block nonspecific intraventricular conduction delay right ventricular pacing right bundle branch block procedure characteristic follows mean fluoroscopy time minute lbbap capture threshold v m r wave amplitude mv lot crt resulted significantly greater narrowing qrs complex m baseline m p biv crt m p lbbap m p follow month ejection fraction improved left ventricular end diastolic diameter decreased mm n terminal pro b type natriuretic peptide level decreased pg ml pacing parameter stable clinical improvement noted patient new york heart association class v conclusion lot crt feasible safe provides greater electrical resynchronization compared biv crt could alternative especially suboptimal electrical resynchronization obtained biv crt randomized controlled trial comparing lot crt biv crt needed:0.0257623349394466",
    "77262": "background bundle pacing hbp physiologic form pacing associated higher threshold lower success patient purkinje conduction disease recent report described transvenous left bundle branch area pacing lbbap objective aimed prospectively evaluate feasibility electrophysiologic echocardiographic characteristic lbbap method patient requiring pacing bradycardia heart failure indication failed left ventricular lv lead prospectively enrolled lbbap performed medtronic lead presence left bundle branch lbb potential paced qrs morphology duration peak lv activation time plvat recorded implant pacing threshold sensing assessed implant follow echocardiography performed assess approximate lead location impact tricuspid valve function result lbbap successful patient mean age year men left bundle branch block right bundle branch block intraventricular conduction defect indication pacing atrioventricular av block sinus node dysfunction av node ablation cardiac resynchronization therapy hbp lead failure baseline qrs duration m paced qrs duration m lbb potential observed patient left bundle branch ventricle lbb v interval m plvat m pacing threshold implant v m r wave mv remained stable median follow month lead depth septum approximately cm conclusion lbbap feasible high percentage patient low threshold acute follow hbp lbbap may significantly increase overall success physiologic pacing:0.0257221528743837",
    "107902": "background cardiac resynchronization therapy crt established therapy patient cardiomyopathy left bundle branch block heart failure bundle pacing hbp may also improve clinical outcome narrowing qrs duration qrs narrowing hbp may always optimal aim study determine crt could optimized sequential hbp followed left ventricular lv pacing optimized crt hot crt maximize electrical resynchronization method attempted permanent hbp patient left bundle branch block intraventricular conduction defect right ventricular pacing referred crt addition lv lead hbp followed lv pacing delay equal ventricular interval qrs duration baseline hbp biventricular pacing hot crt measured echocardiographic parameter new york heart association functional class assessed baseline follow result hot crt successful patient age year men ischemic qrs duration baseline m significantly narrowed m biventricular pacing p m hbp p m hot crt p mean follow month lv ejection fraction improved p new york heart association functional class changed twenty one patient clinical responder showed echocardiographic response conclusion feasibility cohort hot crt resulted improved electrical resynchronization hot crt may improve clinical echocardiographic outcome advanced heart failure patient requiring crt:0.0257022694825890",
    "54886": "background antiarrhythmic proarrhythmic effect cardiac resynchronization therapy crt remain controversial hypothesized reverse electrical remodeling rer crt associated reduced frequency ventricular tachyarrhythmias vt method width native paced qrs measured lead ii electrocardiogram month implantation crt defibrillator device patient mean age male bundle branch block bbb patient left bbb three patient bifascicular block nonspecific intraventricular conduction delay patient new york heart association class iii iv heart failure biventricular pacing inhibited second record native qrs rer defined decrease native qrs duration m compared preimplant patient followed prospectively month assessment electrical remodeling result rer observed patient among qrs duration decreased m p similar heart rate qrs morphology native qrs duration increased m patient p baseline mean ejection fraction differ patient without rer v n year follow patient vt patient died rer associated fourfold decrease risk death sustained vt requiring appropriate implantable cardioverter defibrillator therapy whichever came first hazard ratio confidence interval p conclusion rer native conduction crt associated decreased mortality antiarrhythmic effect crt:0.0253175973803331",
    "63626": "cardiac resynchronization therapy crt established therapeutic option symptomatic heart failure reduced ejection fraction evidence left ventricular lv conduction delay qrs width m especially typical left bundle branch block present rationale behind crt restoration aberrant lv electrical activation considerable heterogeneity lv electrical activation pattern among crt candidate individualized approach targeting lv lead region latest electrical activation avoiding scar tissue may enhance crt response echocardiography electro anatomic mapping cardiac magnetic resonance imaging late gadolinium enhancement helpful guide targeted lv lead placement however important limitation remains anatomy coronary sinus often allow concordant lv lead placement optimal region epicardial lv lead placement minimal invasive surgery endocardial lv lead placement transseptal punction may overcome limitation obviously increased complication risk furthermore recent pacing algorithm suggest superiority lv versus biventricular pacing patient preserved atrio ventricular av conduction typical lbbb pattern finally pacing one lv site might overcome wide electrical dispersion often seen patient lv conduction delay therefore multisite pacing gained significant interest improve crt response use multiple lv lead may potentially lead favorable reverse remodeling improved functional capacity quality life crt candidate adverse event shorter battery span frequent extra lead use one multipolar lv lead increase number pacing configuration within coronary sinus side branch within small distance without use additional lead small observational study suggest effective resynchronization achieved approach finally many reason non effective crt delivery carefully selected patient adequately implanted device multidisciplinary post implantation care inside dedicated crt clinic ensures optimal crt delivery improves response rate considered standard care:0.0252258822264484",
    "13596": "introduction cardiac resynchronization therapy crt well established therapy patient moderate severe heart failure hf left ventricular dysfunction ejection fraction qrs surface electrocardiogram msec device optimization often performed adjusting timing rv lv stimulation produce pacing sequence yield best global cardiac performance however standard guideline exist optimization many invasive non invasive technique employed mixed result aim present study determine whether clinical predictor optimal v v setting patient implanted crt device method result prospectively evaluated consecutive patient hf referred device optimization clinic mean patient age year patient sinus rhythm atrial fibrillation prior device implant patient left bundle branch block lbbb intra ventricular conduction delay ivcd rv paced sixty two percent male mean qrs duration m mean lvef non ischemic cardiomyopathy overall patient required sequential pacing requiring lv pre excitation produce best global cardiac function determined aortic velocity time integral vti cohort none clinical characteristic evaluated including etiology cardiomyopathy qrs duration lvef pre implant rhythm av delay predictive optimal simultaneous sequential v v setting conclusion none clinical variable tested analysis predicted optimal rv lv setting result suggest individual optimization programming v v setting necessary inability predict optimal setting likely reflects unique characteristic patient support need individualized programming device:0.0252222226436510",
    "165330": "background cardiac resynchronization therapy crt biventricular pacing well established therapy left bundle branch area pacing lbbap safe technique providing physiological pacing lbbap optimized crt lot crt shown provide better electrical resynchronization traditional crt however report shock lead placement left bundle branch area lbba crt defibrillator crt implantation case summary year old woman heart failure dilated cardiomyopathy presented left bundle branch block pattern qrs duration m left ventricular ejection fraction cardiac resynchronization therapy defibrillator implantation performed due worsening symptom reshaping agilis hispro catheter adding septal curve shock lead placed deep ventricular septum narrowing qrs duration m left ventricular activation time m defibrillation threshold test confirmed successful treatment without adverse event month follow left ventricular ejection fraction improved patient condition improving new york heart association class iii class discussion reported qrs narrowing crt related long term mortality lot crt decreased qrs duration compared lbbp biventricular pacing increased response rate combining lbbap coronary sinus pacing potentially achieve superior electrical resynchronization lack suitable tool direct shock lead placement lbba necessitated additional lbbap lead conventional lot crt successful lot crt procedure minimal number lead agilis hispro catheter reshaping enabled direct lbba shock lead placement:0.0251164236393895"
  },
  "Topic 14": {
    "73022": "importance prior study demonstrated lower cause mortality individual overweight compared normal body mass index bmi whether may come cost greater burden cardiovascular disease cvd unknown objective calculate lifetime risk estimate incident cvd subtypes cvd estimate year lived without cvd weight status design setting participant population based study used pooled individual level data adult baseline age year across large u prospective cohort million person year follow participant free clinical cvd baseline available bmi index cvd outcome data data analyzed october july exposure world health organization standardized bmi category main outcome measure total cvd cvd subtype including fatal nonfatal coronary heart disease stroke congestive heart failure cvd death height weight measured directly investigator study bmi calculated weight kilogram divided height meter squared performed modified kaplan meier analysis estimate lifetime risk adjusted competing cox model estimate joint cumulative risk cvd noncardiovascular death irwin restricted mean estimate year lived free cvd result person examination included study mean sd age year men year woman patient female compared individual normal bmi defined bmi lifetime risk incident cvd higher middle aged adult overweight obese group compared normal weight among middle aged men woman competing hazard ratio incident cvd ci ci respectively overweight bmi ci ci obesity bmi ci ci morbid obesity bmi higher bmi strongest association incident heart failure among cvd subtypes average year lived cvd longer middle aged adult overweight obese group compared adult normal bmi group similar pattern observed younger older adult conclusion relevance study obesity associated shorter longevity significantly increased risk cardiovascular morbidity mortality compared normal bmi despite similar longevity compared normal bmi overweight associated significantly increased risk developing cvd earlier age resulting greater proportion life lived cvd morbidity:0.0297160579044989",
    "138687": "high office blood pressure variability obpv midlife increase risk cardiovascular disease cvd impact obpv older adult without previous cvd unknown conducted post hoc analysis aspree trial aspirin reducing event elderly participant aged year older u minority without history cvd event baseline examine risk incident cvd associated long term visit visit obpv cvd prespecified adjudicated secondary end point aspree estimated obpv using within individual sd mean systolic bp baseline first annual visit cox proportional hazard regression used calculate hazard ratio hr ci association cvd event participant survived year without event highest tertile obpv increased risk cvd event adjustment multiple covariates compared participant lowest tertile hr ci p similar increased risk observed ischemic stroke hr ci p heart failure hospitalization death hr ci p cause mortality hr ci p finding consistent stratifying participant use antihypertensive drug sensitivity analysis suggested increased risk especially individual whose bp uncontrolled obpv estimation period finding support increased obpv risk factor cvd event healthy older adult without hypertension event previously registration url http www clinicaltrials gov unique identifier nct url http www isrctn com unique identifier isrctn:0.0287931082503149",
    "136490": "importance american heart association ideal cardiovascular health cvh score associated risk cardiovascular disease cvd mortality however unclear whether number year spent ideal cvh associated morbidity mortality objective evaluate whether living longer higher cvh score midlife associated lower risk hypertension diabetes chronic kidney disease cvd subtypes coronary heart disease stroke congestive heart failure peripheral artery disease cause mortality later life design setting participant prospective cohort study used data participant participated community based framingham heart study offspring investigation conducted massachusetts cvh score participant assessed examination cycle respectively individual excluded analysis association duration cvh score outcome outcome interest seventh examination median follow approximately year data analyzed april october cvh score category poor score intermediate score ideal score composite score derived based smoking status diet physical activity resting blood pressure level body mass index fasting blood glucose level total serum cholesterol level main outcome measure number event number risk main outcome including incident hypertension diabetes chronic kidney disease cvd cause mortality seventh examination result eligible participant mean sd age year woman number event number risk main outcome seventh examination incident hypertension diabetes chronic kidney disease cvd cause mortality seventh examination participant mostly poor intermediate cvh score antecedent examination cycle year duration participant intermediate ideal cvh less likely develop adverse outcome hazard ratio ci incident hypertension ci diabetes ci chronic kidney disease ci cvd ci cause mortality relative living amount time poor cvh referent group effect modification observed age sex conclusion relevance result suggest time spent better cvh midlife may salutary cardiometabolic benefit may associated lower mortality later life:0.0287174504541445",
    "35588": "objective assess prospective association metabolic syndrome mets cardiovascular disease cvd older people evaluate effect lowering threshold impaired fasting glucose ifg prevalence ifg mets risk cvd design prospective cohort study setting four field center u community participant three thousand five hundred eighty five subject cardiovascular health study free diabetes mellitus cvd baseline mean age female black measurement baseline measure mets component adjudicated incident cvd event mets defined first using original criterion third adult treatment panel report national cholesterol education program following large waist circumference woman cm men cm elevated triglyceride mmol l low high density lipoprotein cholesterol men mmol l woman mmol l elevated fasting glucose mmol l high blood pressure mmhg self reported use medication hypertension subject also classified according revised definition mets applies lower threshold fasting glucose mmol l result follow median year coronary heart disease chd stroke congestive heart failure chf event occurred age race adjusted hazard ratio hr chd stroke chf confidence interval ci ci ci woman ci ci ci men respectively overall woman men mets likely experience cvd event subject without mets using lower cut point ifg resulted near tripling ifg prevalence additional classified mets hr similar estimated original mets criterion high blood pressure component strongly associated incident chd conclusion result study elderly population based cohort provide support earlier investigation primarily middle aged population link presence mets development cvd underscore importance recognizing treating individual component particularly high blood pressure:0.0286405930886689",
    "160402": "importance epidemiologic evidence regarding outcome dietary sodium intake mortality remains limited low income individual particularly black people objective investigate association excessive dietary sodium cause cause specific mortality among predominantly low income black white american design setting participant cohort study included participant aged year southern community cohort study recruited community health center southeastern state analysis conducted march june exposure dietary sodium intake assessed using validated food frequency questionnaire baseline main outcome measure multivariable adjusted cox regression used estimate hazard ratio hr ci mortality outcome cause cardiovascular disease cvd coronary heart disease chd stroke heart failure cancer associated sodium intake nonlinear association population attributable risk par mortality burden associated excess sodium assessed result among participant black white female mean sd age study enrollment year black participant year white counterpart mean sd dietary sodium intake mg black individual mg white individual black individual white individual exceeded current dietary recommendation mg median iqr follow year death documented including cvd adjustment potential confounders black individual hr per mg increase daily sodium intake ci ci death total cvd chd respectively white individual corresponding hr ci ci significant association found cancer mortality par estimate suggest sodium intake recommended threshold may account total cvd chd heart failure death low income southern population conclusion relevance cohort study low income american nearly study participant consumed sodium exceeding current recommended daily amount associated cvd mortality public health program targeted reduce sodium intake among underserved population may beneficial:0.0284480122892939",
    "139110": "importance self identified black race associated higher hypertension prevalence worse blood pressure bp control compared race ethnic group contribution genetic west african ancestry racial disparity appears completely determined objective determine association proportion west african ancestry response antihypertensive medication bp control kidney function risk adverse cardiovascular cv event among self identified black individual systolic blood pressure intervention trial sprint design setting participant post hoc analysis sprint trial incorporated data multicenter study self identified black participant available west african ancestry proportion estimated using biallelic autosomal ancestry informative genetic marker recruitment started october ended august data analyzed may september main outcome measure trajectory bp kidney function parameter follow trial assessed across tertiles proportion west african ancestry using linear mixed effect modeling adjustment potential confounders multivariable adjusted cox model evaluated association west african ancestry risk composite cv event nonfatal myocardial infarction cv death heart failure event result among participant current analysis woman median west african ancestry interquartile range composite cv event mean sd year follow baseline mean sd high density lipoprotein cholesterol level higher tertile mg dl v tertile mg dl p smoking prevalence never smoking tertile v tertile p mean sd framingham risk score tertile v tertile p lower baseline bp different across increasing tertiles west african ancestry follow evidence difference longitudinal trajectory bp kidney function parameter left ventricular mass cornell voltage electrocardiogram across tertiles west african ancestry either intensive standard treatment arm adjusted cox model higher west african ancestry associated lower risk composite cv event adjustment potential confounders adjusted hazard ratio per higher west african ancestry ci conclusion relevance among self reported black individual enrolled sprint trajectory bp kidney function left ventricular mass time different across tertiles proportion west african ancestry higher proportion west african ancestry associated modestly lower risk cv event finding suggest extrinsic structural societal factor genetic ancestry may major driver well established racial disparity cardiovascular health associated hypertension:0.0281874966315177",
    "181068": "importance education social determinant health quantifying association lifetime cardiovascular disease cvd risk public health importance objective calculate lifetime risk estimate incident cvd cvd subtypes estimate year lived without cvd education design setting participant included community based cohort study adjudicated cardiovascular event used pooled individual level data prospective cohort study study team assessed association education lifetime cvd risk modified kaplan meier cox model accounting competing risk noncardiovascular death study team estimated year lived without cvd education irwin restricted mean utility adding educational attainment cvd risk assessment participant baseline year old year old without cvd baseline complete education cardiovascular risk factor prospective cvd outcome data data analyzed january september exposure educational attainment less high school high school completion college college graduate main outcome measure cardiovascular event fatal nonfatal coronary heart disease heart failure stroke cvd related death total cvd encompassing event result participant female mean sd age year male year female compared college graduate less high school high school completion higher lifetime cvd risk among middle aged men competing hazard ratio hr cvd event ci ci ci less high school high school college respectively compared college completion among woman competing hr ci ci ci individual higher education longer duration life prior incident cvd education provided limited contribution toward enhancing cvd risk prediction conclusion relevance lower education associated lifetime cvd risk across adulthood higher education translated healthy longevity educational policy initiative may associate long term health benefit:0.0281774456018807",
    "105066": "importance coronary artery calcium cac associated coronary heart disease chd cardiovascular disease cvd however prognostic data cac limited younger adult objective determine cac adult aged year associated incident clinical chd cvd cause mortality year follow design setting participant coronary artery risk development young adult cardia study prospective community based study recruited black white participant aged year march june cohort surveillance year cac measured n n n year recruitment mean follow period incident event year year computed tomographic scan august main outcome measure incident chd included fatal nonfatal myocardial infarction acute coronary syndrome without myocardial infarction coronary revascularization chd death incident cvd included chd stroke heart failure peripheral arterial disease death included cause probability developing cac age year estimated using clinical risk factor measured year apart age year result year study among participant mean sd age year men woman individual cac geometric mean agatston score interquartile range participant followed year incident chd event incident cvd event observed adjusting demographic risk factor treatment cac experienced fold increase chd event hazard ratio hr ci fold increase cvd event hr ci within cac score stratum hr chd ci ci ci respectively cac score incidence death per participant hr ci death participant cac score adjudicated chd event risk factor cvd early adult life identified median risk developing cac applied selective cac screening strategy could reduce number people screened cac number imaged needed find person cac conclusion relevance presence cac among individual aged year associated increased risk fatal nonfatal chd year follow cac score associated early death adult younger year cac even low score identified computed tomographic scan elevated risk clinical chd cvd death selective use screening cac might considered individual risk factor early adulthood inform discussion primary prevention:0.0276691952517872",
    "200051": "importance positive health outcome high cardiovascular health cvh score demonstrated largely single cvh assessment midlife whereas association cumulative cvh young adulthood premature cardiovascular disease cvd particularly kidney outcome remains unclear objective examine association cumulative cvh year age risk cvd kidney event midlife design setting participant population based cohort study used korean national health insurance health screening claim data adult aged year without prior cvd chronic kidney disease ckd data analyzed may april exposure ten year cumulative cvh score calculated area cvh score curve year age range per visit cumulative range point x year based american heart association life essential construct main outcome measure primary outcome cvd event myocardial infarction ischemic stroke heart failure cardiovascular death kidney event incident ckd kidney replacement therapy kidney related death year age among participant result among adult male n aged year examination visit year age visit median number visit iqr cvd event kidney event occurred median follow year iqr highest quintile quintile q point x year cumulative cvh year age associated low incidence cvd per year adjusted hazard ratio hr ci v q kidney event per year adjusted hr ci v q midlife point x year higher cumulative cvh eg point higher cvh score x year associated lower hazard cvd event lower hazard kidney event association similar sex event subtypes remained significant adjustment cvh score year age slope cvh change conclusion relevance finding suggest higher cumulative cvh score year age associated markedly lower risk cvd kidney event midlife highlighting importance sustained primordial prevention effort throughout early life:0.0276127552956928",
    "154965": "importance histologic lesion kidney may reflect contribute systemic process may lead adverse cardiovascular event objective assess association kidney histopathologic lesion severity risk incident major adverse cardiovascular event mace design setting participant prospective observational cohort study included participant without history myocardial infarction stroke heart failure boston kidney biopsy cohort recruited academic medical center boston massachusetts data collected september november data analyzed march november exposure semiquantitative severity score kidney histopathologic lesion adjudicated kidney pathologist modified kidney pathology chronicity score primary clinicopathologic diagnostic category main outcome measure main outcome composite death incident mace included myocardial infarction stroke heart failure hospitalization cardiovascular event independently adjudicated investigator cox proportional hazard model estimated association histopathologic lesion score cardiovascular event adjusted demographic characteristic clinical risk factor estimated glomerular filtration rate egfr proteinuria result included participant woman mean sd age year mean sd egfr ml min per median iqr urine protein creatinine ratio common primary clinicopathologic diagnosis lupus nephritis iga nephropathy diabetic nephropathy median iqr year follow composite death incident mace occurred participant per person year compared reference group individual proliferative glomerulonephritis risk death incident mace highest individual nonproliferative glomerulopathy hazard ratio hr ci p diabetic nephropathy hr ci p kidney vascular disease hr ci p fully adjusted model presence mesangial expansion hr ci p arteriolar sclerosis hr ci p associated increased risk death mace compared minimal chronicity greater chronicity significantly associated increased risk death mace severe hr ci p moderate hr ci p mild hr ci p fully adjusted model conclusion relevance study specific kidney histopathological finding associated increased risk cvd event result provide potential insight mechanism heart kidney relationship beyond provided egfr proteinuria:0.0271513239846623"
  },
  "Topic 15": {
    "187318": "importance kidney health received increasing focus part comprehensive heart failure hf treatment effort however occurrence clinically relevant kidney outcome contemporary population hf well studied objective examine rate incident dialysis acute kidney injury aki among medicare beneficiary hf hospitalization design setting participant retrospective cohort study evaluated adult aged year older hospitalized hf across site get guideline heart failure registry u january december patient younger year requiring dialysis either prior hospitalization excluded data analyzed may march main outcome measure primary outcome inpatient dialysis initiation year hf hospitalization ascertained via linkage medicare claim data cause cause specific hospitalization also evaluated covariate adjusted association discharge estimated glomerular filtration rate egfr year postdischarge outcome examined using cox proportional hazard regression model result overall among patient included analysis mean sd age year woman mean sd left ventricular ejection fraction mean sd egfr ml min per egfr less ml min per year hf hospitalization progressed dialysis progressed dialysis end stage kidney disease readmitted aki incident dialysis increased steeply lower discharge egfr category compared patient egfr ml min per individual egfr less less ml min per higher rate dialysis readmission adjusted hazard ratio ahr ci ahr ci lower discharge egfr per ml min per decrease independently associated higher rate readmission dialysis ahr ci dialysis end stage kidney disease ahr ci aki ahr ci similar finding cause mortality cause readmission hf readmission baseline left ventricular ejection fraction modify covariate adjusted association lower discharge egfr kidney outcome conclusion relevance study older adult hf substantial risk kidney complication estimated progressing dialysis year hf hospitalization finding emphasize need health care approach prioritizing kidney health high risk population:0.0255806534349506",
    "185946": "aim sex difference long term outcome following hospitalization heart failure hf across ejection fraction ef subtypes well described study evaluated risk mortality rehospitalization among male female across spectrum ef year follow following index hf hospitalization event method result patient hospitalized hf january december american heart association get guideline heart failure registry available year follow using medicare part claim data included association sex risk mortality readmission year follow period hf subtype hf reduced ef hfref ef hf mildly reduced ef hfmref ef hf preserved ef hfpef ef assessed using adjusted cox model effect modification hf subtype association sex outcome assessed including multiplicative interaction term model total patient median age year female included year follow male female comparably poor survival post discharge however female v male greater year survival lost hf compared median age sex matched u population hfpef v year hfref v year hfmref v year age group year adjusted analysis female v male lower risk year mortality adjusted hazard ratio ahr confidence interval ci p risk difference pronounced among patient hfref ahr ci p interaction sex hf subtype female v male higher adjusted risk hf readmission year follow ahr ci p risk difference pronounced among patient hfpef ahr ci p interaction sex hf subtype conclusion female v male lower adjusted mortality female experienced significantly greater loss survival time median age sex matched u population greater risk rehospitalization year following hf hospitalization:0.0243444997515098",
    "144611": "background contemporary data exist evaluating care pattern outcome heart failure hf across spectrum kidney function objective study sought characterize difference quality care outcome patient hospitalized hf degree kidney dysfunction method guideline directed medical therapy evaluated among patient hospitalized hf site gwtg hf get guideline heart failure registry discharge ckd epi chronic kidney disease epidemiology collaboration derived estimated glomerular filtration rate egfr additionally evaluated risk adjusted association admission egfr hospital mortality result among hospitalization age year left ventricular ejection fraction ef median discharge egfr ml min interquartile range ml min egfr ml min dialysis egfr distribution remained stable among patient hf reduced ef discharge guideline directed medical therapy including beta blocker lowest discharge egfr ml min dialysis p triple therapy angiotensin converting enzyme inhibitor angiotensin receptor blocker angiotensin receptor neprilysin inhibitor beta blocker mineralocorticoid receptor antagonist used egfr ml min dialysis respectively p mortality higher graded fashion lower admission egfr group respectively p steep covariate adjusted association admission egfr mortality observed across ef subgroup slightly stronger hf reduced ef compared hf mid range preserved ef p interaction conclusion despite facing elevated risk mortality patient comorbid hf reduced ef kidney disease optimally treated evidence based medical therapy even level egfr therapy would contraindicated kidney dysfunction effort required mitigate risk comorbid hf kidney disease:0.0237695707294978",
    "159667": "background worsening heart failure hf often requires hospitalization case may managed outpatient emergency department ed setting predictor clinical significance ed visit without admission v hospitalization unclear method ascend hf trial included u patient hospitalized hf reduced preserved ejection fraction clinical characteristic compared patient subsequent cause ed visit ed discharge within day v cause readmission within day factor associated type care assessed multivariable model multivariable model landmarked day evaluated association type care subsequent day mortality result day follow patient ed discharge readmission neither urgent visit patient ed discharge v readmission similar respect age sex systolic blood pressure ejection fraction coronary artery disease whereas ed discharge patient modestly lower creatinine p among patient either event within day higher creatinine prior hf hospitalization associated higher likelihood readmission compared ed discharge p landmarked day rate death subsequent day patient readmitted patient discharged ed compared patient readmitted ed discharge independently associated lower day mortality adjusted hazard ratio confidence interval p conclusion cohort u patient hospitalized hf worse renal function prior hf hospitalization associated higher likelihood early postdischarge readmission compared ed discharge although subsequent mortality high discharge ed risk mortality significantly lower patient readmitted hospital:0.0237440360818083",
    "111786": "background hospitalization heart failure hf associated increased risk death among patient chronic hf degree hospitalization hf distinct biologic entity independent prognostic value versus marker higher risk chronic hf patient unclear method excluding patient new onset hf ascend hf trial acute study clinical effectiveness nesiritide decompensated heart failure included patient hospitalized worsening chronic hf reduced preserved ejection fraction present analysis compared patient presence absence prior hf hospitalization within month timing prior hf hospitalization relative index hospitalization association day cause mortality assessed including adjustment prespecified clinical factor result overall patient hf hospitalization within prior month mortality rate day respectively unadjusted analysis prior hf hospitalization associated increased risk day mortality hr ci p adjustment point estimate attenuated association statistically significant hr ci p similarly adjustment compared patient without prior hospitalization prior hf hospitalization associated mortality irrespective timing month hr ci p month hr ci p month hr ci p month hr ci p conclusion cohort patient hospitalized worsening hf prior hf hospitalization associated day mortality comprehensively accounting patient characteristic measured index patient visit clinical confounders measured point care may explain previously observed association prior hf hospitalization mortality clinical factor may direct mean predicting patient survival registration url http www clinicaltrials gov unique identifier nct:0.0235233791508938",
    "194204": "background chronic kidney disease ckd defined kdigo kidney disease improving global outcome guideline abnormal kidney structure function present month implication health kdigo defined ckd associated poor outcome patient heart failure hf less known whether association vary left ventricular ejection fraction objective study aim determine prevalence outcome kdigo defined ckd heart failure preserved ejection fraction hfpef heart failure mildly reduced ejection fraction hfmref heart failure reduced ejection fraction hfref method veteran hf diagnosis national veteran affair electronic health record data data ef kdigo defined ckd normal kidney function nkf ckd defined value measured day apart estimated glomerular filtration rate egfr ml min categorized egfr stage based last egfr ml min ml min ml min ml min urinary albumin creatinine ratio uacr mg g albuminuria nkf defined value measured day apart egfr ml min without egfr ml min albuminuria year hf diagnosis patient categorized hfpef ef n hfmref ef n hfref ef n hr ci year cause mortality hf hospitalization december associated ckd group v nkf estimated using cox regression result among patient hf nkf mortality occurred hf hospitalization occurred hfpef hfmref hfref respectively compared nkf ckd associated higher multivariable adjusted risk death patient hfpef hfmref hfref respectively respective risk hf hospitalization higher egfr associated risk incrementally higher decreasing egfr except egfr ml min likely initiation dialysis follow albuminuria associated higher multivariable adjusted risk death hf hospitalization hfpef hfmref hfref respectively association statistically significant conclusion finding based kdigo defined ckd nkf provide new information best estimate true prevalence outcome ckd hfpef hfmref hfref:0.0233184610222059",
    "154079": "aim worsening renal function may impact long term outcome heart failure hf however little known longitudinal trajectory renal function relation hf hospitalization high risk clinical event impact renal outcome method result paragon hf evaluated association recency prior hf hospitalization occurring pre randomization subsequent first renal composite outcome time decline estimated glomerular filtration rate egfr ii development end stage renal disease iii death attributable renal cause total patient history prior hf hospitalization incident rate renal outcome highest recently hospitalized decreased longer time last hospitalization treatment effect renal outcome sacubitril valsartan versus valsartan similar patient hazard ratio hr confidence interval ci without hr ci p interaction prior history hf hospitalization appeared consistent regardless timing prior hospitalization hf p interaction serial egfr measurement leading hf hospitalization occurring study period estimated egfr trajectory using repeated measure regression model restricted cubic spline also examined patient experiencing post randomization hf hospitalization significant decline egfr prior hospitalization patient without hf hospitalization experienced relatively stable egfr trajectory p change rate decline egfr trajectory observed month preceding hf hospitalization continued post discharge window month following hospitalization conclusion heart failure hospitalization denotes increased risk kidney disease progression continues following recovery hf decompensation patient hf preserved ejection fraction clinical trial registration paragon hf prospective comparison arni arb global outcome hf preserved ejection fraction clinicaltrials gov nct:0.0232919212224384",
    "197646": "background prognostic implication mineralocorticoid receptor antagonist mra initiation context worsening renal function wrf patient acute heart failure ahf remain unknown method post hoc analysis using data japanese ahf registry nara hf nara registry analysis heart failure wet hf west tokyo heart failure reality ahf registry focused early presentation treatment emergency department acute heart failure mra naive patient baseline included comprising patient hf reduced ejection fraction hfref heart failure mildly reduced preserved ejection fraction hfmr pef divided group mra initiated without wrf hfref n hfmr pef n mra initiated wrf hfref n hfmr pef n mra initiation hfref n hfmr pef n wrf defined mg dl increase admission discharge composite death hf hospitalization discharge assessed result year follow event occurred patient hfref hfmr pef respectively overall mra initiation hospitalization ahf independently associated better prognosis hazard ratio hr mainly driven hf hospitalization among patient hfref group mra without wrf showed lower incidence outcome mra group even adjusting risk factor hr respectively among patient hfmr pef mra initiation without wrf independently associated better prognosis hr mra initiation wrf conclusion initiating mra ahf hospitalization associated better postdischarge outcome hfref irrespective creatinine elevation whereas consistent association observed hfmr pef:0.0229860718969449",
    "125100": "aim outpatient treatment worsening sign symptom heart failure hf usually incorporated main outcome hf trial patient hf preserved ejection fraction hfpef may experience frequent episode outpatient worsening hf aim study evaluate frequency prognostic impact effect spironolactone outpatient diuretic intensification odi among patient enrolled topcat america method result time updated cox model win ratio analysis odi defined post randomization loop diuretic dose increase new initiation median follow year baseline patient taking loop diuretic follow patient experienced odi associated higher risk subsequent cardiovascular event death adjusted hazard ratio hr hf hospitalization cardiovascular death confidence interval ci hr cardiovascular death ci hr cause mortality ci p outcome adding odi composite hf hospitalization cardiovascular death increased event rate three fold placebo group event per person year spironolactone treatment led relative reduction extended composite odi hf hospitalization cardiovascular death hr ci p compared relative reduction hf hospitalization cardiovascular death hr ci p using win ratio provided similar estimate conclusion hfpef odi frequent independently associated subsequent cardiovascular event spironolactone significantly reduced extended composite outcome incorporating odi:0.0228196233047385",
    "106424": "background patient heart failure hf poor prognosis categorized ejection fraction ef objective study sought characterize difference outcome patient hospitalized heart failure preserved ejection fraction hfpef ef heart failure borderline ejection fraction hfbef ef heart failure reduced ejection fraction hfref ef method data gwtg hf get guideline heart failure linked medicare data longitudinal follow multivariable model constructed examine year outcome compare survival median survival u result total patient hospital admitted hf included hfpef hfbef hfref overall median survival year risk adjusted survival analysis group similar year mortality hfref v hfpef hazard ratio confidence interval hfbef v hfpef hazard ratio confidence interval risk adjusted analysis composite mortality rehospitalization similar subgroup cardiovascular hf readmission rate higher hfref hfbef compared hfpef compared u population hf patient across age ef group markedly lower median survival conclusion among patient hospitalized hf patient across ef spectrum similarly poor year survival elevated risk cardiovascular hf admission finding underscore need improve treatment patient hf:0.0226251334606845"
  },
  "Topic 16": {
    "1184": "background aim present study assess early clinical outcome following primary coronary angioplasty elderly patient aged year compared younger patient year method study population included consecutive patient mean age year acute st elevation myocardial infarction mi underwent primary percutaneous coronary intervention pci within hour symptom onset elderly patient accounted patient primary pci performed using balloon coronary stent well glycoprotein iib iiia inhibitor primary endpoint hospital incidence major adverse cardiac event including death stroke reinfarction target vessel revascularization new onset heart failure result elderly patient frequently female v p comorbid disease prior stroke v p extensive cardiovascular disease previous acute mi v p multivessel disease v p significantly lower ejection fraction v p despite similar rate timi flow presentation v p n similar use stent v p glycoprotein iib iiia inhibitor infusion v p comparable angiographic residual stenosis v p n final rate timi flow significantly lower elderly population v p although hospital ischemic event rate age significantly different hospital mortality higher elderly compared younger patient v p even patient cardiogenic shock time admission excluded v p furthermore patient aged hospital heart failure v p whole population multivariate analysis identified baseline killip class iii iv independent predictor event elderly patient multivariate analysis identified baseline killip class iii iv time onset chest pain pci independent predictor event conclusion data suggest elderly patient acute st elevation mi primary pci yield positive result successful reperfusion achieved high proportion elderly patient mortality rate lower reported non pci registry high killip class late reperfusion therapy predict unfavorable outcome elderly patient treated primary pci:0.0295818499019016",
    "156009": "objective goal retrospective study reveal prevalence angiographic characteristic clinical presentation long term outcome non st segment elevation myocardial infarction nstemi patient wellens syndrome background procedural result percutaneous coronary intervention pci acute coronary syndrome ac improved recent year however still paucity available clinical trial data wellens syndrome even though well known high risk ac method among total patient ac underwent angioplasty cardiovascular center beijing friendship hospital nstemi patient culprit left anterior descending lad vessel enrolled study according electrocardiographic criterion wellens syndrome patient divided wellens group n non wellens group n primary endpoint cardiac death secondary endpoint main adverse cardiovascular cerebrovascular event macces composite cause death cardiac death heart failure target lesion revascularization recurrent myocardial infarction stroke medical follow data obtained institutional database result incidence wellens syndrome ac patient among patient wellens syndrome nstemi proportion significant decrease percentage preexisting coronary heart disease chd prior myocardial infarction previous pci p wellens group compared non wellens group coronary angiography single vessel lesion common wellens group v p almost patient received drug eluting stent notably wellens group higher proportion early pci non wellens group v p month statistically significant difference cardiac death p two group macces comparable wellens v non wellens p age year largest independent risk factor adverse prognosis conclusion early recognition aggressive intervention wellens syndrome longer risk factor adverse prognosis patient nstemi current pci era:0.0278937004896420",
    "178491": "background aimed compare clinical outcome immediate staged complete revascularization primary percutaneous coronary intervention pci treating st segment elevation myocardial infarction stemi multivessel disease mvd method total patient enrolled prospective randomized multicenter registry immediate revascularization defined one time pci culprit non culprit lesion initial procedure staged revascularization defined pci non culprit lesion later date mean day interquartile range following initial culprit revascularization end point major adverse cardiovascular event mace composite total death recurrent myocardial infarction revascularization individual component mace cardiac death stent thrombosis stroke month result follow year mace occurred patient immediate revascularization group patient staged revascularization group hazard ratio hr confidence interval ci incidence total death numerically higher immediate group staged group v hr ci significant difference group risk individual component mace cardiac death stroke hospital complication need transfusion bleeding acute renal failure acute heart failure study prematurely terminated due halt production everolimus eluting stent manufactured promus element boston scientific natick massachusetts conclusion due limited power definite conclusion drawn regarding complete revascularization strategy present study large randomized clinical trial would warranted confirm optimal timing complete revascularization patient stemi mvd:0.0272293709650687",
    "175571": "background aim beneficial effect pre treatment unfractionated heparin ufh first medical contact fmc primary percutaneous coronary intervention ppci comer st elevation myocardial infarction stemi remains uncertain method help pci investigator initiated randomized controlled trial conducted clinical centre china patient stemi presenting h symptom onset undergoing ppci randomly assigned intravenous administration ufh u kg fmc cath lab catheter sheath primary endpoint thrombolysis myocardial infarction flow grade tfg infarct related artery ira diagnostic angiography ppci secondary outcome complete epicardial myocardial reperfusion ppci major adverse cardiac cerebrovascular event macce defined composite cause death cardiac death heart failure hospitalization infarction stent thrombosis unplanned revascularization stroke month safety outcome day bleeding academic research consortium barc type bleeding result total patient stemi undergoing ppci randomly assigned receive either ufh administration fmc n cath lab n pre treated population fmc showed higher frequency tfg ira compared cath lab group v odds ratio confidence interval p significant difference secondary endpoint safety endpoint including month macce complete epicardial myocardial reperfusion major bleeding conclusion pre treatment loading dose ufh fmc associated improvement spontaneous reperfusion ira without increasing risk major bleeding:0.0270434007397810",
    "77513": "objective aimed assess sex difference invasive parameter acute microvascular reperfusion injury infarct characteristic cardiac mri st segment elevation myocardial infarction stemi method patient stemi undergoing emergency percutaneous coronary intervention pci prospectively enrolled index microcirculatory resistance imr coronary flow reserve cfr measured culprit artery post pci contrast enhanced mri used assess infarct characteristic microvascular obstruction myocardial haemorrhage day month post stemi prespecified outcome follows cause death first heart failure hospitalisation ii cardiac death non fatal myocardial infarction urgent coronary revascularisation major adverse cardiovascular event mace year median follow result patient stemi woman mean age year men mean age year woman anterior stemi less often fewer prescription beta blocker discharge higher baseline n terminal pro b type natriuretic peptide level p following emergency pci fewer woman men thrombolysis myocardial infarction timi myocardial perfusion grade v p woman lower corrected timi frame count v p however imr cfr microvascular obstruction myocardial haemorrhage infarct size myocardial salvage index left ventricular remodelling ejection fraction differ significantly sex female sex associated mace cause death first heart failure hospitalisation conclusion sex difference microvascular pathology patient acute stemi woman less anterior infarct men beta blocker therapy discharge prescribed less often woman trial registration number nct:0.0266012173554659",
    "90645": "influence preinfarction angina pectoris ap long term clinical outcome patient st segment elevation myocardial infarction stemi underwent primary percutaneous coronary intervention pci remains controversial patient acute myocardial infarction ami enrolled coronary revascularization demonstrating outcome study kyoto ami registry present study population consisted patient stemi underwent primary pci within hour symptom onset data preinfarction ap available preinfarction ap defined ap occurring within hour hospital arrival present patient patient preinfarction ap younger often anterior ami longer total ischemic time whereas less often history heart failure atrial fibrillation shock presentation infarct size estimated peak creatinine phosphokinase significantly smaller patient patient without preinfarction ap median interquartile range iu l v iu l p cumulative year incidence death significantly lower patient preinfarction ap v p median follow interval day adjusting confounders preinfarction ap independently associated lower risk death hazard ratio confidence interval p lower risk year mortality patient preinfarction ap consistently observed across subgroup stratified total ischemic time initial thrombolysis myocardial infarction flow grade hemodynamic status infarct location diabetes mellitus conclusion preinfarction ap independently associated lower year mortality patient stemi underwent primary pci:0.0264152592778247",
    "43933": "objective sought compare outcome st segment elevation myocardial infarction stemi patient undergoing primary percutaneous coronary intervention pci without previous coronary artery bypass graft cabg background limited information exists regarding procedural success clinical outcome stemi patient cabg undergoing primary pci method apex ami assessment pexelizumab acute myocardial infarction trial randomized placebo controlled trial pexelizumab stemi patient planned primary pci patient prior cabg clinical procedural characteristic culprit vessel infarct related artery ira day clinical outcome compared result patient previous cabg frequently men older higher incidence comorbidities multivessel disease patient versus without prior cabg pci performed less frequently versus prior cabg receiving pci thrombolysis myocardial infarction timi flow grade also restored less often versus p prior cabg nearly even designation ira bypass graft n versus native vessel n ira post pci timi flow grade achieved versus respectively p prior cabg patient increased day death composite day death congestive heart failure shock excess death remained significant multivariable adjustment hazard ratio confidence interval p prior cabg patient stratified type ira discrimination increased day death bypass graft n versus native vessel n p respectively conclusion prior cabg patient stemi less likely undergo acute reperfusion worse angiographic outcome following primary pci higher day mortality finding especially applicable ira bypass graft:0.0263467995687756",
    "103584": "background examined whether efficacy early invasive strategy fibrinolysis st segment elevation myocardial infarction stemi differs relation initial troponin status method trial routine angioplasty stenting fibrinolysis enhance reperfusion acute myocardial infarction transfer ami patient stemi presenting non percutaneous coronary intervention pci capable hospital received fibrinolysis randomized either pharmacoinvasive standard strategy subsequent angiography pci post hoc subgroup analysis compared efficacy strategy relation initial troponin status hospital presentation primary composite end point mortality reinfarction recurrent ischemia heart failure cardiogenic shock day assessed heterogeneity treatment effect initial troponin status using breslow day test tested interaction adjustment baseline global registry acute coronary event grace risk score result among patient abnormal initial troponin level n older worse killip class longer time symptom onset fibrinolysis higher grace thrombolysis myocardial infarction risk score patient abnormal troponin level higher rate primary end point v p cumulative mortality reinfarction year v p stratified analysis pharmacoinvasive management reduced primary end point among patient normal initial troponin status however significant treatment heterogeneity p interaction initial troponin status treatment assignment adjusting grace risk score conclusion patient stemi abnormal initial troponin level worse short term long term outcome accounting overall baseline risk grace risk score troponin status modulate efficacy pharmacoinvasive management:0.0262730302764370",
    "134393": "background despite successful treatment culprit artery lesion primary percutaneous coronary intervention pci stent implantation thrombotic embolisation occurs case impairs prognosis patient st segment elevation myocardial infarction stemi aimed assess clinical outcome deferred stent implantation versus standard pci patient stemi method open label randomised controlled trial four primary pci centre denmark eligible patient aged year acute onset symptom lasting h less st segment elevation mv least two contiguous electrocardiographic lead newly developed left bundle branch block patient randomly assigned via electronic web based system permuted block size two six receive either standard primary pci immediate stent implantation deferred stent implantation h index procedure stabilised flow could obtained infarct related artery primary endpoint composite cause mortality hospital admission heart failure recurrent infarction unplanned revascularisation target vessel within year follow patient investigator treating clinician masked treatment allocation analysis intention treat trial registered clinicaltrials gov number nct finding march feb randomly assigned patient receive either standard pci n deferred stent implantation n median follow time month iqr event comprising primary endpoint occurred patient standard pci patient deferred stent implantation hazard ratio ci p procedure related myocardial infarction bleeding requiring transfusion surgery contrast induced nephopathy stroke occurred patient conventional pci group versus patient deferred stent implantation group significant difference group interpretation patient stemi routine deferred stent implantation reduce occurrence death heart failure myocardial infarction repeat revascularisation compared conventional pci result ongoing randomised trial might shed light concept deferred stenting patient population funding danish agency science technology innovation danish council strategic research:0.0259960121704184",
    "12661": "background controversy ideal type revascularization context primary angioplasty percutaneous coronary intervention pci acute myocardial infarction ami presence additional stenosis especially complex impact prognosis objective evaluate medium term year prognosis according presence complex additional stenosis primary pci population method retrospective study consecutive patient admitted unit st segment elevation ami underwent primary pci patient followed year divided group without complex additional stenosis n year male complex additional stenosis n year male p n evaluated demographic characteristic risk factor coronary artery disease previous cardiac history sign heart failure admission angiographic characteristic medication pci outcome also evaluated impact variable combined end point death reinfarction myocardial revascularization year assessed result angiographic success rate twenty four percent patient aged year total population killip class iv admission anterior ami slightly common non complex additional stenosis group v p inferior ami complex additional stenosis group v p one vessel disease prevalent group without complex additional stenosis expected v p stent implantation also frequent group v p difference variable death reinfarction revascularization frequent group complex additional stenosis v p sixty seven per cent event occurred first day follow year univariate predictor outcome killip class timi flow infarct related vessel pci non use glycoprotein iib iiia receptor antagonist beta blocker statin multivessel disease presence complex additional stenosis log rank p using multivariate regression analysis independent predictor outcome year killip class ci p presence complex additional stenosis ci p conclusion presence complex additional stenosis primary pci worse prognosis year suggesting need intervention stabilize plaque particularly first day ami:0.0259588387008234"
  },
  "Topic 17": {
    "146064": "importance million people living either mitral aortic valve disease worldwide heart valve replacement surgery performed year u transcatheter valve repair emerged important therapeutic option patient candidate heart valve replacement observation transcatheter valve therapy involve multidisciplinary team interventional cardiologist cardiothoracic surgeon radiologist echocardiographers nurse social worker termed heart team determine optimal approach managing patient transcatheter aortic valve implantation tavi aortic valve replacement procedure performed percutaneously currently approved patient severe symptomatic aortic stenosis surgical risk category tavi procedure performed using balloon expandable self expanding valve low risk cohort patient partner placement aortic transcatheter valve trial rate death cause stroke rehospitalization patient receiving tavi patient undergoing surgical aortic valve replacement decision making regarding therapy choice based individual anatomy including number leaflet annular size peripheral arterial anatomy comorbidities including concomitant coronary artery disease aortopathies patient preference guide mitral transcatheter edge edge repair device approved u food drug administration high risk patient degenerative functional mitral regurgitation excellent safety efficacy population coapt cardiovascular outcome assessment mitraclip percutaneous therapy heart failure patient functional mitral regurgitation trial annualized rate hospitalization heart failure among patient underwent transcatheter edge edge repair received medical therapy compared among patient medical therapy alone group transcatheter tricuspid valve repair replacement trial ongoing show promise treatment patient tricuspid regurgitation previously limited therapeutic option multimodality imaging includes transthoracic echocardiography transesophageal echocardiography computed tomography intracardiac echocardiography important preprocedural planning device selection optimal outcome conclusion relevance approximately tavi procedure transcatheter mitral valve repair take place yearly u treat patient severe symptomatic aortic stenosis mitral regurgitation respectively transcatheter valve therapy expanded therapeutic option patient including previously viable surgical option:0.0310395552472686",
    "194398": "background management recurrent mitral regurgitation mr relevant iatrogenic mitral valve mv stenosis mitral transcatheter edge edge repair teer emerges increasingly relevant clinical issue surgery teer associated higher morbidity mortality electrosurgical leaflet laceration stabilization implant elasta clip followed transcatheter mitral valve replacement tmvr innovative less invasive treatment option patient teer failure objective author sought evaluate early result elasta clip followed transapical tmvr patient symptomatic failed teer defined persistent recurrent mr iatrogenic mv stenosis method data symptomatic patient failed teer underwent elasta clip followed compassionate use commercial transapical tmvr using abbott tendyne system retrospectively collected tertiary care center country safety efficacy procedure assessed year according mitral valve academic research consortium mvarc criterion result total patient mean age year female high surgical risk euroscore ii sts score symptomatic residual mr n iatrogenic mv stenosis n failed teer followed median period q q month elasta clip procedure transseptal transapical followed tmvr successful patient technical success according mvarc achieved patient without left ventricular outflow tract obstruction conversion sternotomy day patient paravalvular leak progression ischemic stroke occurred patient baseline mr reduced grade less patient durable result p nyha functional class significantly improved ii discharge p last follow p day patient alive three patient rehospitalized heart failure uncontrolled atrial fibrillation case underwent reintervention valve retensioning conclusion transapical tmvr elasta clip feasible less invasive option management failed teer performed acceptable result carefully selected patient population particular attention required avoid paravalvular leakage measure minimize risk periprocedural cerebrovascular event need implemented future larger scale prospective study longer term follow:0.0299320452201053",
    "75906": "valvular heart disease one frequent cause heart failure degenerative disease aortic mitral valve well dysfunctional tricuspid valve disease result worse clinical outcome severe minimal invasive surgical catheter based structural heart disease shd intervention recently seen dramatic increase transcatheter aortic valve implantation tavi severe aortic stenosis disruptive technology next generation device careful patient selection minimize limitation tavi paravalvular leak conductance disturbance ischemic stroke vascular complication indication tavi continues shift toward lower risk patient patient complex anatomy bicuspid native pure aortic regurgitation successful clinical result tavi generated considerable interest transcatheter technology targeting mitral regurgitation mr also toward tricuspid regurgitation tr efficacy safety edge edge without annuloplasty leaflet repair mimicking surgical repair confirmed technical improvement device development emerging study transcatheter mitral valve implantation might alternative strategy patient symptomatic severe mr favorable anatomy possible interventional treatment approach tr gained attention improvement development shd intervention enabled patient receive minimally invasive heart valve intervention procedure prolonged life improved quality life many patient previously considered unsuitable surgery continued technical device improvement accumulated evidence expand possibility future shd intervention:0.0293080262496443",
    "91737": "objective many patient severe symptomatic mitral valve regurgitation denied surgical valve replacement repair due high operative risk describe early series case transcatheter implantation cardiaq mitral valve via transapical approach method three consecutive patient society thoracic surgeon sts mortality score selected transcatheter mitral valve implantation tmvi compassionate ground patient elderly severe mitral regurgitation mr class iv heart failure deemed unsuitable mitraclip two patient functional mr setting ischaemic cardiomyopathy left ventricular ejection fraction lvef deemed remaining patient chordal rupture extensive anterior leaflet flail preserved lvef comorbidities included previous coronary artery bypass surgery n severe pulmonary hypertension n moderate severe chronic renal failure n cardiaq mitral valve implanted using fluoroscopy transoesophageal tee guidance via standard transapical approach result accurate prosthesis positioning deployment immediate elimination mr achieved case two patient made full clinical recovery discharged home post procedural tee performed day day showed good valve function stable valve position minimal lvot gradient one patient expired postoperative day due pneumonia conclusion tmvi using cardiaq device via transapical approach feasible effective:0.0291035553290778",
    "81799": "report first case mitral stenosis following mitra clip insertion patient symptomatic nyha iv heart failure secondary severe mitral regurgitation mr year old female history prior aortic valve replacement underwent percutaneous mitral valve mv repair single clip advanced coaxially onto mv toe guidance anterior posterior leaflet clipped together p toe confirmed significant reduction mr grade grade despite initial symptomatic relief represented month later similar symptom repeat toe confirmed well positioned mitra clip mild residual mr however possibility significant mitral stenosis raised due presence significant turbulence bi orifice valve peak gradient mm hg addition evidence severe functional tricuspid valve tv regurgitation elevated pulmonary artery pressure pap mm hg confirmed subsequent right heart catheterization repeated heart team discussion failure optimal medical therapy despite logistic euroscore minimally invasive surgical replacement mv simultaneous tv repair undertaken via right thoracotomy despite procedural success initial good postoperative response patient died subsequently combination hospital acquired pneumonia significant gastrointestinal bleeding post operative day mitra clip promising novel approach mv repair establishment clinical echocardiographic based selection criterion help identify correct patient treatment:0.0283782528813523",
    "95387": "background mitral valve surgery patient failing bioprosthesis annuloplasty ring patient advanced mitral annular calcification mac associated high morbidity mortality rate percutaneous antegrade transseptal transcatheter mitral valve implantation tmvi recently successfully performed patient high prohibitive surgical risk data patient treated tmvi sparse study sought evaluate short midterm outcome patient treated tmvi site clinical practice method result october february seven patient six woman one man high prohibitive surgical risk underwent tmvi site three procedure performed tmvi failed mitral valve bioprostheses tmvi viv valve valve one procedure performed tmvi failed mitral annuloplasty ring tmvi r three procedure performed tmvi advanced native mitral annular calcification tmvi mac mean age population treated year mean log euroscore patient edward sapien transcatheter heart valve implanted toe fluoroscopic guidance using transvenous transseptal access indication tmvi presence advanced heart failure symptom patient nyha class iii iv predominant dysfunction mitral valve treated severe regurgitation n severe stenosis n patient tmvi technically successful procedure clinical success functional improvement least one nyha class procedure compared procedure also achieved patient median nyha class improved significantly procedure tmvi p mitral valve regurgitation reduced trace mild one patient showed moderate mr tmvi mac patient prosthesis mismatch lvot obstruction occurred tmvi two patient underwent interventional asd closure hospital course due large persisting atrial septal defect transseptal access one patient underwent pacemaker implantation due complete av block tmvi one patient died hospital day procedure due severe hospital acquired pneumonia sepsis hospital mortality rate high risk population hospital discharge death occurred clinical improvement according nyha functional class remained stable one year follow conclusion small single center series tmvi appears promising patient high prohibitive surgical risk either failing mitral bioprostheses annuloplasty ring native mitral valve dysfunction combination advanced mac gaining experience tmvi new valve improve safety efficacy new treatment option:0.0282964493840002",
    "104075": "background symptomatic mitral regurgitation mr associated high morbidity mortality ameliorated surgical valve repair replacement despite many patient mr undergo surgery transcatheter mitral valve replacement tmvr may option selected patient severe mr objective study aimed examine effectiveness safety tmvr cohort patient native valve mr high risk cardiac surgery method patient underwent transcatheter transapical delivery self expanding mitral valve prosthesis examined prospective registry short term day outcome result thirty patient age year men grade mr underwent tmvr mr etiology secondary n primary n mixed pathology n society thoracic surgeon predicted risk mortality successful device implantation achieved patient acute death stroke myocardial infarction one patient died day tmvr hospital acquired pneumonia prosthetic leaflet thrombosis detected patient follow resolved increased oral anticoagulation warfarin day transthoracic echocardiography showed mild central mr patient residual mr remaining patient valve situ left ventricular end diastolic volume index decreased ml baseline v ml follow p left ventricular end systolic volume index ml v ml p seventy five percent patient reported mild symptom follow new york heart association functional class ii successful device implantation free cardiovascular mortality stroke device malfunction day conclusion tmvr effective safe therapy selected patient symptomatic native mr evaluation tmvr using prosthesis specifically designed mitral valve warranted intervention may help address unmet need patient high risk surgery early feasibility study tendyne mitral valve system global feasibility study nct:0.0268767718352728",
    "148007": "introduction paravalvular leak pvl common serious complication associated prosthetic valve implantation objective aim study report single center experience retrospective review analyze possible predictor success method performed percutaneous pvl closure patient female mean age year mitral prosthesis studied previously transesophageal echocardiography tee aortic prosthesis tee tee fluoroscopy used assessment planning guidance intervention twelve patient also underwent computed tomography angiography better characterization anatomic detail result eighteen patient admitted due heart failure new york heart association nyha iii iv seven heart failure hemolysis one due hemolysis regarding leak aortic mitral prosthesis mechanical biological prosthesis transcatheter aortic valve implant aortic patient severe aortic regurgitation furthermore mitral patient one moderate severe severe mitral regurgitation closure successful patient partially successful four unsuccessful five procedure nyha ii hemolysis worsened three patient despite successful closure required valvular surgery two died regarding angiographic echocardiographic procedural success analyzed age gender type prosthesis mechanical biological location aortic mitral clinical data maximum leak diameter anatomic regurgitant orifice leak location anterior posterior inferior lateral mitral leak left right non coronary sinus aortic leak number device plug used closure parameter presented significant relationship success excepting previous hemolysis relationship clinical improvement reduction pvl p follow cardiac related event new hospital admission cardiac valvular surgery need transfusion frequent patient partially successful unsuccessful closure p relationship cardiac related event death p conclusion percutaneous pvl closure emerged alternative treatment pvl predictor procedural success difficult establish survival related reduction regurgitation improvement nyha functional class:0.0268476804246354",
    "180501": "background degenerative mitral regurgitation dmr associated substantial morbidity mortality left untreated surgical repair remains gold standard mitral transcatheter edge edge repair teer established alternative patient high surgical risk however recurrent mr initial teer remains therapeutic challenge associated poor outcome case summary year old patient presented recurrent heart failure symptom due mr prior carillon r device implantation secondary mr external hospital september transoesophageal echocardiography revealed degenerative mitral valve disease characterized complex combination posterior leaflet prolapse anterior leaflet flail resulting severe eccentric regurgitant jet patient underwent successful teer mitraclip r system december june patient hospitalized recurrent heart failure symptom imaging revealed severe recurrent mr originating lateral implanted device redo teer performed using pascal r system requiring careful navigation narrow residual lateral orifice procedure resulted durable reduction mild mr sustained clinical stability month follow discussion case illustrates anatomical challenge dmr demonstrates feasibility durability redo teer high surgical risk patient recurrent mr emphasizes importance individualized anatomical assessment tailored device selection complex valve anatomy:0.0266586677662730",
    "196457": "background symptomatic high risk patient severe mitral valve regurgitation mr eligible surgery transcatheter edge edge repair teer transcatheter mitral valve replacement tmvr may option especially surgical mitral valve repair annuloplasty performed earlier tmvr appropriate anticoagulation regimen still matter debate case presentation report year old frail lady heart failure atrial fibrillation underwent surgical reconstruction mitral valve nine year ago due high surgical risk heart team discussion tmvr using transcatheter aortic valve prosthesis valve ring concept performed successfully via transapical access route several month later excellent result could confirmed since surgical excision left atrial appendage carried first surgery oral anticoagulation withdrawn two month later patient presented massive la thrombus mass severe stenosis mitral valve prosthesis requiring surgery conclusion management anticoagulation patient atrial fibrillation successfully performed laa excision still matter debate particular transcatheter heart valve implantation mitral position tmvr device may thrombogenic thus caution used whenever discontinuing oral anticoagulation patient despite lack evidence withdrawal anticoagulation avoided especially absence bleeding complication left atrial appendage closure excision influence decision:0.0259624220051435"
  },
  "Topic 18": {
    "197506": "background depression recognized leading global contributor disease burden mortality etiology depression involves complex interplay biological psychological social factor precise pathophysiological mechanism remain incompletely understood albumin bilirubin albi score originally developed objective measure hepatic function demonstrated prognostic value diverse clinical context including liver disease brain tumor chronic heart failure however relationship albi score depression systematically investigated study aim examine association albi score depression nationally representative cohort method population based cross sectional study utilized data national health nutrition examination survey nhanes spanning seven survey cycle albi score calculated using established formula albi log bilirubin mumol l x albumin g l x depression assessed using patient health questionnaire phq weighted multivariable logistic regression model constructed analyze association albi depression adjusting potential covariates nonlinear relationship explored using restricted cubic spline rcs robustness result validated subgroup analysis relationship albi depression symptom severity evaluated via anova prognostic analysis cox proportional hazard regression model assessed link albi clinical outcome complemented kaplan meier k survival curve rcs plot illustrate trend result weighted multivariable logistic regression model revealed significant association elevated albi score depression risk participant higher albi albi demonstrated increased odds depression compared reference albi adjusted ci p restricted cubic spline analysis confirmed linear relationship continuous albi score depression risk subgroup analysis stratified age gender race education smoking drinking diabetes consistently identified high albi independent risk factor depression analysis variance revealed significant dose response relationship albi depression symptom severity p cox proportional hazard model revealed significant association albi increment mortality risk depression cohort cause mortality unit albi elevation associated increased risk adjusted hr ci p cancer related mortality showed risk escalation per albi unit hr ci p non cancer death exhibited stronger association increased risk hr ci p conclusion analyzing data seven cycle nhanes database study identified positive association albi score depression among u adult albi score also linked severity depressive symptom associated cause mortality cancer related mortality individual depression trial registration clinical trial number applicable:0.0365326855715535",
    "128775": "aim body roundness index bri obesity related anthropometric index combine waist circumference height better reflect body fat study aim prospectively explore relationship bri risk heart failure hf based community based cohort method result total individual without tumour hf baseline included kailuan cohort study demographic information anthropometric parameter biochemical index collected measured participant followed december death diagnosed hf whichever came first cox proportional hazard model used calculate hazard ratio hr confidence interval ci incident hf restricted cubic spline analysis applied evaluate possible non linear dose response relationship bri risk hf median follow period year identified hf event participant grouped four group according quartile bri q q q q adjustment potential confounders compared group participant lowest quartile bri adjusted hr ci ci ci ci subject q q q group respectively standard deviation bri increasing risk hf increased hr ci subgroup analysis indicated association bri hf prominent younger people hr ci older hr ci p interaction significant linear dose response relationship bri hf also observed p non linearity conclusion study suggests higher bri associated increased risk hf finding replicated population future study need examine whether lowering bri may lower risk incident hf:0.0365115681587047",
    "180310": "background heart failure hf major global public health problem identifying modifiable environmental risk factor important prevention evaluated association blood cadmium level risk hf u adult method analyzed data national health nutrition examination survey nhanes total adult complete information blood cadmium hf status included weighted multivariable logistic regression model used assess relationship blood cadmium self reported hf restricted cubic spline rcs regression two piecewise linear model applied explore potential dose response relationship result cohort u adult nhanes dataset analyzed including individual diagnosed hf fully adjusted weighted logistic regression model elevated blood cadmium level significantly correlated increased prevalence hf specifically mug l increment blood cadmium associated higher likelihood hf odds ratio confidence interval ci p participant highest quartile blood cadmium level exhibited threefold increase odds hf compared lowest quartile ci p significant linear trend observed across quartile p rcs analysis demonstrated monotonic positive relationship apparent inflection point approximately mug l beyond risk continued escalate association generally consistent across various subgroup notably stronger among smoker p interaction conclusion elevated blood cadmium independent risk factor hf united state finding suggest reducing cadmium exposure may novel strategy hf prevention prospective study warranted clarify causal relationship underlying mechanism:0.0348908987532905",
    "192089": "background aim uric acid hdl cholesterol ratio uhr novel marker metabolism inflammation investigated various disease however potential association incidence cardiovascular disease cvd dyslipidemia remain unclear study aimed examine relationship uhr incidence cvd dyslipidemia primary objective evaluate role uhr predicting cvd dyslipidemia whereas secondary objective analyze predictive effect uhr different subgroup method conducted cross sectional analysis using data national health nutrition examination survey nhanes included adult aged year weighted binary logistic regression subgroup analysis performed evaluate independent association uhr risk various cardiovascular condition including overall cvd congestive heart failure myocardial infarction angina coronary heart disease dyslipidemia investigate potential nonlinear relationship uhr outcome restricted cubic spline modeling applied elucidate association result among participant included study diagnosed cvd elevated uhr value strongly associated greater incidence cvd subtypes including congestive heart failure myocardial infarction angina coronary heart disease p accounting weighted factor participant higher uhr quartile presented progressively higher rate cvd quartile quartile quartile quartile nonlinear relationship uhr risk developing cvd identified restricted cubic spline rcs analysis among subgroup participant dyslipidemia multivariable linear regression analysis demonstrated significant positive association uhr dyslipidemia ci association remained robust even adjusting covariates ci rcs analysis confirmed nonlinear nature relationship subgroup analysis revealed significant interaction uhr overall cvd cvd related variable congestive heart failure myocardial infarction angina coronary heart disease however dyslipidemia bmi showed significant interaction indicating positive association uhr dyslipidemia risk influenced participant bmi conclusion high uhr associated increased risk various cardiovascular condition dyslipidemia incorporation routine uhr monitoring clinical practice support early identification high risk individual facilitate timely intervention reduce burden cardiovascular metabolic disease:0.0337374353320033",
    "175602": "background c reactive protein triglyceride glucose index cti emerged innovative composite marker evaluating metabolic inflammatory dysregulation integrating marker insulin resistance systemic inflammation however association cti cardiovascular disease cvd mortality rarely studied study sought examine cti association cvd mortality cvd incidence cause mortality method study included adult national health nutrition examination survey nhanes cti derived ln crp mg l ln tg mg dl x fpg mg dl participant categorized quartile employed kaplan meier curve cox proportional hazard model logistic regression analysis restricted cubic spline rcs evaluate cti association cvd mortality total cvd incidence cause mortality across sex stratified age specific glycemic subgroup result study cti significantly positively associated cvd mortality total cvd incidence cause mortality cti significantly predicted cvd mortality hr cause mortality hr additionally cti index correlated risk total cvd ci congestive heart failure ci coronary heart disease ci angina pectoris ci heart attack ci stroke ci specifically association similar male female similar young participant elderly participant different glycemic status high level cti found linked increased risk cvd individual without diabetes mellitus dm however association observed individual dm conclusion analysis revealed elevated cti level significantly associated cvd incidence mortality cti may emerge unique predictive marker cvd risk:0.0336869190617471",
    "197901": "background functional deficiency vitamin b prevalent condition among heart failure hf patient despite specific sensitive marker deficiency study methylmalonic acid mma context hf infrequent method seven hundred forty seven individual hf incorporated cross sectional study participated national health nutrition examination survey nhanes two period hazard ratio hr confidence interval ci risk cause mortality estimated using weighted multivariable cox proportional hazard model non linear association mma level cause mortality investigated using restricted cubic spline rcs analysis result among hf participant death recorded follow period year elevated serum mma level significantly associated increased risk cause mortality tertile compared tertile adjusted hr ci p demonstrating dose response pattern increased mortality risk per unit increase lnmma b intake diet significantly associated mortality risk p although minor statistically significant association observed serum b level mortality p disappeared multivariate regression analysis moreover correlation mma mortality risk prominent hf population poorer health status advanced age current smoker hypertension diabetes overweight low estimated glomerular filtration rate egfr conclusion study indicated higher mma level associated increased cause mortality risk hf population particularly aged current smoker hypertension diabetes overweight insufficient physical activity lower egfr ml min:0.0332433544481689",
    "190150": "background triglyceride glucose tyg index emerging surrogate indicator insulin resistance demonstrated risk factor various cardiovascular disease including coronary syndrome stent restenosis heart failure however association tyg index incident aortic dissection ad aortic aneurysm aa remains investigated method study included participant without baseline ad aa large scale prospective uk biobank cohort primary outcome incident ad aa comprising ad aa multivariable adjusted cox proportional hazard regression model restricted cubic spline rcs analysis applied assess relationship tyg index onset ad aa addition association tyg index incident ad aa examined within subgroup defined age gender smoking status drinking status diabetes hypertension bmi result median follow period year ad aa case occurred incidence ad aa rose along elevated tyg index rcs curve showed linear trend tyg index risk incident ad aa tyg index positively associated risk incident ad aa adjusting age gender smoking status drinking status bmi hypertension ldl c hba c adjusted hr reference ci ci ci tyg index quartile respectively especially participant highest tyg index quartile highest risk developing aa adjusted hr ci conclusion tyg index independently associated higher risk incident ad aa indicating importance using tyg index risk assessment ad aa especially aa:0.0328513108223627",
    "170118": "background limited data available regarding association serum transferrin saturation tsat level heart failure hf method utilized data national health nutrition examination survey nhanes analysis data tast hf covariates extracted analyzed weighted logistic regression subgroup analysis used explore independent association tsat hf furthermore interaction test also carried evaluate stratum difference subsequently assessed whether non linear relationship using restricted cubic spline rcs threshold effect model result total participant identified hf among total population participant hf significantly lower tsat level compared without hf v p fully adjusting potential confounders weighted multiple logistic regression model revealed reduced risk hf unit tsat increased also negative association elevated tsat developed risk hf quartile group q q ci q ci q ci subgroup analysis result remained consistent across stratum strong negative correlation tsat hf interaction test showed dependence gender age body mass index race diabetes hypertension hyperlipidemia ratio family income poverty education negative association tsat hf p interaction rcs threshold effect model indicated linear negative correlation tsat hf pronounced tsat conclusion overall finding suggest consistent negative association tsat level presence hf among middle aged older adult united state:0.0324036482340341",
    "192410": "cardiovascular disease cvd mortality remain significant public health challenge especially among middle aged older adult however relationship uric acid high density lipoprotein cholesterol ratio uhr extensively studied u population study aimed examine association adult aged based national health nutrition examination survey nhanes participant data nhanes retrospectively analyzed multivariable logistic regression cox proportional hazard model restricted cubic spline rcs analysis subgroup analysis used assess association uhr various cvd outcome among participant reported history cvd positive association observed uhr risk total cvd including coronary heart disease heart attack heart failure angina pectoris stroke p uhr associated increased risk cause mortality hr ci cvd specific mortality hr ci uhr linear dose response relationship cvd nonlinear relationship cause mortality rcs analysis subgroup analysis confirmed association remained stable across different group finding highlight uhr significant predictor cvd risk mortality middle older age adult given strong association adverse health outcome uhr valuable indicator facilitating early identification individual elevated cardiovascular risk:0.0323182025958289",
    "79814": "aim examined relationship forced expiratory volume fev airflow obstruction incident heart failure hf black white middle aged men woman four u community method result lung volume standardized spirometry information covariates collected atherosclerosis risk community aric cohort participant incident hf ascertained hospital record death certificate eligible participant average follow year participant developed new onset hf age height adjusted hazard ratio hr hf increased monotonically descending quartile fev gender race group smoking status multivariable adjustment traditional cardiovascular risk factor height hr confidence interval ci hf comparing lowest highest quartile fev white woman white men black woman black men association weakened remained statistically significant additional adjustment systemic marker inflammation multivariable adjusted incidence hf higher fev forced vital capacity v hr ci among men among woman consistent positive association hf seen self reported diagnosis emphysema chronic obstructive pulmonary disease asthma conclusion large population based cohort long term follow low fev obstructive respiratory disease strongly independently associated risk incident hf:0.0322950533793022"
  },
  "Topic 19": {
    "20194": "background cardiac resynchronisation therapy crt become valuable therapeutic tool patient advanced chronic heart failure chf search optimal method assessment crt efficacy still underway aim evaluate impact implantation crt device patient chf adaptation circulatory respiratory system maximal exercise assessed cardiopulmonary exercise test cpx minute walking test mwt method investigated patient male female year crt device implanted due advanced chf resulted ischaemic dilated cardiomyopathy patient implantation underwent echocardiography cpx expired gas analysis mwt investigation repeated month crt implantation cpx evaluated peak oxygen uptake peak vo oxygen pulse maximal minute ventilation carbon dioxide production vco max slope vco slope vo slope vo anaerobic threshold cardiac respiratory reserve mwt evaluated walking distance heart rate blood pressure response exercise result noted statistically higher mean peak vo crt implantation studied group v ml kg min p v l min p higher value expired co v l min p pulse rose ml beat p also observed significant reduction vco slope crt crt p significant decrease vo slope p vco max fell p patient estimated dyspnoea borg scale peak exercise point crt point p crt patient could walk longer distance mwt crt v p conclusion cardiac resynchronisation therapy improves exercise tolerance measured mean cpx mwt improves respiratory system efficiency restores adaptive mechanism exercise patient advanced chf better exercise adaptation crt may objectively measured cpx parameter correlate improvement clinical symptom cpx seems helpful tool assessing result crt:0.0363133629972527",
    "124350": "objective cardiopulmonary function patient chronic heart failure chf severely limited holistic integrative exercise pathophysiology still unclear method signed consent form eighty three patient severe chf october october fuwai hospital performed ramp incremental loading program cardiopulmonary exercise testing cpet normal subject served control cpet performed according standard harbor ucla mc circulatory respiratory metabolic parameter cpet measured analyzed result peak oxygen uptake peak vo chf ml min kg pred significantly lower control ml min kg pred core parameter cpet anaerobic threshold peak oxygen pulse oxygen uptake efficiency platform ouep lowest carbon dioxide output ventilation ratio lowest vco carbon dioxide output ventilation slope vco slope chf significantly different control group p core parameter lung function forced expiratory volume first second fev forced vital capacity fvc fev fvc carbon monoxide diffusion dlco significantly decreased p systolic blood pressure stage cpet chf significantly lower control group p heart rate peak recovery stage significantly lower control p minute ventilation tidal volume respiratory frequency rest warm significantly higher control p tidal volume recovery significantly higher control p vo peak recovery stage chf significantly higher control p oxygen pulse peak significantly higher control p pulse oxygen saturation stage cpet chf significantly lower control p conclusion decreased holistic functional capacity cardiogenic chf dominantly due circulatory limitation secondly due respiratory metabolic limitation:0.0354616824039552",
    "46496": "objective study sought discover key determinant exercise capacity maximal oxygen consumption oxygen uptake vo ventilatory efficiency ventilation carbon dioxide output vco slope assess prognostic potential metabolic exercise testing hypertrophic cardiomyopathy hcm background intrinsic mechanism leading reduced functional tolerance hcm unclear method study sample included hcm patient consecutively enrolled january january complete clinical assessment including rest stress echocardiography cardiopulmonary exercise test cpet impedance cardiography patient also followed composite outcome cardiac related death heart transplant functional deterioration leading septal reduction therapy myectomy septal alcohol ablation result abnormality cpet response frequent n sample showing reduced exercise tolerance vo max predicted n characterized impaired ventilatory efficiency vco slope variable strongly associated exercise capacity expressed metabolic equivalent peak cardiac index r p age r p male sex r p indexed right ventricular end diastolic area r p resulting r p peak cardiac index main predictor peak vo r p variable strongly related vco slope e e r p indexed left atrial volume index lavi r p model r composite endpoint occurred patient exploratory analysis variable independently associated composite outcome mean follow month peak vo predicted hazard ratio confidence interval ci p vco slope hazard ratio ci p lavi ml hazard ratio ci p conclusion hcm peak cardiac index main determinant exercise capacity significantly related ventilatory efficiency peak vo ventilatory inefficiency lavi associated increased risk major event short term follow:0.0351152548996208",
    "23835": "purpose study investigates relationship ventilatory expired gas cardiac parameter measured exercise testing patient heart failure method twenty five subject male female diagnosed compensated heart failure underwent symptom limited exercise testing ventilatory expired gas analysis metabolic cardiac measure interest collected testing result mean peak oxygen consumption vo minute ventilation carbon dioxide production vco slope percentage age predicted maximal heart rate achieved exercise testing apmhr peak respiratory exchange ratio ml kg min respectively vco slope significantly correlated following apmhr r p peak vo r p vo ventilatory threshold r p dead space tidal volume ratio vd vt r p ability peak vo apmhr predict vco slope significant r r p conclusion study demonstrates importance analyzing multiple exercise test parameter including metabolic measure patient heart failure:0.0348723463266375",
    "10210": "background cardiopulmonary exercise testing cpet variable provide valuable prognostic information heart failure hf population purpose present study assess ability resting end tidal carbon dioxide partial pressure petco predict cardiac related event patient hf method subject diagnosed compensated hf underwent cpet outpatient basis mean age ejection fraction year respectively resting p et co determined immediately prior exercise test seated position peak oxygen consumption vo minute ventilation carbon dioxide production vco slope also acquired cpet result cardiac related hospitalization cardiac related death year following cpet mean resting p et co peak vo vco slope mmhg ml kg min respectively univariate cox regression analysis revealed resting p et co chi square p peak vo chi square p vco slope chi square p significant predictor cardiac related event multivariate cox regression analysis revealed resting p et co added prognostic value vco slope predicting cardiac related event residual chi square p peak vo add additional value removed residual chi square p conclusion result indicate resting ventilatory expired gas variable possesses prognostic value independently combination established prognostic marker cpet resting p et co may therefore valuable objective measure obtain non exercise exercise evaluation patient hf:0.0345872540496474",
    "28511": "aim study aim validate cardiopulmonary exercise testing cpet parameter recommended european society cardiology guideline risk assessment heart failure hf esc predictor verify predictive role supplementary cpet predictor parameter method result followed hf patient cardiovascular death urgent heart transplantation year patient cardiac event esc predictor peak oxygen consumption vo slope minute ventilation v carbon dioxide production vco exertional oscillatory ventilation related outcome univariate multivariable analysis esc prototype based esc predictor presented harrell c concordance index likely chi predictor predicted peak vo peak oxygen pulse peak respiratory exchange ratio peak circulatory power peak vco vco slope normalized peak vo vo efficiency slope ventilatory anaerobic threshold detection peak end tidal co partial pressure peak heart rate peak systolic arterial blood pressure sbp linked outcome univariate analysis individually added esc prototype peak sbp peak pulse significantly improved model discrimination ability esc peak sbp prototype harrell c index reached highest likely chi p conclusion evaluated longest list cpet prognostic parameter yet studied hf esc predictor independent predictor cardiovascular event esc prototype showed convincing predictive capacity whereas none predictor enhanced prognostic performance except peak sbp:0.0345662019735228",
    "7248": "background rate heart rate recovers exercise recently shown strong predictor mortality patient suspected coronary disease prognostic value patient heart failure hf explored sought assess prognostic utility heart rate recovery hrr patient hf method eighty seven subject diagnosed compensated hf underwent cardiopulmonary exercise testing cpx mean age ejection fraction year respectively heart rate minute post cpx subtracted maximal heart rate exercise test produce measure hrr beat per minute subject followed combined death hospitalization end point year cpx result mean peak respiratory exchange ratio peak oxygen consumption vo minute ventilation carbon dioxide production vco slope hrr ml kg min beat min respectively although three variable significant univariate predictor composite end point p multivariate cox regression analysis retained vco slope chi p hrr residual chi p equation hazard ratio subject abnormal vco slope hrr beat min value ci p conclusion result indicate hrr provides additional prognostic information patient hf undergoing cpx moreover given independent prognostic value hrr variable alone may provide valuable clinical information ventilatory expired gas analysis available:0.0345565282723541",
    "157348": "background cardiopulmonary exercise testing cpx essential assessment exercise capacity patient chronic heart failure chf respiratory gas hemodynamic parameter ventilatory efficiency vco slope peak oxygen uptake peak vo heart rate recovery established diagnostic prognostic marker clinical population previous study suggested clinical value metric related respiratory gas collected recovery peak exercise particularly recovery time peak vo current study explores metric detail recovery peak exercise chf method patient chf referred cpx healthy individual without formal diagnosis assessed inclusion subject performed cpx cycle ergometer volitional exhaustion monitored least five minute recovery cpx data analyzed overshoot respiratory exchange ratio rer vco vo ventilatory equivalent oxygen vo end tidal partial pressure oxygen peto peak vo vco result thirty two patient chf control included peak vo differed significantly patient control v ml kg min p mean left ventricular ejection fraction lvef patient chf compared control group vo vco significantly higher patient control p overshoot peto vo rer significantly lower patient control p recovery metric significantly correlated peak vo chf patient lvef conclusion patient chf significantly blunted recovery peak exercise reflected delay vo vco peto rer vo reflecting greater energy required return baseline abnormal respiratory gas kinetics chf negatively correlated peak vo baseline lvef:0.0343918814479174",
    "17566": "background cardiopulmonary exercise testing ventilatory expired gas analysis cpet proven valuable tool assessing patient chronic heart failure chf maximal oxygen uptake peak v used risk stratification patient chf minute ventilation carbon dioxide production relationship vco slope recently demonstrated prognostic significance patient chf method january december performed cpet pt f mean age year stable chf coronary artery disease dilated cardiomyopathy nyha functional class ii n iii n left ventricular ejection fraction lvef ability peak vo vco slope predict cardiac related mortality cardiac related hospitalization within month evaluation examined result peak vo vco slope demonstrated univariate cox regression analysis significant predictor cardiac related mortality hospitalization p respectively non survivor lower peak vo ml kg min v ml kg min p steeper vco slope v p survivor multivariate survival analysis revealed vco slope added additional value vo peak independent prognostic factor chi relative risk ci p result kaplan meier analysis revealed year cardiac related mortality patient vco slope vco slope log rank chi p patient peak vo ml kg min peak vo ml kg min log rank chi p one year cardiac related hospitalization patient vco slope vco slope log rank chi p patient peak vo ml kg min peak vo ml kg min log rank chi p vco slope demonstrated receiver operating characteristic curve analysis equivalent peak vo predicting cardiac related mortality v although area receiver operating characteristic curve vco slope greater peak vo predicting cardiac related hospitalization v difference statistically significant p conclusion result add present body knowledge supporting use cpet chf patient vco slope index ventilatory response exercise excellent prognostic parameter improves risk stratification chf patient easier obtain parameter maximal exercise capacity equivalent prognostic importance peak vo:0.0343143777726326",
    "125159": "background advanced heart failure hf levosimendan increase peak oxygen uptake vo investigated whether peak vo increase linked cardiovascular respiratory muscular performance change method result twenty patient hospitalized advanced hf underwent shortly levosimendan infusion different cardiopulmonary exercise test personalized ramp protocol repeated arterial blood gas analysis standard spirometry including alveolar capillary gas diffusion measurement rest peak exercise b step incremental workload cardiopulmonary exercise testing continuous near infrared spectroscopy analysis cardiac output assessment bioelectrical impedance analysis levosimendan significantly decreased natriuretic peptide improved peak vo interquartile range ml kg min p decreased minute ventilation carbon dioxide production relationship slope p parallel spirometry showed minor increase forced expiratory volume whereas peak exercise dead space ventilation unchanged however exercise smaller edema formation observed levosimendan infusion inferable change diffusion component membrane diffusion capillary volume end tidal pressure co isocapnic buffering period increased levosimendan mm hg mm hg p exercise cardiac output increased parallel vo levosimendan total oxygenated tissue hemoglobin deoxygenated hemoglobin increased exercise phase conclusion advanced hf levosimendan increase peak vo decrease formation exercise induced lung edema increase ventilation efficiency owing decrease reflex hyperventilation increase cardiac output muscular oxygen delivery extraction:0.0342973056816982"
  },
  "Topic 20": {
    "178045": "background heart failure hf common complication patient end stage renal disease esrd also major cause death although clinical study shown close relationship mechanism occurrence unclear aim study explore molecular mechanism hf esrd comprehensive bioinformatics analysis providing new perspective crosstalk two disease method hf esrd datasets downloaded gene expression omnibus geo database identified analyzed common differentially expressed gene degs first gene ontology go kyoto encyclopedia gene genome kegg gene set variation analysis gsva applied explore potential biological function construct protein protein interaction ppi network also four algorithm namely random forest rf boruta algorithm logical regression selection operator lasso support vector machine recursive feature elimination svm rfe used identify candidate gene subsequently diagnostic efficacy hub gene hf esrd evaluated using extreme gradient boosting xgboost algorithm cibersort used analyze infiltration immune cell thereafter predicted target micrornas mirnas using database mirtarbase tarbase enocri transcription factor tfs identified using chea database cytoscape software applied construct mrna mirna tf regulatory network finally drug signature database dsigdb used identify potential drug candidate result total common degs identified enrichment analysis result suggest immune response inflammatory factor may common feature pathophysiology hf esrd total four hub gene bcl ccl cnn pcnt validated using rf lasso boruta svm rfe algorithm auc value greater immune infiltration analysis showed immune cell macrophage neutrophil nk cell altered hf myocardial tissue neutrophil significantly correlated four hub gene finally target mirnas tfs obtained mirna mrna tf regulatory network construction performed addition gene targeted drug discovered conclusion study revealed important crosstalk hf esrd common pathway pivotal gene may provide new idea clinical treatment experimental study:0.0561869783192027",
    "190676": "aim heart failure hf non alcoholic fatty liver disease nafld significant global health issue complex interrelationship study investigates shared biomarkers causal relationship using bioinformatics mendelian randomization mr approach method analysed nafld hf datasets gene expression omnibus geo gse dataset included liver biopsy sample healthy individual obese subject nafl patient non alcoholic steatohepatitis nash patient gse dataset comprised nash sample healthy control gse dataset included cardiac muscle sample hf patient ischaemic heart disease patient idiopathic dilated cardiomyopathy patient healthy control gse dataset consisted end stage hf patient healthy heart procured organ donor identified differentially expressed gene degs constructed protein protein interaction ppi network functional pathway elucidated enrichment analysis using gene ontology go kyoto encyclopedia gene genome kegg genemania annotation single nucleotide polymorphism snp data hf nafld sourced genome wide association study gwas hf dataset included sample experimental control nafld dataset comprised sample experimental control mr analysis investigates causal interrelation result analysis revealed degs gse degs gse top hub gene cd vsig cxcl fcer g fpr c qb ccr c orf mrc cd significantly enriched immune response calcium ion concentration regulation positive regulation monocyte chemotaxis cibersort analysis indicated association hub gene natural killer nk cell macrophage transcription factor tf target prediction cd cxcl ccr highlighted related tfs two sample mr analysis confirmed bidirectional causal relationship nafld hf main method inverse variance weighted ivw demonstrated significant positive causal relationship nafld hf p odds ratio confidence interval ci similarly hf associated increase risk nafld p ci conclusion finding reveal novel molecular signature common nafld hf confirm bidirectional causality highlighting potential targeted therapeutic intervention prompting investigation intricate relationship:0.0558970071575664",
    "173969": "background heart failure hf end stage various cardiovascular disease identifying new biomarkers essential early diagnosis prognosis treatment study applied bioinformatics identify potential hf biomarkers explore role immune microenvironment method gene expression data obtained gene expression omnibus geo database differential expression analysis weighted gene co expression network analysis wgcna used identify key gene gene ontology go kyoto encyclopedia gene genome kegg gene set enrichment analysis performed feature gene determined using two machine learning algorithm random forest rf least absolute shrinkage selection operator lasso diagnostic accuracy assessed via receiver operating characteristic roc curve nomogram screen hub gene external datasets used validation quantitative reverse transcription polymerase chain reaction rt qpcr used validate expression level hub gene clinical sample single sample gene set enrichment analysis cibersort algorithm applied evaluate immune cell infiltration hf relationship hub gene result differential analysis identified differentially expressed gene degs wgcna revealed blue module showing significant correlation hf integration degs blue module gene identified common gene kegg pathway enrichment analysis suggested gene may involved cytoskeleton muscle cell pathway lasso rf algorithm confirmed key gene potential biomarkers hf analysis using roc curve identified hub gene good diagnostic value namely high mobility group n hmgn myosin heavy chain myh high temperature requirement htra microfibrillar associated protein mfap validated external dataset rt qpcr immune infiltration analysis revealed significant infiltration immune cell hf cell nk cell monocyte macrophage play important role development hf hub gene closely associated multiple immune cell type conclusion study identifies hmgn htra mfap myh novel diagnostic biomarkers potential therapeutic target hf gene closely related immune microenvironment providing new insight early diagnosis treatment mechanistic exploration hf:0.0556971048330536",
    "128151": "background heart failure health burden responsible high morbidity mortality worldwide dilated cardiomyopathy dcm one common cause heart failure dcm disease heart muscle characterized enlargement dilation least one ventricle alongside impaired contractility left ventricular ejection fraction also associated abnormality cytoskeletal protein mitochondrial atp transporter microvasculature fibrosis however pathogenesis potential biomarkers dcm remain investigated aim investigate candidate gene pathway involved dcm patient method two expression datasets gse gse downloaded gene expression omnibus database differentially expressed gene degs dcm patient healthy individual identified using r package linear model microarray data pathway common degs analyzed via gene ontology go kyoto encyclopedia gene genome kegg gene set enrichment analysis moreover protein protein interaction network ppi constructed identify hub gene module microrna database applied predict micrornas mirnas targeting hub gene additionally immune cell infiltration dcm analyzed using cibersort result total degs upregulated downregulated identified go analysis showed degs mainly enriched response growth factor extracellular matrix extracellular matrix structural constituent kegg pathway analysis indicated degs mainly enriched protein digestion absorption interleukin il signaling pathway ppi network suggested collagen type iii alpha chain col col contribute pathogenesis dcm additionally visualization interaction mirnas hub gene revealed hsa mir hsa mir interacted col col thus mirnas might play role dcm immune cell infiltration analysis revealed dcm patient infiltrated plasma cell fewer infiltrated b memory cell follicular helper cell resting dendritic cell conclusion col col targeting mirnas hsa mir hsa mir may play critical role pathogenesis dcm closely related il signaling pathway acute inflammatory response result may provide useful clue diagnosis treatment dcm:0.0554994238097079",
    "193804": "background previous research established chronic kidney disease ckd heart failure preserved ejection fraction hfpef often coexist although preliminary understanding potential correlation hfpef ckd underlying pathophysiological mechanism remain unclear study aimed elucidate molecular mechanism associated ckd hfpef bioinformatics analysis method datasets hfpef ckd obtained gene expression omnibus geo database r software package limma employed conduct differential expression analysis functional annotation performed using kyoto encyclopedia gene genome kegg gene ontology go conducted weighted gene co expression network analysis wgcna correlation analysis autophagy ferroptosis immune related process well transcriptional regulation analysis immune infiltration analysis diagnostic performance evaluation finally diagnostic potential identified hub gene ckd hfpef assessed using roc curve analysis gse result differential expression analysis revealed overlapping gene comprised regulated regulated gene go kegg analysis indicated enriched pathway relevant disorder wgcna identified gene associated ckd comparison differentially expressed gene degs identified three hub gene klf scd sel l linked autophagy ferroptosis immune process condition additionally mirna mrna regulatory network involving mirnas transcription factor tfs constructed roc curve analysis performed evaluate diagnostic utility hub gene ckd hfpef conclusion study elucidated shared pathogenic mechanism identified diagnostic marker common hfpef ckd identified hub gene show promise potential tool early diagnosis treatment strategy condition:0.0544110201447787",
    "122213": "introduction heart failure hf heterogeneous clinical syndrome affect million people world hf occurs cardiac overload injury worldwide complaint aim study screen verify hub gene involved developmental hf well explore active drug molecule method expression profiling high throughput sequencing gse dataset downloaded gene expression omnibus geo database contained sample including heart failure sample non heart failure sample raw data integrated find differentially expressed gene degs analyzed bioinformatics analysis gene ontology go reactome enrichment analysis performed via toppgene protein protein interaction ppi network degs constructed based data hippie interactome database module analysis performed target gene mirna regulatory network target gene tf regulatory network constructed analyzed hub gene validated molecular docking study performed result total degs including regulated gene regulated gene observed degs significantly enriched biological adhesion extracellular matrix signaling receptor binding secretion intrinsic component plasma membrane signaling receptor activity extracellular matrix organization neutrophil degranulation top hub gene esr pyhin ppp r b lck tp pclaf cftr tk ect fkbp identified ppi network module analysis revealed hf associated adaptive immune system neutrophil degranulation target gene mirnas tfs identified target gene mirna regulatory network target gene tf regulatory network furthermore receiver operating characteristic roc curve analysis rt pcr analysis revealed esr pyhin ppp r b lck tp pclaf cftr tk ect fkbp might serve prognostic diagnostic biomarkers therapeutic target hf predicted target active molecule confirmed conclusion current investigation identified series key gene pathway might involved progression hf providing new understanding underlying molecular mechanism hf:0.0542421053685461",
    "170819": "background non alcoholic fatty liver disease nafld heart failure hf related condition increasing incidence however mechanism underlying association remains unclear study aimed explore shared pathogenic mechanism common biomarkers nafld hf bioinformatics analysis experimental validation method nafld hf related transcriptome data extracted gene expression omnibus geo database gse gse differential analysis performed identify common differentially expressed gene co degs nafld hf gene ontology go kyoto encyclopedia gene genome kegg gene set enrichment analysis gsea conducted explore function regulatory pathway co degs protein protein interaction ppi network support vector machine recursive feature elimination svm rfe method used screen common key degs diagnostic value common key degs assessed receiver operating characteristic roc curve validated external datasets gse gse finally expression biomarkers validated mouse model result total co degs screened nafld hf patient go kegg gsea analysis indicated co degs mainly enriched immune related pathway ppi network revealed key degs svm rfe model eventually identified two gene cd ccr common key degs nafld hf expression analysis revealed expression level cd ccr significantly regulated hf nafld patient roc curve analysis showed cd ccr good diagnostic value hf nafld single gene gsea suggested cd ccr mainly engaged immune response inflammation experimental validation indicated unbalanced macrophage polarization hf nafld mouse model expression cd ccr significantly regulated conclusion study identified polarization impairment characterized decreased expression cd ccr common pathogenic pathway nafld hf downregulation cd ccr may reflect key pathological change development progression nafld hf suggesting potential diagnostic therapeutic target:0.0533959588810658",
    "176811": "purpose study explores lactylation pivotal role disease progression heart failure hf method gse dataset encompassing hf sample normal control ctl sourced gene expression omnibus geo differentially expressed gene hf ctl group underwent enrichment analysis using gene ontology go kyoto encyclopedia gene genome kegg pathway weighted correlation network analysis wgcna unsupervised clustering employed identify hf associated gene module subtypes intersected lactate related gene lrgs curated molecular signature database genecards pinpoint hub gene implicated lactylation mediated hf lcy hf least absolute shrinkage selection operator lasso xgboost boruta algorithm protein protein interaction ppi network utilized identify hub gene diagnostic potential biological significance hub gene hf progression assessed using receiver operating characteristic roc curve gene set enrichment analysis gsea immune infiltration analysis result comparison hf ctl sample upregulated downregulated gene identified primarily enriched inflammatory response pathway intersecting lrgs curated database pinpointed six hub gene implicated lcy hf gata hbb jak stat stat war immune infiltration analysis revealed lcy hf hub gene associated macrophage polarization conclusion lactylation play crucial role pathogenesis hf gene gata hbb jak stat stat war emerging potential lactylation biomarkers hf identification lactylation macrophage polarization inflammation axis stand pivotal mechanism driving hf progression:0.0530824244551372",
    "188520": "background despite advancement heart failure hf research early diagnosis hf continues challenging issue clinical practice study aim investigate gene related myocardial fibrosis conduction block goal developing diagnostic model early treatment hf patient method gene expression profile gse gse gse obtained gene expression omnibus geo database merging expression profile data adjusting batch effect differentially expressed gene degs associated conduction block myocardial fibrosis identified gene ontology go resource kyoto encyclopedia gene genome kegg resource gene set enrichment analysis gsea utilized functional enrichment analysis protein protein interaction network ppi constructed using string database potential key gene selected based bioinformatics information mentioned svm lasso employed identify hub gene construct module associated hf mrna level tac mouse external datasets gse gse utilized validating diagnostic model additionally study explores relationship diagnostic model immune cell infiltration result total gene exhibiting differential expression identified functional enrichment analysis revealed specific gene primarily participate biological process pathway associated constituent extracellular matrix ecm immune system process inflammatory response identified diagnostic model consisting hub gene predictive performance validated using external data set transverse aortic coarctation tac mouse model addition observed significant difference mrna expression gene tac mouse model interestingly study also unveiled correlation model gene immune cell infiltration conclusion identified sixteen key gene associated myocardial fibrosis conduction block well diagnostic model heart failure finding significant implication intensive management individual potential genetic variant associated heart failure especially context advancing cell targeted therapy myocardial fibrosis:0.0524703945211642",
    "166566": "background present study investigated differential expressed gene gegs ischemic cardiomyopathy icm construct regulation network study correlation myocardial infarction risk method data set downloaded gene expression omnibus geo screen messenger rna mrna long non coding rna lncrna differentially expressed icm sample normal sample gene ontology go function analysis kyoto encyclopedia gene genome kegg pathway analysis performed differentially expressed mrna lncrna analyzed bioinformatics method used predict analyze microrna mirna competing endogenous rna hub gene regulatory network constructed using limma software package r language degs icm screened non heart failure donor control group condition differential expression ratio less time corrected p value clusterprofiler software package used go enrichment analysis kegg enrichment analysis search tool retrieval interacting gene protein string online database used screen key gene protein protein interaction ppi network analysis result go function analysis kegg pathway analysis showed degs significantly enriched metabolic pathway oxidative phosphorylation extracellular matrix receptor interaction pathway closely related fibrosis collagen catabolic process inflammatory response function hub gene regulatory network related icm lncrna constructed bioinformatics method used effectively analyze degs icm hub gene regulatory network icm successfully constructed conclusion study identified certain risk correlation icm susceptibility gene myocardial infarction:0.0523851980850248"
  },
  "Topic 21": {
    "108496": "diabetes mellitus major risk factor cardiovascular cv disease conversely cv disease responsible majority death patient diabetes many drug trial concentrated blood glucose hemoglobin c reduction strategy reducing microvascular outcome like nephropathy neuropathy little effect reducing macrovascular event like heart attack stroke heart failure postulated hypoglycemia may counterbalance beneficial effect anti hyperglycemic agent proven trial evidence thiazolidinediones rosiglitazone pioglitazone showed increased risk heart failure raised concern increased myocardial infarction heightened awareness potentially harmful cv effect otherwise effective hypoglycemic drug resulted regulatory mandate cv outcome trial ascertain safety newer anti hypoglycemic agent appearing market three new class anti hyperglycemic agent introduced recent year dipeptidyl peptidase dpp inhibitor exhibited increased heart failure hospitalization savor timi trial evaluating saxagliptin secondary analysis examine trial alogliptin effect glucagon like peptide glp analog sodium glucose co transporter sglt inhibitor cv outcome diabetes largely positive leader sustain trial evaluating safety efficacy glp analog liraglutide semaglutide respectively showed statistically significant reduction primary outcome major adverse cardiac event mace cv death myocardial infarction stroke secondary combined outcome compared placebo result tecos trial sitagliptin however neutral net cv benefit harm questioning class effect glp analog result sglt inhibitor trial uniform empa reg evaluating empagliflozin canvas evaluating canagliflozin showed reduction mace end point dapagliflozin net neutral effect mace declare timi three sglt inhibitor however showed significant reduction heart failure hospitalization although initially designed keep potentially harmful anti hyperglycemic agent market cv outcome trial provided clinician new set anti hyperglycemic drug proven cv benefit patient diabetes cv disease thus expanding field cv secondary prevention need inculcate glp analog sglt inhibitor reduce major cv event heart failure hospitalization alongside lifestyle management metformin treatment patient diabetes cv disease:0.0375354089986578",
    "116865": "cardiovascular disease cvd major challenge management type diabetes mellitus glucose lowering agent reduce risk major cardiovascular event would considered major advance recently reported liraglutide semaglutide glucagon like peptide receptor agonist empagliflozin canagliflozin sglt sodium glucose cotransporter type inhibitor dpp dipeptidyl peptidase inhibitor present review devoted cv effect new oral glucose lowering agent dpp inhibitor gliptins showed positive cardiac vascular effect preliminary study initial data phase clinical trial suggested reduction major cardiovascular event however subsequent cv outcome trial alogliptin saxagliptin sitagliptin showed noninferiority failed demonstrate superiority compared placebo patient type diabetes mellitus high cv risk unexpected higher risk hospitalization heart failure reported saxagliptin sglt inhibitor gliflozins promote glucosuria thus reducing glucose toxicity body weight enhance natriuresis thus lowering blood pressure two cv outcome trial type diabetes mellitus patient mainly secondary prevention showed remarkable positive result empagliflozin empa reg outcome empagliflozin cardiovascular outcome event type diabetes mellitus patient reduced major cardiovascular event cv mortality cause mortality hospitalization heart failure canvas canagliflozin cardiovascular assessment study reduction cv mortality canagliflozin failed reach statistical significance despite similar reduction major cardiovascular event underlying protective mechanism sglt inhibitor remain unknown hemodynamic metabolic explanation proposed cvd real study comparative effectiveness cardiovascular outcome new user sodium glucose cotransporter inhibitor limitation observational approach suggested favorable result may considered class effect shared sglt inhibitor including dapagliflozin extrapolated larger population patient type diabetes mellitus primary prevention ongoing cv outcome trial dpp linagliptin sglt dapagliflozin ertugliflozin inhibitor provide additional information cv effect pharmacological class:0.0374829787925882",
    "67327": "randomized controlled trial rcts intensive glucose control patient type diabetes lead modest reduction major cardiovascular event mace associated reduction kidney event reduction eye event fda issued guidance led conduct numerous cardiovascular outcome cvot trial assess cardiovascular safety new antihyperglycemic therapy patient type diabetes result trial show insulin glargine three different dipeptidyl peptidase dpp inhibitor saxagliptin alogliptin sitagliptin lixisenatide glucagon like peptide receptor agonist produce significant difference cvot compared usual care placebo trial newer diabetes drug including empagliflozin canagliflozin two sodium glucose co transporter inhibitor liraglutide semaglutide two glp receptor agonist succeeded demonstrating cv benefit people type diabetes last two decade equation diabetes equal myocardial infarction contributed development preventive therapy risk factor diabetes primary secondary prevention diabetic patient high rate statin aspirin treatment improved cv outcome compared non user drug used reduce glucose level patient type diabetes seem important ultimate cardiovascular outcome combination intensive glycemic control safely attainable newer diabetes drug empagliflozin canagliflozin liraglutide semaglutide may decrease incidence mace nephropathy retinopathy moreover depending drug used cv mortality heart failure may also reduced:0.0373018196333760",
    "188879": "primary treatment autoimmune diabetes mellitus type diabetes mellitus dm insulin therapy unfortunately multitude clinical case demonstrated use insulin sole therapeutic intervention fails address issue comprehensively therefore non insulin adjunct treatment investigated shown successful result clinical trial various hypoglycemia inducing drug metformin glucagon like peptide glp receptor agonist dipeptidyl peptidase dpp inhibitor amylin analog sodium glucose cotransporters sglt inhibitor developed good outcome patient dm currently sglt inhibitor remarkably improved treatment patient diabetes preventing cardiovascular event heart failure hospitalization progression renal disease however pharmacological potential explored enough thus substantial interest sglt inhibitor sglt underline present review begin overview carrier mediated cellular glucose uptake evidencing insulin independent transport system contribution glucose homeostasis essential role sodium glucose cotransporters pharmacological property sglt detailed leading potential application treating dm patient automated insulin delivery aid system result several study demonstrated improvement glycemic control increase time range tir decrease glycemic variability reduced daily insulin requirement without increasing hyperglycemic event benefit weight management however advantage counterbalanced increased risk particularly concerning diabetic ketoacidosis dka several clinical trial reported higher incidence dka patient dm received sglt inhibitor sotagliflozin empagliflozin hand patient dm body mass index bmi kg treated dapagliflozin showed similar reduction hyperglycemia body weight insignificantly increased dka incidence compared overall trial population additional multicenter randomized study required establish safer effective long term strategy based patient selection education continuous ketone body monitoring optimal integration sglt inhibitor dm therapeutic protocol:0.0371329385496441",
    "144234": "pharmacotherapy type diabetes mellitus dm markedly evolved last two decade classical antidiabetic agent sulphonylureas metformin insulin competition new glucose lowering medication alpha glucosidase inhibitor thiazolidinediones glitazones able replace older agent insufficient efficacy poor tolerability safety contrast incretin based therapy dipeptidyl peptidase inhibitor dpp gliptins oral agent glucagon like peptide receptor agonist glp ra subcutaneous injection major breakthrough management dm associated hypoglycaemia weight gain dpp tend replace sulphonylureas add metformin glp ra tend replace basal insulin therapy failure oral therapy furthermore placebo controlled cardiovascular outcome trial demonstrated neutrality dpp cardiovascular protection glp ra patient dm high cardiovascular risk recently sodium glucose cotransporter inhibitor sglt gliflozins oral agent also showed cardiovascular protection especially reduction hospitalization heart failure well renal protection patient without dm high cardiovascular risk established heart failure chronic kidney disease thus glp ra sglt considered preferred drug dm patient high risk atherosclerotic cardiovascular disease whereas sglt specifically recommended patient risk heart failure renal albuminuric disease management dm moving glucocentric approach broader strategy focusing risk factor including overweight obesity organ disease targeted personalized approach:0.0366930006331185",
    "145593": "type diabetes leading cause chronic kidney disease worldwide continues increase prevalence turn significant implication healthcare provision economy recent year multiple advance glucose lowering agent available treatment diabetes modify disease also important benefit term associated cardiovascular outcome cardiovascular outcome trial agent glucagon like peptide receptor agonist glp ra sodium glucose cotransporter inhibitor sglt demonstrated significant benefit reducing major adverse cardiovascular event admission heart failure case mortality secondary analysis trial also indicated significant renoprotective benefit canagliflozin renal outcome type diabetes mellitus nephropathy credence renal specific trial shown major benefit canagliflozin renal outcome diabetic kidney disease similar trial sglt inhibitor either underway awaiting analysis article review current goal treatment diabetes implication advancing renal impairment choice treatment area discussed include diagnosis diabetic kidney disease current treatment strategy diabetic kidney disease ranging lifestyle modification glycaemic control review focus role glp ra sglt inhibitor treating diabetes chronic kidney disease illustrative case clear agent considered first choice combination metformin diabetes increased cardiovascular risk reduced renal function preference class dipeptidyl peptidase dpp inhibitor sulphonylureas:0.0358799024226420",
    "123773": "type diabetes mellitus dm highly prevalent associated two fold increased mortality mostly explained cardiovascular disease trial evidence older glucose lowering agent metformin sulfonylurea limited term cardiovascular efficacy since rosiglitazone observed increase risk myocardial infarction heart failure hf cardiovascular outcome trial cvots required regulator licensing new glucose lowering agent following cvots dipeptidyl peptidase inhibitor dpp shown safe improve mortality morbidity except saxagliptin increased risk hf several glucagon like peptide receptor agonist glp ra sodium glucose cotransporter inhibitor sglt demonstrated reduce risk cardiovascular mortality morbidity sglt shown class effect reduction risk hf event patient dm leading trial testing efficacy safety hf regardless dm dapa hf emperor reduced trial dapagliflozin empagliflozin respectively improved cardiovascular mortality morbidity patient hf reduced ejection fraction hfref without dm therefore drug key part hfref pharmacotherapy soloist whf sotagliflozin reduced cardiovascular mortality morbidity patient dm recent acute episode hf regardless ejection fraction ef emperor preserved empagliflozin reduced cv mortality morbidity patient heart failure mildly reduced hfmref preserved hfpef ef regardless comorbid dm deliver currently testing dapagliflozin patient hfmref hfref strong renal protective role sglt also emerged trial enrolling patient without dm:0.0358391680479310",
    "107325": "patient type diabetes mellitus dm substantially increased risk heart failure hf hf mortality despite lack evidence tight glycemic control reduces incidence cardiovascular cv event growing body evidence suggests choice glucose lowering agent may influence outcome including hf thiazolidinediones associated significant risk hf metformin sulphonylureas insulin little data available indicate impact hf glucagon like peptide glp agonist liraglutide semaglutide shown reduce major cv event affect rate hospitalization hf clinical trial demonstrated diverse effect dipeptidyl peptidase dpp inhibitor hf saxagliptin showed increased risk hf admission alogliptin associated higher rate new hf admission sitagliptin neutral effect sodium glucose cotransporter sglt inhibitor empagliflozin canagliflozin recently shown reduce incidence hf cardiovascular mortality patient without history hf review summarize key finding impact glucose lowering agent cv safety hf associated outcome present available data underlying mechanism benefit sglt inhibitor hf discus strategy improve outcome patient dm high cv risk:0.0354005015161714",
    "121040": "future newer class glucose lowering drug namely dipeptidyl peptidase dpp inhibitor glucagon like peptide receptor agonist glp ra sodium glucose co transporter sglt inhibitor redefined large prospective cardiovascular outcome trial cvots trial confirmed cardiovascular cv safety indeed various cardio renal parameter improved trial glp ra sglt inhibitor type diabetes benefit included reduction major adverse cardiovascular event fatal non fatal myocardial infarction stroke decreased hospitalization heart failure slower decline glomerular filtration rate reduced onset progression albuminuria consequence cvots raised expectation newer glucose lowering agent offer advantage extend beyond glycaemic control weight management address complication comorbidities type diabetes particularly cardio renal disease although large prospective outcome trial incur high cost may prompt reconsideration design trial generating evidence enable exacting effective management type diabetes accompanying cardio renal disease:0.0347558221676249",
    "135656": "type diabetes mellitus dm common patient heart failure hf associated considerable morbidity mortality significant advance recently occurred treatment dm evidence several new glucose lowering medication showing either neutral beneficial cardiovascular effect however agent safety characteristic strong practical implication hf e dipeptidyl peptidase dpp inhibitor glucagon like peptide receptor agonist glp ra sodium glucose co transporter type sglt inhibitor regarding safety dpp inhibitor saxagliptin recommended hf greater risk hf hospitalisation compelling evidence excess hf risk dpp inhibitor glp ra overall neutral effect hf outcome however signal harm suggested two small trial liraglutide patient reduced ejection fraction indicates role remains defined established hf sglt inhibitor empagliflozin canagliflozin dapagliflozin shown consistent reduction risk hf hospitalisation regardless baseline cardiovascular risk history hf accordingly sglt inhibitor could recommended prevent hf hospitalisation patient dm established cardiovascular disease multiple risk factor recently completed trial dapagliflozin shown significant reduction cardiovascular mortality hf event patient hf reduced ejection fraction without dm several ongoing trial assess whether result observed dapagliflozin could extended sglt inhibitor treatment hf either preserved reduced ejection fraction regardless presence dm position paper aim summarise relevant clinical trial evidence concerning role safety new glucose lowering therapy patient hf:0.0346152529971458"
  },
  "Topic 22": {
    "9276": "background chronic heart failure chf associated calcium transient calcium handling protein angiotensin converting enzyme ace inhibitor demonstrated beneficial effect chf yet study addressed relationship ace inhibitor calcium transient chf rare aim study investigate influence ace inhibitor perindopril contractility calcium transient calcium handling protein ventricular myocytes rat experimental heart failure method male wistar rat randomized heart failure group treated perindopril chf mg kg heart failure group without treatment chf c sham operated group p heart failure induced abdominal aortic constriction group followed week left ventricular myocytes isolated single cell shortening fraction ca simultaneously measured laser scanning confocal microscope field stimulation hz reverse transcriptase polymerase chain reaction rt pcr western blot performed evaluate change mrna protein na ca exchanger ncx sarcoplasmic reticulum ca atpase serca phospholamban plb result fraction cell shortening f ca imax nmol l significantly reduced group chf c compared group p f v ca max v p restored least partially chf group chf c group left ventricular mrna ncx plb significantly upregulated comparing p group rncx beta actin v p rplb beta actin v p serca mrna downregulated v p mrna level ncx serca chf group chf c p group difference latter two group significant p chf c chf group protein expression ncx time p group respectively p serca protein level time p group respectively p protein expression ncx serca chf c chf group significantly different p conclusion ace inhibitor could improve cardiac function failing heart directly enhancing contractility single cardiomyocyte effect probably mediated role preventing deleterious change calcium transient calcium handling protein chf:0.0267747614347113",
    "17899": "aim present study investigate alteration thoracic aortic vasomotor function rat chronic heart failure chf post myocardial infarction mi explored possible mechanism pathological change male sprague dawley rat divided sham chf group randomly chf model group rat generated ligating left anterior descending artery sham operated rat ligation placed tightened total rat underwent either sham operated n surgery mi n sham operated rat survived surgical procedure post surgical period whereas total mortality among mi rat mi rat infarct size left ventricle lv included analysis ten week surgery rat anaesthetized hemodynamic measurement contains systolic pressure diastolic pressure left ventricular systolic pressure lvsp left ventricular end diastolic pressure lvedp lv dp dt max lv dp dt max heart rapidly excised weighed myocardial infarct size determined triphenyltetrazolium chloride ttc staining method isolated thoracic artery ring preparation studied wire myograph arterial constrictive response kcl cacl phenylephrine pe caffeine arterial diastolic response acetylcholine ach recorded multi myograph system explore possible mechanism nitric oxide synthase no inhibitor n nitrl l arginine methylester l name non selective cyclooxygenase cox inhibitor indomethacin indo used result obtained follows chf group showed increased contraction response kcl mmol l pe x x mol l reduced endothelium dependent relaxation response ach x x mol l compared observed sham group p p presence l name mmol l endothelium dependent cumulative contraction ach x x mol l significantly enhanced chf group p effect reversed pretreatment indo mumol l chf group vessel incubated indo mumol l showed increased vasodilation induced ach x x mol l p ca free k h solution calcium dependent contraction curve induced cacl x x mol l chf group significantly shifted left compared sham group p vascular contraction induced caffeine mmol l significant change finding suggest thoracic artery rat chf endothelial dysfunction contribution endothelial dilation contraction significantly altered chf rat mechanism could partly associated increased endothelium dependent contracting factor cox pathway increased extracellular ca influx voltage operated channel thus leading elevated vasoconstriction:0.0256497621316388",
    "59100": "vagus nerve stimulation vns targeting imbalanced autonomic nervous system promising therapeutic approach chronic heart failure hf moreover calcium cycling important part cardiac excitation contraction coupling ecc also participates antiarrhythmic effect vns hypothesized low level vns vns could improve cardiac function regulation intracellular calcium handling property experimental hf model established ligation left anterior descending coronary artery lad thirty two male sprague dawley rat divided group follows control group sham operated without coronary ligation n hf vns group hf rat vns n hf s group hf rat sham nerve stimulation n week treatment vns significantly improved left ventricular ejection fraction lvef attenuated myocardial interstitial fibrosis hf vns group compared hf s group elevated plasma norepinephrine dopamine epinephrine partially reduced vns additionally vns restored protein mrna level sarcoplasmic reticulum ca atpase serca na ca exchanger ncx phospholamban plb whereas expression ryanodine receptor ryr well mrna level unaffected thus study result suggest improvement cardiac performance vns accompanied reversal dysfunctional calcium handling property including serca ncx plb may potential molecular mechanism vns hf:0.0250651224137587",
    "135757": "background lingguizhugan decoction lgzg ancient chinese herbal formula used treat cardiovascular disease eastern asia investigated whether lgzg protective activity mechanism underlying effect animal model heart failure hf method rat model hf established administering eight intraperitoneal injection doxorubicin dox cumulative dose mg kg week period subsequently lgzg ml kg administered rat intragastrically daily week body weight heart weight index hwi heart weight tibia length ratio hw tl serum bnp level investigated assess effect lgzg hf echocardiography performed investigate cardiac function h e staining visualize myocardial morphology myocardial ultrastructure tubule sarcoplasmic reticulum tt sr junction observed transmission electron microscopy jp protein level determined western blotting mrna level cacna ryr microrna mir level assayed quantitative rt pcr result four week dox treatment rat developed cardiac damage exhibited significantly increased bnp level compared control rat pg ml versus pg ml p conversely lgzg especially highest dose markedly reduced bnp level pg ml p rat treated dox developed cardiac dysfunction characterized strong decrease left ventricular ejection fraction compared control versus p digoxin lgzg improved cardiac dysfunction respectively preserved left ventricular ejection fraction respectively p lgzg also improved lvedd lvesd f eliminated ventricular hypertrophy indicated decreased hwi hw tl ratio lgzg attenuated morphological abnormality mitochondrial damage myocardium addition high dose lgzg significantly downregulated expression mir compared dox treated rat fold change versus p upregulated expression jp antagonized dox induced tubule tt sr microstructural remodeling activity improved periodic ca transient cell contraction may underly beneficial effect lgzg hf conclusion lgzg exerted beneficial effect dox induced hf rat mediated part improved tt sr microstructural remodeling:0.0248567346811257",
    "73571": "objective elucidate association large conductance calcium activated potassium channel bk ca paraventricular hypothalamic nucleus pvn sympathetic outflow rat chronic heart failure chf method male wistar rat week old randomized sham operated group chf group coronary artery ligation two week operation bk ca inhibitor iberiotoxin ibtx infused pvn osmotic minipumps rat divided following group sham acsf chf acsf sham low dose ibtx nmol nl chf low dose ibtx sham moderate dose ibtx nmol nl chf moderate dose ibtx sham high dose ibtx nmol nl chf high dose ibtx n additional rat grouped follows sham vehicle sham kcnmb knockdown raav kcnmb shrna virus injection pvn chf vehicle chf kcnmb knockdown group n cardiac function determined echocardiography left ventricular hemodynamics measured invasively renal sympathetic nerve activity rsna recorded week coronary artery ligation sham operation content norepinephrine ne n terminal pro b type natriuretic peptide nt probnp plasma determined enzyme linked immunosorbent assay protein mrna expression kcnmb pvn measured immunofluorescence staining western blot real time pcr mrna expression bk ca pvn detected real time pcr result compared sham operation group cardiac function heart failure group significantly reduced p plasma ne serum nt probnp significantly elevated p protein mrna expression kcnmb pvn obviously regulated chf rat p perfusion ibtx kcnmb knockdown microinjection raav kcnmb shrna virus right ventricular weight body weight lung weight body weight ratio well left ventricular end diastolic diameter increased left ventricular ejection fraction decreased p sympathetic driving index increased sham rat change parameter aggravated chf rat p kcnmb knockdown downregulated protein expression pvn chf rat conclusion downregulation blunted function bk ca pvn may contribute sympathoexcitation deterioration cardiac function rat chronic heart failure:0.0247483027038400",
    "31146": "controversy concerning capacity rosuvastatin attenuate heart failure end stage hypertension aim study show whether rosuvastatin might effective heart failure treatment twenty one spontaneously hypertensive rat shrs aged week heart failure randomly divided three group two receiving rosuvastatin mg kg day respectively third placebo comparison seven wistar kyoto rat wkys control week treatment systolic blood pressure sbp echocardiographic feature evaluated mrna level b type natriuretic peptide bnp plasma nt probnp concentration measured heart tissue observed electron microscope em myocardial sarcoplasmic reticulum ca pump serca activity mitochondrion cytochrome c oxidase cco activity measured expression serca phospholamban plb ryanodine receptor ryr sodium calcium exchanger ncx ca calmodulin dependent protein kinase ii camkii protein phosphatase inhibitor ppi detected western blot rt qpcr total phosphorylation protein kinase calpha beta pkcalpha beta measured aged shrs heart failure characterized significantly decreased left ventricular ejection fraction left ventricular fraction shortening enhanced left ventricular end diastolic diameter lv volume accompanied increased plasma nt probnp elevated bnp gene expression damaged myofibril vacuolated mitochondrion swollen sarcoplasmic reticulum observed em myocardium mitochondrion cco serca activity decreased expression plb ncx increased significantly regulation ppi regulation camkii whereas ryr decreased rosuvastatin found ameliorate heart failure aged shrs improve change serca plb ryr ncx camkii ppi pkcalpha beta signal pathway suppressed protective effect rosuvastatin dose dependent conclusion heart failure aged shrs developed end stage hypertension could ameliorated rosuvastatin:0.0247259438403741",
    "10252": "objective investigate influence ace inhibitor perindopril contractility calcium transient calcium handling protein ventricular myocytes rat experimental heart failure method male wistar rat randomized heart failure group treated perindopril chf mg kg heart failure group without treatment chf c sham operated group p heart failure induced constricting abdominal aorta week group followed week left ventricular myocytes isolated single cell shortening fraction ca simultaneously measured laser scanning confocal microscope field stimulation hz rt pcr western blot performed evaluate level mrna protein na ca exchanger ncx sarcoplasmic ca atpase serca phospholamban plb result fraction cell shortening f ca max nmol l significantly smaller group chf c group p f v ca max v p chf group f ca max greater chf c group chf c group left ventricular mrna ncx plb significantly higher p group r ncx beta actin v p r plb beta actin v p yet serca mrna lower p group v p chf group mrna level ncx serca midst chf c p group statistical significance respectively p chf c chf group protein level ncx time p group respectively p serca protein level respectively time high p group p protein expression ncx serca also different chf c chf group p conclusion ace inhibitor could improve cardiac function chf directly enhancing contractility single myocardial cell effect probably mediated role preventing deleterious change calcium transient calcium handling protein chf:0.0246863024281493",
    "108927": "objective study change short chain acyl coa dehydrogenase scad heart failure hf myocardial infarction mi effect aerobic exercise scad method healthy male sprague dawley sd rat divided sham operation group sham group sham operation swimming group sham swim group hf model group lad group hf swimming group lad swim group random number table method rat group left anterior descending branch coronary artery lad ligated establish rat model hf mi sham group one loose knot threaded left coronary artery rest operation lad group rat sham swim group lad swim group given swimming test week operation minute st day minute th day given swimming endurance training nd week onwards minute daily time weekly week row tail artery systolic pressure sbp measured swimming endurance training every week end th week ten week swimming training echocardiography performed measure cardiac output co stroke volume sv left ventricular ejection fraction lvef shortening fraction f left ventricular end systolic diameter lvesd left ventricular end diastolic diameter lvedd left ventricular end systolic volume lvesv left ventricular end diastolic volume lvedv morphological change heart observed masson staining apoptosis myocardial cell detected transferase mediated deoxyuridine triphosphate biotin nick end labeling stain tunel apoptosis index ai calculated reverse transcription polymerase chain reaction rt pcr western blot used detect mrna protein expression myocardial scad respectively addition enzyme activity scad content adenosine triphosphate atp free fatty acid ffa serum myocardium detected according kit instruction step result compared sham group sham swim group showed sbp change significantly obvious eccentric hypertrophy increased myocardial contractility lad group showed persistent hypotension obvious mi thinning left ventricle decreased myocardial systolic diastolic function compared lad group sbp systolic diastolic function mi lad swim group significantly improved sbp mmhg mmhg kpa v week v week v week v week co ml min v sv mul v lvef v f v lvedd mm v lvesd mm v lvedv mul v lvesv mul v ai v p compared sham group mrna protein expression myocardium scad activity scad sham swim group significantly increased content atp slightly increased content serum ffa significantly decreased content myocardial ffa slightly decreased conversely mrna protein expression myocardium scad activity scad content atp lad group significantly decreased content serum myocardial ffa significantly increased compared lad group mrna protein expression myocardium scad content atp significantly increased lad swim group scad mrna deltadeltact v scad gapdh fold increase sham group v atp content mumol g v p content serum myocardial ffa significantly decreased serum ffa nmol l v myocardial ffa nmol g v p activity scad slightly increased ku g v p conclusion expression scad hf significantly regulated expression significantly regulated aerobic exercise intervention indicating swimming may improve severity hf regulating expression scad:0.0245913390759238",
    "27496": "objective investigate effect beta adrenoceptor beta ar antagonist sr cardiac function left ventricular remodeling rat model heart failure induced isoproterenol iso probe mechanism method eight rat randomly selected serve control male adult wistar rat heart failure model reproduced twenty remain rat randomly divided iso group n sr group sr group n iso group received intraperitoneal injection ml saline twice day sr group received intraperitoneal injection nmol sr ml saline twice day control group received treatment parameter determined included echocardiogram expression nitric oxide synthase enos left ventricle technique reverse transcription polymerase chain reaction rt pcr western blotting cyclic guanosine monophosphate cgmp level enzyme linked immunosorbent assay elisa ratio left ventricular weight body weight lvw bw ratio lung weight body weight pw bw result compared control group left ventricular end systolic pressure lvesp maximum minimum first derivative left ventricular pressure dp dtmax significantly decreased p heart rate hr left ventricular end diastolic pressure lvedp significantly increased p iso group compared iso group lvesp dp dtmax markedly higher p p respectively whereas hr lvedp markedly lower p p sr group difference hr sr group control group p lvedp higher r group control group p level enos mrna protein cgmp significantly lower sr group compared iso group p addition compared iso group lvw bw ratio pw bw ratio sr group also decreased p conclusion beta ar antagonist sr block beta ar no cgmp pathway improve cardiac function heart failure rat administered long term sr also improve left ventricular remodeling certain degree:0.0241924319900456",
    "151798": "background diabetes mellitus type risk factor developing heart failure myocardial fibrosis specific therapy diabetic heart disease methoxyphenyl methoxyphenyl propoxy ethyl h imidazole skf regarded inhibitor receptor mediated calcium ion ca entry study aimed explore effect skf diabetic myocardial fibrosis method type diabetic rat model induced high sugar high fat diet combined streptozotocin established thirty specific pathogen free male wistar rat divided randomly three group group blank control group group b diabetes group group c diabetes transient receptor potential canonical channel trpc blocker intervention group group c given micromol kg skf intraperitoneal injection group b given amount normal saline intraperitoneal injection weight blood sugar rat monitored week weight whole heart left ventricle measured heart left ventricular weight ratio calculated haematoxylin eosin staining used observe pathological change myocardial tissue distribution nucleus masson staining used identify collagen muscle fibre myocardial collagen volume fraction cvf calculated semi quantitative reverse transcription polymerase chain reaction used detect messenger ribonucleic acid mrna expression skf target gene value p indicated difference group statistically significant result compared weight rat group weight group b c decreased blood sugar whole heart weight left ventricular weight increased p significant difference body weight rat group b c p staining result showed arrangement cardiomyocytes group b c irregular focal necrosis seen severe case degree diabetic cardiomyopathy dcm group c less severe group b masson staining showed cvf increased group b c group b group c p mrna expression trpc trpc upregulated group b c mrna expression trpc trpc group c downregulated compared group b p compared expression level skf target gene stim orai homer group group b lower administration skf group c affect expression level gene conclusion skf effectively improve myocardial fibrosis type ii diabetic rat:0.0237450772898519"
  },
  "Topic 23": {
    "114284": "objective study sought investigate clinical outcome associated left atrial appendage occlusion laao versus direct oral anticoagulant doacs patient high risk atrial fibrillation af background laao shown noninferior warfarin stroke prevention af however anticoagulation doacs preferred warfarin thromboprophylaxis af method patient af enrolled amulet observational registry n successful laao amplatzer amulet device n compared propensity score matched control cohort incident af patient n treated doacs identified danish national patient registry propensity score matching based covariates cha d vasc congestive heart failure hypertension age year diabetes mellitus prior stroke transient ischemic attack thromboembolism vascular disease age year sex category bled hypertension abnormal renal liver function stroke bleeding labile international normalized ratio elderly drug alcohol score predicting stroke bleeding primary outcome composite ischemic stroke major bleeding bleeding academic research consortium cause mortality follow year result af patient treated laao significantly lower risk primary composite outcome compared patient treated doacs hazard ratio hr confidence interval ci total event event rate per patient year laao v doacs v v respectively risk ischemic stroke comparable group hr ci risk major bleeding hr ci cause mortality hr ci significantly lower patient treated laao conclusion among high risk af patient laao comparison doacs may similar stroke prevention efficacy lower risk major bleeding mortality:0.0336682357743361",
    "107551": "observational study investigate efficacy safety nonvitamin k antagonist oral anticoagulant noacs atrial fibrillation af patient bioprosthetic valve prior surgical valve repair clinical practice total patient mean age female bioprosthetic heart valve surgical valve repair af treated noacs included analysis mean cha d vasc congestive heart failure hypertension age year diabetes mellitus prior stroke transient ischemic attack vascular disease bled hypertension abnormal renal liver function stroke bleeding labile inr international normalized ratio elderly drug alcohol score value respectively total study population taking apixaban mg twice daily bid apixaban mg bid dabigatran mg bid dabigatran mg bid rivaroxaban mg daily qd rivaroxaban mg qd also study population previously warfarin replaced noacs due lack compliance labile inr control time therapeutic range noac therapy af started average day bioprosthetic heart valve implantation surgical repair average duration day study population included patient bioprosthetic mitral valve patient bioprosthetic aortic valve patient previous surgical mitral repair patient previous surgical aortic repair concomitant use noacs patient evaluated thromboembolic event ischemic stroke transient ischemic attack systemic embolism well major bleeding event follow period study population recorded low mean annual incidence thromboembolism major bleeding according data anticoagulation therapy noacs seems effective safe treatment strategy nonvalvular af patient bioprosthetic valve prior surgical valve repair:0.0322655152960969",
    "71057": "objective compare clinical characteristic use oral anticoagulant oac therapy individual aged older atrial fibrillation af individual younger af clinical practice design observational study setting real life multicenter survey evaluating stroke prevention strategy turkey trial nct national observational registry participant turkish adult nonvalvular af nvaf measurement age data collected time entry registry octogenarian subgroup included patient aged year compared background management octogenarian non octogenarian af patient result fifty seven cardiology unit enrolled individual month participant aged older n likely female v p higher prevalence persistant permanent af comorbidities history cerebral vascular accident major bleeding consequence comorbidities congestive heart failure hypertension aged older diabetes mellitus prior stroke transient ischemic attack thromboembolism vascular disease aged female sex cha d vasc v p hypertension abnormal renal liver function stroke bleeding labile international normalized ratio elderly drug alcohol bled v p score higher aged older mean time therapeutic range individual taking warfarin lower aged older younger p anticoagulant therapy prescribed participant younger aged older p higher cha d vasc score lower bled score independent predictor oac prescription participant aged older conclusion nearly one fifth individual nvaf real world sample aged older participant aged older likely female comorbidities younger aged older af less likely receive anticoagulant younger comorbidities individual level characteristic may explain difference prescribed oacs participant aged older poorer quality anticoagulation younger suggesting opportunity improvement:0.0314977980769188",
    "99307": "atrial fibrillation af prevalent arrhythmic disease tends foster thrombus formation due hemodynamic disturbance leading severe disabling even fatal thromboembolic disease meanwhile patient af may also present acute coronary syndrome ac coronary artery disease cad requiring stenting creates clinical dilemma considering majority patient likely receive oral anticoagulant oacs stroke prevention require additional double antiplatelet treatment dapt reduce recurrent cardiac event stent thrombosis case gentle balance bleeding risk atherothromboembolic event need carefully considered study shown congestive heart failure hypertension age year doubled diabetes mellitus previous stroke transient ischemic attack tia doubled vascular disease age year sex category female cha d vasc score outperform scoring system asian population hypertension abnormal renal liver function point stroke bleeding history predisposition labile international normalized ratio inr elderly year drug alcohol concomitantly point bled score simple clinical score predicts bleeding risk patient af particularly among asian performs better bleeding score high bled score used rule oac treatment instead prompt clinician address correctable risk factor therefore current review attempted analyze available data patient nonvalvular af underwent stenting ac cad elaborate direct acting oral anticoagulant doac antiplatelet management among patient majority patient triple therapy comprising oac aspirin clopidogrel considered month following ac however optimal duration triple therapy would depend patient ischemic bleeding risk doacs obviously safer vitamin k antagonist:0.0313580036767178",
    "73123": "background management atrial fibrillation af evolved development direct oral anticoagulant doacs data clinical effectiveness safety outside clinical trial setting limited method raffine registry observational multicenter prospective registry japanese patient af designed follow clinical event year patient enrollment conducted university hospital general hospital private clinic ensure inclusion broad spectrum representative af patient primary outcome event study ischemic stroke systemic embolism major bleeding result enrolled ambulatory patient af university hospital general hospital clinic japan mean patient age year male type af paroxysmal persistent permanent major coexisting disease hypertension diabetes mellitus congestive heart failure history ischemic stroke transient ischemic attack coronary artery disease entire cohort treated warfarin treated doacs prescription doacs exceeded warfarin general hospital clinic risk score chad score cha d vasc score bled score higher patient university hospital patient general hospital clinic conclusion raffine registry baseline described current status anticoagulation therapy japan long term follow data identify outcome vary stratified group patient af doac era umin clinical trial registry umin:0.0309766425577503",
    "142208": "objective identified factor associated thromboembolic bleeding event two contemporary cohort anticoagulated patient atrial fibrillation af treated either vitamin k antagonist vka non vka oral anticoagulant noacs design prospective multicentre observational study setting centre seven european country participant patient receiving vka prevention thromboembolic event european registry atrial fibrillation prefer af derivation cohort patient receiving noac prefer af prolongation validation cohort stroke prevention af outcome measure risk factor thromboembolic event ischaemic stroke systemic embolism major bleeding gastrointestinal bleeding intracerebral haemorrhage life threatening bleeding result mean age patient enrolled prefer af registry year female mean cha d vasc score incidence thromboembolic major bleeding event ci ci year follow respectively abnormal liver function prior stroke transient ischaemic attack labile international normalised ratio inr concomitant therapy antiplatelet non steroidal anti inflammatory drug heart failure older age year independently associated thromboembolic major bleeding event exception unstable inr value risk factor validated patient treated noacs prefer af prolongation study year female cha d vasc single point decrease modifiable bleeding risk scale observed lower risk major bleeding event ci p lower rate thromboembolic event ci p conclusion attending modifiable risk factor important treatment target anticoagulated af patient reduce thromboembolic bleeding event initiation anticoagulation risk stroke prevented elevated bleeding risk score:0.0301867280564437",
    "729": "atrial fibrillation af common cardiac arrhythmia af paroxysmal persistent becomes permanent convert sinus rhythm spontaneously attempted cardioversion fails prevalence af general population increase age octogenarian men age adjusted prevalence generally higher woman af synchronous mechanical atrial activity disturbed resulting haemodynamic impairment give rise thrombus formation embolism systemic circulation thrombus associated af arises frequently left atrial appendage cerebrovascular embolus af patient often manifest transient ischaemic attack ischaemic stroke overall rate ischaemic stroke among patient nonrheumatic af average per year rate increase age patient af higher risk cerebrovascular event cause stroke one every six occurs patient af including transient ischaemic attack silent stroke detected radiographically overall rate cerebrovascular event af patient rise per year although approximately one third due cause secondarily incidentally associated af related anticoagulant therapy antiarrhythmic therapy useful improve cardiac rate function af however reduce first recurrent embolus antithrombotic therapy paramount importance result several randomized clinical trial antithrombotic therapy shown adjusted dose warfarin reduces first recurrent stroke compared placebo patient nonvalvular af anticoagulated odds ischaemic stroke intracranial bleeding favour inr acetylsalicylic acid less efficacious warfarin af patient reducing risk stroke therefore antiplatelet agent used af patient low risk anticoagulation current treatment modality af patient high intermediate risk e patient history transient ischaemic attack stroke aged year history hypertension diabetes heart failure structural heart disease valvular disease significant systolic dysfunction benefit dual antiplatelet regimen af patient unknown combining antiplatelet agent different mechanism action important topic future investigation:0.0301840682116345",
    "182783": "result large randomized trial update clinical guideline antithrombotic therapy following percutaneous coronary intervention pci changed recent year patient nonvalvular atrial fibrillation nvaf purpose study investigate real world data antithrombotic regimen discharge evolving trend well compare effect different therapy incidence major cardiovascular cerebrovascular ischemic event macces bleeding event elderly patient analysis stent implantation patient carried retrospectively atrial fibrillation af patient age older divided two group according antithrombotic regimen prescribed hospital discharge dual antiplatelet aggregation treatment group dapt anticoagulant treatment antiplatelet aggregation treatment group att baseline characteristic efficacy endpoint macces cerebrovascular ischemic event safety endpoint bleeding event analysed compared different antithrombotic regiment use oral anticoagulant oac increased p trend since introduction non vitamin k antagonist oral anticoagulant noacs warfarin usage decreased noacs rapidly replaced warfarin rate persistent af att group significantly higher rate dapt group v p att group used proton pump inhibitor ppi dapt group v p significant decrease observed macces v p cerebrovascular ischemic event v p att group compared dapt group according att subgroup analysis significant difference incidence overall bleeding triple anticoagulant therapy group dual anticoagulant therapy group dt v p macces predicted independently att cha d vasc congestive heart failure hypertension age year diabetes stroke transient ischemic attack vascular disease age year sex category score whereas bleeding predicted independently ppi use bled hypertension abnormal renal liver function stroke bleeding history predisposition labile international normalized ratio elderly drug alcohol score result noac introduction use combination antithrombotic regimen discharge elderly patient af pci changed rapidly past year toward higher use atts whereas patient af undergoing pci still rarely receive appropriate antithrombotic regimen essential conduct att elderly patient undergoing pci dt may appropriate:0.0299814484353222",
    "136850": "background atrial fibrillation af chronic kidney disease ckd associated increased risk ischemic stroke aim study compare clinical characteristic incidence left atrial appendage laa thrombus predictor spontaneous echo contrast sec population patient af depending estimated glomerular filtration rate egfr value method study included patient underwent transesophageal echocardiographic examination prior cardioversion ablation year three cardiac center result quarter af patient decreased egfr ml min characterized high risk population comorbidities higher thromboembolic bleeding risk compared normal renal function oral anticoagulation oac prescribed patient decreased normal egfr respectively higher prevalence prescribed non vitamin k antagonist oral anticoagulant noacs incidence laa thrombus sec increase simultaneously decrease egfr ml min respectively among patient prescribed reduced dos noac decreased egfr often observed laa thrombus v non paroxysmal af heart failure previous bleeding predictor laa thrombus irrespective egfr value ckd predictor laa thrombus patient including non paroxysmal af male without diabetes without hypertension cha d vasc conclusion despite oac patient concomitant af ckd remain high risk laa thrombus formation:0.0296858325368583",
    "110299": "background several non vitamin k antagonist oral anticoagulant noac alternative warfarin available stroke prevention atrial fibrillation af aimed describe factor associated selection noacs versus warfarin patient new onset af method orbit af ii study national u prospective observational cohort study anticoagulation treatment patient af receiving noacs warfarin united state measured factor associated oral anticoagulant selection patient recently diagnosed af result baseline patient started warfarin noacs latter started dabigatran rivaroxaban apixaban receiving noacs slightly younger patient median age v p less likely prior stroke v p prior bleeding v p better kidney function mean estimated glomerular filtration rate ml min v ml min p fewer patient high stroke risk cha d vasc score congestive heart failure hypertension age year diabetes mellitus prior stroke transient ischemic attack tia thromboembolism vascular disease age year sex category female v p multivariable analysis factor associated noac selection versus warfarin included renal function prior stroke valve replacement rhythm control af management strategy treatment cardiologist higher patient education level conclusion contemporary clinical practice three fourth patient new onset af initially treated noac stroke prevention selected noac treatment lower stroke bleeding risk profile likely treated cardiologist higher socioeconomic status trial registration clinicaltrials gov identifier nct:0.0294744360635593"
  },
  "Topic 24": {
    "55790": "incomplete inhibition renin angiotensin aldosterone system raas may responsible residual organ damage event rate still occur spite apparent blood pressure control patient hypertension diabetes chronic kidney disease heart failure treated angiotensin converting enzyme inhibitor acei angiotensin receptor blocker arb additional antiproteinuric effect diabetic non diabetic chronic kidney disease reduction hospitalization patient heart failure already receiving single raas antagonist achieved incremental inhibition raas dual therapy uptitration individual agent conventional dosage however synergistic increase plasma renin activity pra angiotensin ii escape could reduce expected benefit obtained dual therapy result ontarget showing lack additional outcome benefit monotherapy concomitant increase risk hyperkalemia renal impairment hypotension discourage use acei arb combination patient high risk cardiovascular event occured despite lower albumin excretion dual versus single raas blockade indicating incremental antiproteinuric effect automatically translated clinical outcome benefit efficacy safety acei arb combination versus monotherapy patient overt proteinuria currently evaluated lirico va nephron clinical trial long lasting direct renin inhibitor aliskiren acting first rate limiting step raas cascade prevents reactive increase pra combined aceis arb diuretic aspire higher programme involving patient hypertension heart failure kidney disease diabetes currently evaluating efficacy safety aliskiren top standard therapy clinical benefit adding mineralocorticoid receptor blocker mrbs control resistant hypertension proteinuric kidney disease prevention mortality patient heart failure top conventional treatment evidence pathogenic role inadequately suppressed aldosterone cause suboptimal response conventional raas inhibition present review focus pathophysiological ground evidence provided clinical trial assessing efficacy safety recent strategy prevention cardiovascular event target organ damage progression via enhanced raas inhibition:0.0334019925026453",
    "23949": "recent trial helped clarify indication initial pharmacological therapy hypertension joint national committee prevention detection evaluation treatment high blood pressure jnc vi world health organization international society hypertension ish recommendation revised recent trial indicate diuretic beta blocker appear effective reducing overall morbidity mortality agent swedish trial old patient hypertension stop united kingdom prospective diabetes study ukpds intervention goal hypertension treatment insight nordic diltiazem nordil use blocker result cardiovascular event especially congestive heart failure compared diuretic antihypertensive therapy lipid lowering heart attack trial allhat use angiotensin converting enzyme ace inhibitor result fewer myocardial infarction episode heart failure calcium channel blocker elderly diabetic patient fosinopril v amlodipine cardiovascular event randomized trial facet appropriate blood pressure control diabetes abcd stop data captopril prevention project cappp suggest use ace inhibitor preferred diabetic patient overall cardiovascular event similar calcium channel blocker compared diuretic however fewer stroke non dihydropyridine calcium channel blocker nordil trend towards increase heart failure myocardial infarction either dihydropyridine non dihydropyridine calcium channel blocker compared diuretic insight nordil angiotensin receptor blocker arb decrease proteinuria slow progression renal disease type diabetic patient compared regimen include arb ace inhibitor reduction endpoint niddm angiotensin ii antagonist losartan renaal irbesartan type ii diabetic nephropathy trial idnt irbesartan type ii diabetes microalbuminuria irma il debate initial therapy may moot high risk hypertensive patient probably treated initially combination therapy one diuretic use diuretic beta blocker well ace inhibitor alone diuretic considered initial therapy change jncvi alpha blocker reserved special situation e prostatic hypertrophy contrast ish recommendation ace inhibitor arb usually along diuretic considered preferred therapy hypertensive diabetic patient data suggest equal greater reduction stroke calcium channel blocker medication:0.0327087018716211",
    "44000": "role renin angiotensin aldosterone system raas regulating volume composition extracellular fluid blood pressure bp well onset progression cardiovascular renal disease studied year compound block vital stage raas cascade ace inhibitor acei receptor blocker arb aldosterone receptor antagonist importantly extended treatment option however positive therapeutic effect compound also certain negative consequence administration aceis arb interrupt physiological feedback renal renin release lead reactive elevation circulating active renin greater production angiotensin angiotensin ii subsequent return aldosterone secretion pre treatment level escape phenomenon possible adverse effect intermediary product incomplete raas blockade leading organ complication facilitated effort develop compound blocking initial stage renin angiotensin cascade e direct renin blocker several year unsuccessful attempt recent year seen development first non peptide orally long term effective renin inhibitor aliskiren fumarate monotherapy combination antihypertensive hydrochlorothiazide arb acei aliskiren reduces bp dose dependent manner mg den aliskiren reduces plasma renin activity pra neutralises hydrochlorothiazide induced raas activation daily administration drug lead longer hour activity prolonged blocking effect kidney basis renoprotectivity addition significant antihypertensive effect clinical study also showed range organoprotective property patient left ventricle hypertrophy allay study heart failure aloft study diabetic nephropathy avoid study similar blocker aliskiren minimum adverse side effect aliskiren hypertension therapy launched clinical practice usa tekturna combination formulation tekturnahcl respectively shortly european union rasilez czech republic aliskiren rasilez released clinical use diabetologists nephrologists patient hypertension concomitant diabetes nephropathy proteinuria dos mg per day recommended monotherapy combination antihypertensive treat condition elevated pra including pra elevation following diuretic acei arb administration aliskiren might used patient tolerate aceis well patient angiotensin ii participates pathogenesis disease reno protective property leading reduction proteinuria delaying renal failure progression observed patient diabetic well non diabetic nephropathy drug subject similar precaution contraindication aceis arb e pregnancy bilateral renal artery stenosis make meaningful conclusion far positive contribution new treatment class broad applicability therapy hypertension cardiovascular disease imperative assess long term effect morbidity mortality well compare agent raas blocker long term clinical study represents research effort another year:0.0326001074579753",
    "17014": "cardiovascular cardiorenal disease continuum comprises transition cardiovascular risk factor endothelial dysfunction atherosclerosis clinical complication myocardial infarction mi stroke development persistent target organ damage ultimately chronic congestive heart failure chf end stage renal disease premature death renin angiotensin aldosterone system raas involved step along pathway raas blockade ace inhibitor angiotensin receptor antagonist angiotensin receptor blocker arb turned beneficial patient outcome throughout disease continuum ace inhibitor arb prevent reverse endothelial dysfunction atherosclerosis thereby reducing risk cardiovascular event drug shown reduce end organ damage heart kidney brain aldosterone antagonist spironolactone eplerenone increasingly recognized third class raas inhibitor potent risk reducing property especially solely respect inhibition cardiac remodelling possible prevention heart failure secondary prevention head head comparison ace inhibitor arb recent ontarget study provided evidence addition better tolerability arb non inferior ace inhibitor prevention clinical endpoint mi stroke cardiovascular high risk patient however combination ramipril telmisartan maximally tolerated dosage achieved benefit associated adverse event symptomatic hypotension renal dysfunction acute mi complicated heart failure valiant trial shown similar effect ace inhibition captopril arb treatment valsartan dual raas blockade reduce event chf meta analysis resolvd valheft charm added shown combined raas inhibition ace inhibitor arb significantly reduced morbidity endpoint certain patient subgroup compared standard therapy however clinical practice dual raas blockade rarely employed seen instance corona trial rale ephesus trial investigating effect aldosterone blockade cardiovascular outcome chf patient revealed addition aldosterone antagonist standard heart failure therapy conferred powerful relative risk reduction morbidity mortality future study elucidate whether also hold true patient asymptomatic heart failure preserved ejection fraction selected patient renal disease several study suggested combined raas blockade brings additional renoprotective antiproteinuric effect independent blood pressure reduction large trial robust endpoint underway summary combined therapy several raas inhibitor recommended patient along cardiorenovascular continuum patient chf incomplete neuroendocrine blockade indicated example repetitive cardiac decompensation refractory symptom might benefit dual therapy long safety issue well controlled finally novel pharmacological agent direct renin inhibitor aliskiren may provide additional therapeutic tool role yet established:0.0322199365502937",
    "2667": "angiotensin ii receptor blocker arb represent new class effective well tolerated orally active antihypertensive agent recent clinical trial shown added benefit arb hypertensive patient reduction left ventricular hypertrophy improvement diastolic function decrease ventricular arrhythmia reduction microalbuminuria improvement renal function cardioprotective effect patient heart failure several large long term study progress assess beneficial effect arb cardiac hypertrophy renal function cardiovascular cerebrovascular morbidity mortality hypertensive patient without diabetes mellitus value drug patient heart disease diabetic nephropathy arb specifically block interaction angiotensin ii receptor thereby relaxing smooth muscle increasing salt water excretion reducing plasma volume decreasing cellular hypertrophy agent exert blood pressure lowering effect mainly reducing peripheral vascular resistance usually without rise heart rate commercially available arb control blood pressure h daily dosing sustained efficacy blood pressure control without evidence tachyphylaxis demonstrated long term administration year arb efficacy arb similar thiazide diuretic beta blocker angiotensin converting enzyme inhibitor calcium channel blocker patient similar degree hypertension higher daily dos dietary salt restriction concomitant diuretic ace inhibitor administration amplify antihypertensive effect arb arb low incidence adverse effect headache upper respiratory infection back pain muscle cramp fatigue dizziness even elderly patient approval losartan five arb candesartan cilexetil eprosartan irbesartan telmisartan valsartan three combination hydrochlorothiazide irbesartan losartan valsartan approved antihypertensive agent compound various stage development arb non peptide compound varied structure candesartan losartan irbesartan valsartan common tetrazolo biphenyl structure except irbesartan active arb carboxylic acid group candesartan cilexetil prodrug losartan metabolite exp active parent drug metabolite arb contribute significantly antihypertensive effect variation molecular structure arb result difference binding affinity receptor pharmacokinetic profile difference observed lipid solubility absorption distribution plasma protein binding bioavailability biotransformation plasma half life systemic elimination influence time onset duration action efficacy arb basis daily mg dose antihypertensive potency arb follows sequence candesartan cilexetil telmisartan approximately losartan irbesartan approximately valsartan eprosartan oral administration arb rapidly absorbed time peak plasma level h wide range bioavailability low eprosartan high irbesartan food influence bioavailability except valsartan reduction eprosartan increase limited dose peak plasma level area plasma level time curve proportionality observed arb drug high plasma protein binding irbesartan lowest binding among group steady state volume distribution vary low l candesartan high l telmisartan abstract truncate:0.0317428804598668",
    "14723": "systolic blood pressure sbp increase age hypertension affect approximately two third adult u aged year blood pressure bp increase consequence age related structural change large artery lead loss elasticity reduced vascular compliance increased pulse wave velocity augments sbp resulting high prevalence isolated systolic hypertension age elevates cardiovascular risk effective treatment hypertension older aged year patient population prevents many event per patient treated treatment younger hypertensive patient recommendation treating hypertension similar older patient compared general population seventh report joint national committee detection prevention evaluation treatment high blood pressure recommends target bp goal mmhg patient uncomplicated hypertension mmhg diabetes mellitus renal disease recent guideline position paper extended aggressive treatment goal include patient coronary artery disease type vascular disease heart failure randomized clinical trial demonstrated efficacy calcium channel antagonist calcium channel blocker ccbs low dose diuretic ace inhibitor angiotensin ii type receptor antagonist angiotensin receptor blocker arb reducing risk stroke adverse cardiovascular outcome older patient beta adrenoceptor antagonist less effective term endpoint reduction majority older patient require two drug achieve bp goal despite active treatment half patient achieve target bp part reluctance physician intensify treatment phenomenon referred clinical inertia arb effective antihypertensive agent older patient shown reduce cardiovascular endpoint patient hypertension diabetic nephropathy cerebrovascular disease heart failure arb produce additive bp reduction combined diuretic ccbs also advantage placebo like tolerability contributes favourably patient compliance long term treatment prerequisite reducing morbidity mortality:0.0314643506070360",
    "20057": "hypertension control rare clinical practice particularly high risk patient large factor therapeutic inertia deriving poorly prescribed lifestyle change excess monotherapy use scarce treatment modification use drug combination significantly improves blood pressure bp control particular fixed combination improve therapy without increasing daily pill intake thereby favouring patient compliance therapy continuation widely used fixed combination based thiazide diuretic added either angiotensin converting enzyme ace inhibitor angiotensin ii receptor blocker arb several large scale clinical trial conducted showing combination effective lowering bp however thiazide diuretic reduce metabolic benefit derived renin angiotensin aldosterone system raas inhibitor high metabolic risk patient contrast ace inhibitor arb combined dihydropyridine calcium channel antagonist dhpcas exert marked antihypertensive effect without decreasing metabolic protection raas blockade recent jikei heart study approximately patient affected hypertension heart failure coronary heart disease combination valsartan arm simultaneously treated dhpcas note reduction primary endpoint combined morbidity mortality reported valsartan compared non valsartan arm furthermore recent multinational study hypertensive patient treated valsartan dhcpa amlodipine reported concontrolled bp week treatment expected amlodipine negatively influence metabolic profile patient thereby supporting role arb dhpca combination effective promising tool hypertension treatment summary combination arb dhpcas effective strategy hypertension treatment synergy antihypertensive vascular protective action persistent metabolic benefit deriving raas inhibition reduced incidence side effect:0.0314525365877442",
    "57804": "background renin angiotensin system ra major regulator blood pressure bp vascular response injury increasing evidence ra inhibition may provide end organ protection independent bp lowering two drug class directly target angiotensin ii complementary mechanism angiotensin converting enzyme ace inhibitor block conversion angiotensin active peptide angiotensin ii increase availability bradykinin angiotensin receptor blocker arb selectively antagonize angiotensin ii receptor may also increase activation receptor modulate effect angiotensin ii breakdown product objective paper present overview clinical data supporting use ra inhibitor ace inhibitor arb monotherapy combination therapy based known role ra bp regulation vascular response injury considers implication data future treatment method relevant experimental clinical study identified searching medline june using primary search term renin angiotensin system angiotensin converting enzyme inhibitor angiotensin ii receptor blocker dual ra blockade trial included review large patient prospective randomized controlled study evaluating effect ra inhibition end organ protection various high risk population result eleven clinical trial identified evaluated effect ace inhibitor arb monotherapy end organ protection five trial identified evaluated effect combination therapy ace inhibitor arb compared treatment either agent alone different patient population using different end point hypertensive patient type diabetes microalbuminuria combination ace inhibitor arb therapy resulted better bp control either agent alone mean difference mm hg systolic p mm hg diastolic p well greater reduction microalbuminuria mean difference albumin creatinine ratio p compared monotherapy dual ra inhibition reduced occurrence doubling serum creatinine concentration end stage renal disease patient nondiabetic renal disease p v ace inhibitor alone p v arb alone recently published study reported nonsignificant benefit combination therapy monotherapy subset hypertensive patient high level microalbuminuria baseline v reduction respectively patient heart failure left ventricular ejection fraction relative risk cardiovascular death hospitalization heart failure reduced received arb added ace inhibitor compared received placebo added ace inhibitor p another study found benefit mortality cardiovascular end point combination therapy compared ace inhibitor monotherapy ongoing study investigating dual ra blockade patient high risk end organ damage well effective dos use combination regimen conclusion accumulating evidence antihypertensive regimen inhibit ra may provide incremental end organ protection combining ace inhibitor arb provide extensive ra inhibition may provide greater antihypertensive efficacy end organ protection use either class alone future strategy treating high risk patient focus early intervention prevent delay end organ damage:0.0312841384497918",
    "42520": "elevated blood pressure level highly prevalent major reason cardiovascular event thus place significant financial burden healthcare system worldwide guideline recommend five first line anti hypertensive drug class compelling indication may indicate favoring one drug class another angiotensin receptor blocker arb demonstrated blood pressure lowering efficacy least comparable drug class including ace inhibitor ace beta blocker calcium channel blocker diuretic addition lower side effect profile drug class patient arb persistent therapy compelling indication use arb heart failure post myocardial infarction diabetic nephropathy proteinuria microalbuminuria left ventricular hypertrophy atrial fibrillation metabolic syndrome ace induced cough arb irbesartan demonstrated high efficacy lowering blood pressure shown least comparable ace superior arb losartan valsartan translated better cost effectiveness irbesartan valsartan losartan treatment hypertension addition irbesartan shown effective early late stage diabetic nephropathy demonstrated considerable cost saving standard therapy including beta blocker diuretic non dihydropyridine calcium channel blocker stage kidney disease based efficacy data irbesartan diabetic nephropathy trial reduction endpoint niddm non insulin dependant diabetes melitis angiotensin ii antagonist losartan study also demonstrated cost saving losartan late stage renal disease losartan irbesartan registered treatment late stage diabetic nephropathy irbesartan also registered early stage diabetic nephropathy eu summary data randomized clinical trial efficacy antihypertensive drug provides indication real value patient addition observational data clinical practice proven end organ protection diabetic nephropathy provides evidence true value irbesartan compared arb treatment hypertension:0.0311523870491726",
    "20080": "cardiovascular disease represents continuum start risk factor hypertension progress atherosclerosis target organ damage ultimately myocardial infarction heart failure stroke death renin angiotensin system ra blockade angiotensin converting enzyme ace inhibitor angiotensin receptor blocker arb turned beneficial stage continuum class agent prevent reverse endothelial dysfunction atherosclerosis thereby reducing risk cardiovascular event reduction shown mainly ace inhibitor patient coronary artery disease recent study revealed arb inferior respect however data currently available combination drug ace inhibitor arb shown reduce target organ damage organ kidney brain heart decrease cardiovascular mortality morbidity patient congestive heart failure experimental data point influence ace inhibitor arb number function endothelial progenitor cell revealing additional mechanism action drug valiant trial shown equivalent effect arb valsartan ace inhibitor captopril patient post myocardial infarction dual ra blockade compared monotherapy reduce event secondary prevention recently published ontarget study provides evidence top better tolerability receptor antagonist equal ace inhibitor prevention clinical endpoint like cardiovascular mortality morbidity myocardial infarction stroke combined ra blockade however achieved benefit vascular high risk patient associated adverse event chronic heart failure valheft charm added shown combined ra inhibition ace inhibitor valsartan candesartan reduced morbidity mortality certain patient subgroup accumulating evidence also point benefit combination therapy individual proteinuric nephropathy conclusion combined ra inhibition generally indicated patient along cardio reno vascular continuum already proven effective heart failure patient incomplete neuroendocrine blockade secondary prevention monotherapy either ra inhibitor equally efficacious furthermore novel pharmacologic agent renin inhibitor may prove useful preventing common side effect ra blockade angiotensin escape receptor upregulation giving clinician additional therapeutic tool optimally treat individual patient:0.0308672445137951"
  },
  "Topic 25": {
    "186716": "objective modified item frailty index mfi comorbidity based risk stratification tool predict adverse event following various neurologic surgery study aim quantify association increased mfi postoperative complication mortality following surgical fixation traumatic thoracolumbar fracture method american college surgeon national surgical quality improvement program ac nsqip dataset used identify patient undergoing fusion surgery thoracolumbar spine fracture mfi score calculated based presence major comorbidities congestive heart failure within day surgery insulin dependent noninsulin dependent diabetes mellitus chronic obstructive pulmonary disease partially dependent totally dependent functional health status time surgery hypertension requiring medication multivariate analysis assessed independent impact increasing mfi score postoperative day morbidity mortality controlling baseline clinical characteristic result total patient included analysis female mean age year univariate analysis higher mfi score significantly associated increased risk superficial surgical site infection deep surgical site infection wound dehiscence unplanned reoperation pneumonia unplanned intubation postoperative ventilator use progressive renal insufficiency acute renal failure urinary tract infection stroke myocardial infarction cardiac arrest pulmonary embolism deep vein thrombosis bleeding requiring transfusion sepsis septic shock longer hospital length stay los multivariate logistic regression increasing mfi score versus mfi score zero associated higher odds overall complication mfi odds ratio ci p mfi ci p day mortality mfi ci p conclusion study demonstrates frailty measured using mfi independently predicts postoperative complication hospital los day mortality surgical repair thoracolumbar fracture finding important risk stratification patient undergoing thoracolumbar fusion surgery standardization reporting outcome procedure:0.0331171776262773",
    "160212": "objective study sought determine incidence risk factor blood transfusion among patient undergoing total knee revision tkr using nationwide database method retrospective data analysis conducted based nationwide inpatient sample ni enrolling patient underwent tkr complete information patient divided two group based whether received blood transfusion demographic characteristic race sex age length stay los total charge hospitalization hospital characteristic admission type insurance type bed size teaching status location region hospital hospital mortality comorbidities perioperative complication analyzed finally conducted univariate multivariate logistic regression identify factor associated tkr patient require blood transfusion result ni database included patient underwent tkr among patient received blood transfusion incidence blood transfusion dramatic decrease incidence year dropping tkr patient requiring transfusion experienced longer los incurred higher total medical expense utilized medicare frequently increased hospital mortality rate p independent predictor blood transfusion included advanced age female gender iron deficiency anemia rheumatoid disease chronic blood loss anemia congestive heart failure coagulopathy uncomplicated diabetes lymphoma fluid electrolyte disorder metastatic carcinoma neurological disease paralysis peripheral vascular disorder pulmonary circulation disorder renal failure valvular disease weight loss addition risk factor transfusion tkr surgery included sepsis acute myocardial infarction deep vein thrombosis pulmonary embolism gastrointestinal bleeding heart failure renal insufficiency pneumonia wound infection lower limb nerve injury hemorrhage seroma hematoma wound rupture non healing urinary tract infection acute renal failure postoperative delirium conclusion finding highlight importance recognizing risk factor blood transfusion tkr reduce occurrence adverse event:0.0329712672739985",
    "192009": "introduction cardiac surgery play crucial role treating wide range cardiovascular condition offering life saving intervention patient disease coronary artery disease heart valve disorder heart failure however procedure without significant risk including complication stroke acute kidney injury respiratory failure infection important recognize potential complication associated procedure also identify high risk patient early treatment process aging population increasing burden comorbidities growing number patient likely present suboptimal functional status prior cardiac surgery incorporating functional status preoperative evaluation healthcare provider improve patient selection enhance perioperative care improve outcome high risk patient population therefore study aim investigate whether preoperative dependent functional status associated increased risk postoperative major adverse outcome patient undergoing cardiac surgery method performed retrospective cohort analysis adult cardiac surgery patient based american college surgeon national surgical quality improvement program ac nsqip database compared primary composite outcome consisting post surgery outcome independent partially totally dependent patient primary outcome defined experiencing following adverse event superficial incisional deep incisional organ space surgical site infection death within day post operation stroke cerebral vascular accident cva cardiac arrest requiring cardiopulmonary resuscitation cpr myocardial infarction pulmonary embolism pe deep vein thrombosis dvt thrombophlebitis progressive renal insufficiency ventilator use hour post operation unplanned intubation reoperation sepsis septic shock pneumonia confounding variable age gender race emergency case comorbidities baseline laboratory marker used multivariable logistic regression analysis obtain adjusted odds ratio confidence interval ci result patient included study female male group year old prevalence dependent status compared independent patient dependent higher incidence primary outcome v yielding crude ci association remained significant ci adjustment age gender race body mass index bmi emergency case comorbidities diabetes hypertension heart failure preoperative blood transfusion sepsis laboratory marker conclusion patient preoperative dependent functional status found significantly greater risk complication cardiac surgery even adjusting demographic comorbidities laboratory marker perioperative characteristic investigation needed explore development clinical application predictive tool includes functional status could help identify high risk patient facilitate timely intervention prehabilitation program enhance functional capacity:0.0323046927813561",
    "128629": "objective calculate risk postoperative complication mortality corrective surgery adult spinal deformity asd patient using american college surgeon national surgical quality improvement program ac nsqip surgical risk calculator src method patient aged year undergoing corrective surgery asd identified current procedural terminology cpt code assessed patient international classification disease ninth revision icd scoliosis diagnosis calculated perioperative complication risk average via ac nsqip surgical calculator compared observed complication rate outcome assessed follows serious complication complication pneumonia cardiac complication surgical site infection urinary tract infection venous thromboembolism renal failure readmission return operating room death discharge nursing rehabilitation sepsis total length hospital stay predictive performance calculator analyzed computation brier score brier score sum squared difference binary outcome predicted risk range maximum brier score mean observed outcome mean observed outcome value closer suggestive better predictive performance length stay los assessed bland altman plot plot average observed los x axis difference observed predicted los axis result total asd patient year female kg identified procedure involved decompression involved fusion mean individual patient characteristic entered online risk calculator interface follows functional status independent partially dependent totally dependent emergent case wound class clean clean contaminated contaminated dirty infected american society anesthesiologist class ii iii iv v steroid use chronic condition ascites within day prior surgery systemic sepsis within hour surgery ventilator dependent disseminated cancer diabetes mellitus use hypertensive medication congestive heart failure dyspnea history smoking within year chronic obstructive pulmonary disease dialysis acute renal failure predictive day postoperative complication ranged across cpt code actual rate cohort demonstrated good predictive performance via brier score maximum predicted observed percentage outcome assessed associated brier score brier maximum calculated mean difference observed predicted los day ci conclusion ac nsqip src predicts surgical risk patient undergoing asd corrective surgery tool used resource preoperative optimization deformity surgeon level evidence:0.0312291414091106",
    "170705": "background past decade prevalence obesity risen united state parallel demand anterior cervical discectomy fusion acdf prior study evaluated role obesity class cervical spine surgery smaller patient population aimed evaluate potential correlation national population sample utilizing large multicenter database purpose purpose study analyze obesity level influence perioperative complication rate patient undergoing acdf study design setting retrospective cohort large multicenter database study patient sample american college surgeon national surgical quality improvement program ac nsqip database queried identify patient undergone elective acdf procedure using current procedural terminology cpt code outcome measure medical surgical complication within thirty day operation method patient categorized four bmi group nonobese bmi kg obese class bmi kg obese class ii bmi kg obese class iii bmi kg univariate analysis conducted demographic variable preoperative comorbidities identified age sex race smoking status hypertension requiring medication diabetes history congestive heart failure history bleeding disorder chronic obstructive pulmonary disease risk factor chi square test used compare incidence complication among group multivariable logistic regression analysis subsequently performed adjust preoperative risk factor compare obesity class iii nonobese patient result patient identified nonobese obese class obese class ii obese class iii obese class iii patient higher incidence surgical site infection v p pulmonary embolism pe v p obese class iii lower incidence blood transfusion v p obese class obese class ii obese class iii independently increased risk pe ci ci ci respectively conclusion risk postoperative pe acdf significantly higher obese class iii compared nonobese patient finding may support use additional prophylaxis measure precaution perioperative setting:0.0312211295328982",
    "145638": "objective examine incidence risk factor hospital prosthesis related complication prc following total knee arthroplasty tka using large scale national database method retrospective database analysis performed based nationwide inpatient sample ni patient underwent tka included recruited case divided two group according occurrence prc patient demographic age sex race hospital characteristic type admission payer bedsize teaching status location region hospital length stay los total charge hospitalization hospital mortality comorbidities perioperative complication analyzed result total tkas captured ni database case hospital prc tka overall incidence slight downward trend annually periprosthetic joint infection pji main category among prc followed mechanical loosening dislocation periprosthetic fracture ppf patient suffered hospital prc year younger year v year likely male v compared nonaffected population p additionally patient experiencing hospital prc tka less likely elective admission v likely teaching hospital v without complication p furthermore occurrence hospital prc associated longer los day v day p total charge v p higher hospital mortality v p multivariate logistic regression performed identify independent risk factor hospital prc tka included younger age male non elective admission teaching hospital deficiency chronic blood loss anemia coagulopathy congestive heart failure depression diabetes chronic complication fluid electrolyte disorder pulmonary circulation disorder metastatic cancer weight loss besides hospital prc tka associated secondary osteoarthritis inflammatory arthritis prior knee arthroscopy acute renal failure acute myocardial infarction deep vein thrombosis sepsis transfusion wound dehiscence conclusion beneficial study risk factor hospital prc tka ensure appropriate management optimize consequence although relatively low incidence identified:0.0307920603588380",
    "184539": "objective explore association diabetes outcome thyroidectomy patient method retrospective cohort analysis used american college surgeon national surgery quality improvement program database current procedural terminology cpt code used identify thyroidectomy case demographic comorbidities complication incidence compared diabetic nondiabetic patient using pearson chi square test fisher exact test appropriate independent effect diabetes outcome analyzed using binary logistic regression result total nondiabetic diabetic patient undergoing thyroidectomy identified chi square analysis demonstrated diabetic patient higher incidence obesity v p dyspnea v p poor functional status v p ventilator dependence v p chronic obstructive pulmonary disease copd v p congestive heart failure v p acute renal failure v p hypertension v p dialysis v p open wound v p steroid use v p bleeding disorder v p preoperative blood transfusion v p systemic sepsis v p demographic characteristic significantly different cohort including gender p age p race p hispanic ethnicity p adjusting factor logistic regression analysis showed diabetes associated acute renal failure ci p wound disruption ci p prolonged length stay ci p unplanned readmission ci p superficial incisional surgical site infection ci p urinary tract infection occurrence ci p organ space surgical site infection occurrence ci p pneumonia occurrence ci p medical complication ci p complication ci p conclusion diabetes mellitus significant factor associated increased odds complication following thyroidectomy level evidence laryngoscope:0.0306602991337046",
    "160806": "introduction laminectomy one common orthopedic spine surgery performed united state compared spine operation fusion laminectomy isolation lower morbidity however complication may arise result readmission inpatient healthcare facility purpose study identify demographic risk factor associated unplanned day readmission following laminectomy method american college surgeon national surgical quality improvement program ac nsqip database queried patient underwent laminectomy procedure using cpt code query yielded case demographic lifestyle comorbidity peri operative factor recorded independent sample student test chi squared appropriate fisher exact test used univariate analysis identify demographic lifestyle peri operative variable related day readmission following laminectomy procedure multivariate logistic regression modeling subsequently performed odds ratio or confidence interval ci calculated reported result patient included sample readmitted within day surgery corresponding readmission rate result univariate analysis revealed statistically significant relationship readmission status following patient variable patient age sex bmi asa classification race bleeding disorder chronic obstructive pulmonary disease copd diabetes hypertension congestive heart failure chf chronic steroid use total operative time tobacco use p multivariate logistic regression modeling confirmed following patient variable associated statistically significantly increased odds readmission age greater p female sex p bleeding disorder p diabetes p current smoker p copd p steroid use p asa class ii p total operative time p conclusion unplanned day readmission laminectomy infrequent however increasing age female sex steroid use current smoker bleeding disorder diabetes copd chf higher asa classification longer operative time independent risk factor readmission following laminectomy:0.0302257296744015",
    "193673": "background frailty become increasingly recognized perioperative risk stratification tool frailty strongly correlated worsening surgical outcome individual determinant frailty rarely investigated setting aortic disease aim study examine determinant factor modified frailty index mfi mortality postoperative complication patient undergoing endovascular aortic aneurysm repair evar method data national surgical quality improvement program database queried patient undergoing nonemergent evar univariate logistic regression used assess association mfi variable complication occurring within day surgery significant variable used multivariate analysis variable included mfi scoring diabetes nonindependent functional status chronic obstructive pulmonary disease congestive heart failure myocardial infarction mi previous percutaneous coronary intervention cardiac surgery angina hypertension requiring medication peripheral vascular disease impaired sensorium previous transient ischemic attack cerebrovascular accident overall complication included superficial surgical site infection deep incisional surgical site infection deep vein thrombosis readmission reintervention bleeding requiring transfusion major adverse event maes mortality maes included classified clavien dindo grade iv defined life threatening complication requiring intensive care unit level management single multiple organ failure odds ratio or calculated using spss result total patient identified resulting cohort male average age year binary regression revealed significant increase day mortality confidence interval ci p overall complication ci p maes ci p stroke ci p prolonged mechanical ventilation ci p acute kidney injury ci p cardiac arrest ci p mi ci p per point increase mfi score multivariate analysis demonstrated functional dependency highly associated increased odds outcome except stroke cardiac arrest mi impaired sensorium highly associated day mortality conclusion mfi strong predictor postoperative complication mortality patient undergoing nonemergent evar measurement frailty considered preoperative assessment patient evaluated evar particular attention risk benefit aortic repair dependent functional status impaired sensorium:0.0302036090413593",
    "117131": "background hospital readmission associated increased mortality morbidity cost also current health care reform tied significant financial administrative penalty study show patient undergoing vascular surgery may higher average readmission rate recently released nationwide readmission database nrd comprehensive national source readmission data gathering discharge information geographically dispersed state accounting total u resident population u hospitalization aim study use power nrd obtain nationally representative readmission information patient admitted claudication critical limb ischemia cli underwent revascularization procedure method nrd queried patient admitted claudication international classification disease ninth revision icd cli icd underwent percutaneous transluminal angioplasty peripheral bypass aortofemoral bypass patient demographic comorbidities length stay los mortality readmission rate associated cost collected univariable multivariable logistic regression analysis implemented claudication cli group outcome interest common readmission diagnosis code diagnosis group also identified result total patient admitted peripheral vascular disease claudication cli day readmission readmission rate claudication cli respectively significant difference found claudication cli respectively initial cost admission v p readmission cost v p los day v day p day readmission day v day p mortality initial admission v p mortality admission v p univariate multivariate logistic regression analysis found claudication cli angioplasty peripheral bypass aortofemoral bypass female sex age charlson comorbidity index los primary expected payer status significant predictor day overall readmission varying degree common disease readmission group found vascular procedure amputation lower limb except toe sepsis heart failure postoperative device infection abovementioned group common diagnosis included postoperative infection sepsis atherosclerosis native artery gangrene complication due vascular device implant graft conclusion result demonstrate significant difference readmission rate cost morbidity patient admitted claudication cli furthermore based regression analysis multiple clear risk factor associated worse clinical economic outcome study needed predict patient require increased vigilance hospital stay prevent readmission worse outcome level evidence care management epidemiological level iv:0.0297188027393460"
  }
}